#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Connectome-based prediction of cocaine abstinence
#Text=Objective:
#Text=To identify a brain-based predictor of cocaine abstinence using a recently developed machine learning approach, connectome-based predictive modeling (CPM).
1-1	0-16	Connectome-based	_	
1-2	17-27	prediction	_	
1-3	28-30	of	_	
1-4	31-38	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[1]	
1-5	39-49	abstinence	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[1]	
1-6	50-59	Objective	_	
1-7	59-60	:	_	
1-8	61-63	To	_	
1-9	64-72	identify	_	
1-10	73-74	a	_	
1-11	75-86	brain-based	_	
1-12	87-96	predictor	_	
1-13	97-99	of	_	
1-14	100-107	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[2]	
1-15	108-118	abstinence	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[2]	
1-16	119-124	using	_	
1-17	125-126	a	_	
1-18	127-135	recently	_	
1-19	136-145	developed	_	
1-20	146-153	machine	_	
1-21	154-162	learning	_	
1-22	163-171	approach	_	
1-23	171-172	,	_	
1-24	173-189	connectome-based	_	
1-25	190-200	predictive	_	
1-26	201-209	modeling	_	
1-27	210-211	(	_	
1-28	211-214	CPM	_	
1-29	214-215	)	_	
1-30	215-216	.	_	

#Text=CPM is a predictive tool and a method of identifying networks that underlie specific behaviors (‘neural fingerprints’).
2-1	217-220	CPM	_	
2-2	221-223	is	_	
2-3	224-225	a	_	
2-4	226-236	predictive	_	
2-5	237-241	tool	_	
2-6	242-245	and	_	
2-7	246-247	a	_	
2-8	248-254	method	_	
2-9	255-257	of	_	
2-10	258-269	identifying	_	
2-11	270-278	networks	_	
2-12	279-283	that	_	
2-13	284-292	underlie	_	
2-14	293-301	specific	_	
2-15	302-311	behaviors	_	
2-16	312-313	(	_	
2-17	313-314	‘	_	
2-18	314-320	neural	_	
2-19	321-333	fingerprints	_	
2-20	333-334	’	_	
2-21	334-335	)	_	
2-22	335-336	.	_	

#Text=Methods:
#Text=Fifty-three individuals participated in neuroimaging protocols at the start of treatment for cocaine-use disorder, and again at the end of 12-week treatment.
3-1	337-344	Methods	_	
3-2	344-345	:	_	
3-3	346-357	Fifty-three	_	
3-4	358-369	individuals	_	
3-5	370-382	participated	_	
3-6	383-385	in	_	
3-7	386-398	neuroimaging	_	
3-8	399-408	protocols	_	
3-9	409-411	at	_	
3-10	412-415	the	_	
3-11	416-421	start	_	
3-12	422-424	of	_	
3-13	425-434	treatment	_	
3-14	435-438	for	_	
3-15	439-450	cocaine-use	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[3]	
3-16	451-459	disorder	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[3]	
3-17	459-460	,	_	
3-18	461-464	and	_	
3-19	465-470	again	_	
3-20	471-473	at	_	
3-21	474-477	the	_	
3-22	478-481	end	_	
3-23	482-484	of	_	
3-24	485-487	12	_	
3-25	487-488	-	_	
3-26	488-492	week	_	
3-27	493-502	treatment	_	
3-28	502-503	.	_	

#Text=CPM with leave-one-out cross-validation was run to identify pre-treatment networks that predicted abstinence (percent cocaine-negative urines during treatment).
4-1	504-507	CPM	_	
4-2	508-512	with	_	
4-3	513-526	leave-one-out	_	
4-4	527-543	cross-validation	_	
4-5	544-547	was	_	
4-6	548-551	run	_	
4-7	552-554	to	_	
4-8	555-563	identify	_	
4-9	564-577	pre-treatment	_	
4-10	578-586	networks	_	
4-11	587-591	that	_	
4-12	592-601	predicted	_	
4-13	602-612	abstinence	_	
4-14	613-614	(	_	
4-15	614-621	percent	_	
4-16	622-638	cocaine-negative	_	
4-17	639-645	urines	_	
4-18	646-652	during	_	
4-19	653-662	treatment	_	
4-20	662-663	)	_	
4-21	663-664	.	_	

#Text=Networks were applied to post-treatment fMRI data to assess changes over time and ability to predict abstinence during follow-up.
5-1	665-673	Networks	_	
5-2	674-678	were	_	
5-3	679-686	applied	_	
5-4	687-689	to	_	
5-5	690-704	post-treatment	_	
5-6	705-709	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
5-7	710-714	data	_	
5-8	715-717	to	_	
5-9	718-724	assess	_	
5-10	725-732	changes	_	
5-11	733-737	over	_	
5-12	738-742	time	_	
5-13	743-746	and	_	
5-14	747-754	ability	_	
5-15	755-757	to	_	
5-16	758-765	predict	_	
5-17	766-776	abstinence	_	
5-18	777-783	during	_	
5-19	784-793	follow-up	_	
5-20	793-794	.	_	

#Text=The predictive ability of identified networks was then tested in separate, heterogeneous sample of individuals scanned prior to treatment for cocaine use disorder (n=45).
6-1	795-798	The	_	
6-2	799-809	predictive	_	
6-3	810-817	ability	_	
6-4	818-820	of	_	
6-5	821-831	identified	_	
6-6	832-840	networks	_	
6-7	841-844	was	_	
6-8	845-849	then	_	
6-9	850-856	tested	_	
6-10	857-859	in	_	
6-11	860-868	separate	_	
6-12	868-869	,	_	
6-13	870-883	heterogeneous	_	
6-14	884-890	sample	_	
6-15	891-893	of	_	
6-16	894-905	individuals	_	
6-17	906-913	scanned	_	
6-18	914-919	prior	_	
6-19	920-922	to	_	
6-20	923-932	treatment	_	
6-21	933-936	for	_	
6-22	937-944	cocaine	_	
6-23	945-948	use	_	
6-24	949-957	disorder	_	
6-25	958-959	(	_	
6-26	959-960	n	_	
6-27	960-961	=	_	
6-28	961-963	45	_	
6-29	963-964	)	_	
6-30	964-965	.	_	

#Text=Results:
#Text=CPM predicted abstinence during treatment, as indicated by a high correspondence between predicted and actual abstinence values (r(df=52)=0.42, p=0.001).
7-1	966-973	Results	_	
7-2	973-974	:	_	
7-3	975-978	CPM	_	
7-4	979-988	predicted	_	
7-5	989-999	abstinence	_	
7-6	1000-1006	during	_	
7-7	1007-1016	treatment	_	
7-8	1016-1017	,	_	
7-9	1018-1020	as	_	
7-10	1021-1030	indicated	_	
7-11	1031-1033	by	_	
7-12	1034-1035	a	_	
7-13	1036-1040	high	_	
7-14	1041-1055	correspondence	_	
7-15	1056-1063	between	_	
7-16	1064-1073	predicted	_	
7-17	1074-1077	and	_	
7-18	1078-1084	actual	_	
7-19	1085-1095	abstinence	_	
7-20	1096-1102	values	_	
7-21	1103-1104	(	_	
7-22	1104-1105	r	_	
7-23	1105-1106	(	_	
7-24	1106-1108	df	_	
7-25	1108-1109	=	_	
7-26	1109-1111	52	_	
7-27	1111-1112	)	_	
7-28	1112-1113	=	_	
7-29	1113-1117	0.42	_	
7-30	1117-1118	,	_	
7-31	1119-1120	p	_	
7-32	1120-1121	=	_	
7-33	1121-1126	0.001	_	
7-34	1126-1127	)	_	
7-35	1127-1128	.	_	

#Text=Identified networks included connections within and between canonical networks implicated in cognitive/ executive control (frontoparietal, medial frontal) and in reward responsiveness (subcortical, salience, motor/sensory).
8-1	1129-1139	Identified	_	
8-2	1140-1148	networks	_	
8-3	1149-1157	included	_	
8-4	1158-1169	connections	_	
8-5	1170-1176	within	_	
8-6	1177-1180	and	_	
8-7	1181-1188	between	_	
8-8	1189-1198	canonical	_	
8-9	1199-1207	networks	_	
8-10	1208-1218	implicated	_	
8-11	1219-1221	in	_	
8-12	1222-1231	cognitive	_	
8-13	1231-1232	/	_	
8-14	1233-1242	executive	_	
8-15	1243-1250	control	_	
8-16	1251-1252	(	_	
8-17	1252-1266	frontoparietal	_	
8-18	1266-1267	,	_	
8-19	1268-1274	medial	_	
8-20	1275-1282	frontal	_	
8-21	1282-1283	)	_	
8-22	1284-1287	and	_	
8-23	1288-1290	in	_	
8-24	1291-1297	reward	_	
8-25	1298-1312	responsiveness	_	
8-26	1313-1314	(	_	
8-27	1314-1325	subcortical	_	
8-28	1325-1326	,	_	
8-29	1327-1335	salience	_	
8-30	1335-1336	,	_	
8-31	1337-1342	motor	_	
8-32	1342-1343	/	_	
8-33	1343-1350	sensory	_	
8-34	1350-1351	)	_	
8-35	1351-1352	.	_	

#Text=Connectivity strength did not change with treatment, and strength at post-treatment also predicted abstinence during follow-up (r(df=39)=0.34, p=0.03).
9-1	1353-1365	Connectivity	_	
9-2	1366-1374	strength	_	
9-3	1375-1378	did	_	
9-4	1379-1382	not	_	
9-5	1383-1389	change	_	
9-6	1390-1394	with	_	
9-7	1395-1404	treatment	_	
9-8	1404-1405	,	_	
9-9	1406-1409	and	_	
9-10	1410-1418	strength	_	
9-11	1419-1421	at	_	
9-12	1422-1436	post-treatment	_	
9-13	1437-1441	also	_	
9-14	1442-1451	predicted	_	
9-15	1452-1462	abstinence	_	
9-16	1463-1469	during	_	
9-17	1470-1479	follow-up	_	
9-18	1480-1481	(	_	
9-19	1481-1482	r	_	
9-20	1482-1483	(	_	
9-21	1483-1485	df	_	
9-22	1485-1486	=	_	
9-23	1486-1488	39	_	
9-24	1488-1489	)	_	
9-25	1489-1490	=	_	
9-26	1490-1494	0.34	_	
9-27	1494-1495	,	_	
9-28	1496-1497	p	_	
9-29	1497-1498	=	_	
9-30	1498-1502	0.03	_	
9-31	1502-1503	)	_	
9-32	1503-1504	.	_	

#Text=Network strength in the independent sample predicted treatment response with 64% accuracy by itself, and with 71% accuracy when combined with baseline cocaine-use.
10-1	1505-1512	Network	_	
10-2	1513-1521	strength	_	
10-3	1522-1524	in	_	
10-4	1525-1528	the	_	
10-5	1529-1540	independent	_	
10-6	1541-1547	sample	_	
10-7	1548-1557	predicted	_	
10-8	1558-1567	treatment	_	
10-9	1568-1576	response	_	
10-10	1577-1581	with	_	
10-11	1582-1585	64%	_	
10-12	1586-1594	accuracy	_	
10-13	1595-1597	by	_	
10-14	1598-1604	itself	_	
10-15	1604-1605	,	_	
10-16	1606-1609	and	_	
10-17	1610-1614	with	_	
10-18	1615-1618	71%	_	
10-19	1619-1627	accuracy	_	
10-20	1628-1632	when	_	
10-21	1633-1641	combined	_	
10-22	1642-1646	with	_	
10-23	1647-1655	baseline	_	
10-24	1656-1667	cocaine-use	_	
10-25	1667-1668	.	_	

#Text=Conclusions:
#Text=These data demonstrate that individual differences in large-scale neural networks contribute to variability in treatment outcomes for cocaine use disorder.
11-1	1669-1680	Conclusions	_	
11-2	1680-1681	:	_	
11-3	1682-1687	These	_	
11-4	1688-1692	data	_	
11-5	1693-1704	demonstrate	_	
11-6	1705-1709	that	_	
11-7	1710-1720	individual	_	
11-8	1721-1732	differences	_	
11-9	1733-1735	in	_	
11-10	1736-1747	large-scale	_	
11-11	1748-1754	neural	_	
11-12	1755-1763	networks	_	
11-13	1764-1774	contribute	_	
11-14	1775-1777	to	_	
11-15	1778-1789	variability	_	
11-16	1790-1792	in	_	
11-17	1793-1802	treatment	_	
11-18	1803-1811	outcomes	_	
11-19	1812-1815	for	_	
11-20	1816-1823	cocaine	_	
11-21	1824-1827	use	_	
11-22	1828-1836	disorder	_	
11-23	1836-1837	.	_	

#Text=They identify specific abstinence networks that may be targeted in novel interventions.
12-1	1838-1842	They	_	
12-2	1843-1851	identify	_	
12-3	1852-1860	specific	_	
12-4	1861-1871	abstinence	_	
12-5	1872-1880	networks	_	
12-6	1881-1885	that	_	
12-7	1886-1889	may	_	
12-8	1890-1892	be	_	
12-9	1893-1901	targeted	_	
12-10	1902-1904	in	_	
12-11	1905-1910	novel	_	
12-12	1911-1924	interventions	_	
12-13	1924-1925	.	_	

#Text=Introduction
#Text=Addictions are a leading cause of disability worldwide.
13-1	1926-1938	Introduction	_	
13-2	1939-1949	Addictions	_	
13-3	1950-1953	are	_	
13-4	1954-1955	a	_	
13-5	1956-1963	leading	_	
13-6	1964-1969	cause	_	
13-7	1970-1972	of	_	
13-8	1973-1983	disability	_	
13-9	1984-1993	worldwide	_	
13-10	1993-1994	.	_	

#Text=Despite advances, the effectiveness of most substance-use interventions remains highly variable across individuals and multiple quit-attempts are standard.
14-1	1995-2002	Despite	_	
14-2	2003-2011	advances	_	
14-3	2011-2012	,	_	
14-4	2013-2016	the	_	
14-5	2017-2030	effectiveness	_	
14-6	2031-2033	of	_	
14-7	2034-2038	most	_	
14-8	2039-2052	substance-use	_	
14-9	2053-2066	interventions	_	
14-10	2067-2074	remains	_	
14-11	2075-2081	highly	_	
14-12	2082-2090	variable	_	
14-13	2091-2097	across	_	
14-14	2098-2109	individuals	_	
14-15	2110-2113	and	_	
14-16	2114-2122	multiple	_	
14-17	2123-2136	quit-attempts	_	
14-18	2137-2140	are	_	
14-19	2141-2149	standard	_	
14-20	2149-2150	.	_	

#Text=While a growing body of research suggests that variability in treatment response is linked to individual differences in neural functioning, the search for brain-based predictors has yet to yield a reliable indicator of future treatment response or abstinence.
15-1	2151-2156	While	_	
15-2	2157-2158	a	_	
15-3	2159-2166	growing	_	
15-4	2167-2171	body	_	
15-5	2172-2174	of	_	
15-6	2175-2183	research	_	
15-7	2184-2192	suggests	_	
15-8	2193-2197	that	_	
15-9	2198-2209	variability	_	
15-10	2210-2212	in	_	
15-11	2213-2222	treatment	_	
15-12	2223-2231	response	_	
15-13	2232-2234	is	_	
15-14	2235-2241	linked	_	
15-15	2242-2244	to	_	
15-16	2245-2255	individual	_	
15-17	2256-2267	differences	_	
15-18	2268-2270	in	_	
15-19	2271-2277	neural	_	
15-20	2278-2289	functioning	_	
15-21	2289-2290	,	_	
15-22	2291-2294	the	_	
15-23	2295-2301	search	_	
15-24	2302-2305	for	_	
15-25	2306-2317	brain-based	_	
15-26	2318-2328	predictors	_	
15-27	2329-2332	has	_	
15-28	2333-2336	yet	_	
15-29	2337-2339	to	_	
15-30	2340-2345	yield	_	
15-31	2346-2347	a	_	
15-32	2348-2356	reliable	_	
15-33	2357-2366	indicator	_	
15-34	2367-2369	of	_	
15-35	2370-2376	future	_	
15-36	2377-2386	treatment	_	
15-37	2387-2395	response	_	
15-38	2396-2398	or	_	
15-39	2399-2409	abstinence	_	
15-40	2409-2410	.	_	

#Text=Identification of brain-based predictors of abstinence may not only expand existing biological knowledge of addictions pathophysiology (which may itself be used to refine existing interventions), but may ultimately be used to directly inform real-world clinical practice via assignment of patients to therapies based on individual patterns of neural function; i.e., neuromarkers.
16-1	2411-2425	Identification	_	
16-2	2426-2428	of	_	
16-3	2429-2440	brain-based	_	
16-4	2441-2451	predictors	_	
16-5	2452-2454	of	_	
16-6	2455-2465	abstinence	_	
16-7	2466-2469	may	_	
16-8	2470-2473	not	_	
16-9	2474-2478	only	_	
16-10	2479-2485	expand	_	
16-11	2486-2494	existing	_	
16-12	2495-2505	biological	_	
16-13	2506-2515	knowledge	_	
16-14	2516-2518	of	_	
16-15	2519-2529	addictions	_	
16-16	2530-2545	pathophysiology	_	
16-17	2546-2547	(	_	
16-18	2547-2552	which	_	
16-19	2553-2556	may	_	
16-20	2557-2563	itself	_	
16-21	2564-2566	be	_	
16-22	2567-2571	used	_	
16-23	2572-2574	to	_	
16-24	2575-2581	refine	_	
16-25	2582-2590	existing	_	
16-26	2591-2604	interventions	_	
16-27	2604-2605	)	_	
16-28	2605-2606	,	_	
16-29	2607-2610	but	_	
16-30	2611-2614	may	_	
16-31	2615-2625	ultimately	_	
16-32	2626-2628	be	_	
16-33	2629-2633	used	_	
16-34	2634-2636	to	_	
16-35	2637-2645	directly	_	
16-36	2646-2652	inform	_	
16-37	2653-2663	real-world	_	
16-38	2664-2672	clinical	_	
16-39	2673-2681	practice	_	
16-40	2682-2685	via	_	
16-41	2686-2696	assignment	_	
16-42	2697-2699	of	_	
16-43	2700-2708	patients	_	
16-44	2709-2711	to	_	
16-45	2712-2721	therapies	_	
16-46	2722-2727	based	_	
16-47	2728-2730	on	_	
16-48	2731-2741	individual	_	
16-49	2742-2750	patterns	_	
16-50	2751-2753	of	_	
16-51	2754-2760	neural	_	
16-52	2761-2769	function	_	
16-53	2769-2770	;	_	
16-54	2771-2774	i.e	_	
16-55	2774-2775	.	_	
16-56	2775-2776	,	_	
16-57	2777-2789	neuromarkers	_	
16-58	2789-2790	.	_	

#Text=In most cases, treatment-oriented neuroimaging studies in addiction, and other disorders, rely on prospective associations, where the term ‘predicts’ is often inaccurately used to refer to correlation or regression.
17-1	2791-2793	In	_	
17-2	2794-2798	most	_	
17-3	2799-2804	cases	_	
17-4	2804-2805	,	_	
17-5	2806-2824	treatment-oriented	_	
17-6	2825-2837	neuroimaging	_	
17-7	2838-2845	studies	_	
17-8	2846-2848	in	_	
17-9	2849-2858	addiction	_	
17-10	2858-2859	,	_	
17-11	2860-2863	and	_	
17-12	2864-2869	other	_	
17-13	2870-2879	disorders	_	
17-14	2879-2880	,	_	
17-15	2881-2885	rely	_	
17-16	2886-2888	on	_	
17-17	2889-2900	prospective	_	
17-18	2901-2913	associations	_	
17-19	2913-2914	,	_	
17-20	2915-2920	where	_	
17-21	2921-2924	the	_	
17-22	2925-2929	term	_	
17-23	2930-2931	‘	_	
17-24	2931-2939	predicts	_	
17-25	2939-2940	’	_	
17-26	2941-2943	is	_	
17-27	2944-2949	often	_	
17-28	2950-2962	inaccurately	_	
17-29	2963-2967	used	_	
17-30	2968-2970	to	_	
17-31	2971-2976	refer	_	
17-32	2977-2979	to	_	
17-33	2980-2991	correlation	_	
17-34	2992-2994	or	_	
17-35	2995-3005	regression	_	
17-36	3005-3006	.	_	

#Text=However, true predictive models require application of the model to novel data.
18-1	3007-3014	However	_	
18-2	3014-3015	,	_	
18-3	3016-3020	true	_	
18-4	3021-3031	predictive	_	
18-5	3032-3038	models	_	
18-6	3039-3046	require	_	
18-7	3047-3058	application	_	
18-8	3059-3061	of	_	
18-9	3062-3065	the	_	
18-10	3066-3071	model	_	
18-11	3072-3074	to	_	
18-12	3075-3080	novel	_	
18-13	3081-3085	data	_	
18-14	3085-3086	.	_	

#Text=Newly available alternatives such as machine-learning allow for actual prediction, but have not yet been used to identify pre-treatment predictors of abstinence.
19-1	3087-3092	Newly	_	
19-2	3093-3102	available	_	
19-3	3103-3115	alternatives	_	
19-4	3116-3120	such	_	
19-5	3121-3123	as	_	
19-6	3124-3140	machine-learning	_	
19-7	3141-3146	allow	_	
19-8	3147-3150	for	_	
19-9	3151-3157	actual	_	
19-10	3158-3168	prediction	_	
19-11	3168-3169	,	_	
19-12	3170-3173	but	_	
19-13	3174-3178	have	_	
19-14	3179-3182	not	_	
19-15	3183-3186	yet	_	
19-16	3187-3191	been	_	
19-17	3192-3196	used	_	
19-18	3197-3199	to	_	
19-19	3200-3208	identify	_	
19-20	3209-3222	pre-treatment	_	
19-21	3223-3233	predictors	_	
19-22	3234-3236	of	_	
19-23	3237-3247	abstinence	_	
19-24	3247-3248	.	_	

#Text=Nonetheless, prior research indicates that alterations within well-established neural networks – e.g., frontoparietal, salience, default mode – likely contribute to individual differences in treatment outcomes for cocaine-use disorder.
20-1	3249-3260	Nonetheless	_	
20-2	3260-3261	,	_	
20-3	3262-3267	prior	_	
20-4	3268-3276	research	_	
20-5	3277-3286	indicates	_	
20-6	3287-3291	that	_	
20-7	3292-3303	alterations	_	
20-8	3304-3310	within	_	
20-9	3311-3327	well-established	_	
20-10	3328-3334	neural	_	
20-11	3335-3343	networks	_	
20-12	3344-3345	–	_	
20-13	3346-3349	e.g	_	
20-14	3349-3350	.	_	
20-15	3350-3351	,	_	
20-16	3352-3366	frontoparietal	_	
20-17	3366-3367	,	_	
20-18	3368-3376	salience	_	
20-19	3376-3377	,	_	
20-20	3378-3385	default	_	
20-21	3386-3390	mode	_	
20-22	3391-3392	–	_	
20-23	3393-3399	likely	_	
20-24	3400-3410	contribute	_	
20-25	3411-3413	to	_	
20-26	3414-3424	individual	_	
20-27	3425-3436	differences	_	
20-28	3437-3439	in	_	
20-29	3440-3449	treatment	_	
20-30	3450-3458	outcomes	_	
20-31	3459-3462	for	_	
20-32	3463-3474	cocaine-use	_	
20-33	3475-3483	disorder	_	
20-34	3483-3484	.	_	

#Text=For example, functional connectivity strength between the medial prefrontal cortex and temporal pole, when combined with years of education, has been identified as a predictor of relapse.
21-1	3485-3488	For	_	
21-2	3489-3496	example	_	
21-3	3496-3497	,	_	
21-4	3498-3508	functional	_	
21-5	3509-3521	connectivity	_	
21-6	3522-3530	strength	_	
21-7	3531-3538	between	_	
21-8	3539-3542	the	_	
21-9	3543-3549	medial	_	
21-10	3550-3560	prefrontal	_	
21-11	3561-3567	cortex	_	
21-12	3568-3571	and	_	
21-13	3572-3580	temporal	_	
21-14	3581-3585	pole	_	
21-15	3585-3586	,	_	
21-16	3587-3591	when	_	
21-17	3592-3600	combined	_	
21-18	3601-3605	with	_	
21-19	3606-3611	years	_	
21-20	3612-3614	of	_	
21-21	3615-3624	education	_	
21-22	3624-3625	,	_	
21-23	3626-3629	has	_	
21-24	3630-3634	been	_	
21-25	3635-3645	identified	_	
21-26	3646-3648	as	_	
21-27	3649-3650	a	_	
21-28	3651-3660	predictor	_	
21-29	3661-3663	of	_	
21-30	3664-3671	relapse	_	
21-31	3671-3672	.	_	

#Text=However, no prior study has used a whole-brain, machine learning approach to identify neuromarkers of future abstinence.
22-1	3673-3680	However	_	
22-2	3680-3681	,	_	
22-3	3682-3684	no	_	
22-4	3685-3690	prior	_	
22-5	3691-3696	study	_	
22-6	3697-3700	has	_	
22-7	3701-3705	used	_	
22-8	3706-3707	a	_	
22-9	3708-3719	whole-brain	_	
22-10	3719-3720	,	_	
22-11	3721-3728	machine	_	
22-12	3729-3737	learning	_	
22-13	3738-3746	approach	_	
22-14	3747-3749	to	_	
22-15	3750-3758	identify	_	
22-16	3759-3771	neuromarkers	_	
22-17	3772-3774	of	_	
22-18	3775-3781	future	_	
22-19	3782-3792	abstinence	_	
22-20	3792-3793	.	_	

#Text=Connectome-based predictive modeling (CPM) is a machine learning approach for generating brain-behavior models from whole-brain, functional connectivity data (‘connectomes’).
23-1	3794-3810	Connectome-based	_	
23-2	3811-3821	predictive	_	
23-3	3822-3830	modeling	_	
23-4	3831-3832	(	_	
23-5	3832-3835	CPM	_	
23-6	3835-3836	)	_	
23-7	3837-3839	is	_	
23-8	3840-3841	a	_	
23-9	3842-3849	machine	_	
23-10	3850-3858	learning	_	
23-11	3859-3867	approach	_	
23-12	3868-3871	for	_	
23-13	3872-3882	generating	_	
23-14	3883-3897	brain-behavior	_	
23-15	3898-3904	models	_	
23-16	3905-3909	from	_	
23-17	3910-3921	whole-brain	_	
23-18	3921-3922	,	_	
23-19	3923-3933	functional	_	
23-20	3934-3946	connectivity	_	
23-21	3947-3951	data	_	
23-22	3952-3953	(	_	
23-23	3953-3954	‘	_	
23-24	3954-3965	connectomes	_	
23-25	3965-3966	’	_	
23-26	3966-3967	)	_	
23-27	3967-3968	.	_	

#Text=Unlike correlation or regression models, CPM with built-in cross validation protects against over-fitting by testing the strength of the relationship in a novel sample, increasing the likelihood of replication in future studies and thus the applicability to other clinical samples.
24-1	3969-3975	Unlike	_	
24-2	3976-3987	correlation	_	
24-3	3988-3990	or	_	
24-4	3991-4001	regression	_	
24-5	4002-4008	models	_	
24-6	4008-4009	,	_	
24-7	4010-4013	CPM	_	
24-8	4014-4018	with	_	
24-9	4019-4027	built-in	_	
24-10	4028-4033	cross	_	
24-11	4034-4044	validation	_	
24-12	4045-4053	protects	_	
24-13	4054-4061	against	_	
24-14	4062-4074	over-fitting	_	
24-15	4075-4077	by	_	
24-16	4078-4085	testing	_	
24-17	4086-4089	the	_	
24-18	4090-4098	strength	_	
24-19	4099-4101	of	_	
24-20	4102-4105	the	_	
24-21	4106-4118	relationship	_	
24-22	4119-4121	in	_	
24-23	4122-4123	a	_	
24-24	4124-4129	novel	_	
24-25	4130-4136	sample	_	
24-26	4136-4137	,	_	
24-27	4138-4148	increasing	_	
24-28	4149-4152	the	_	
24-29	4153-4163	likelihood	_	
24-30	4164-4166	of	_	
24-31	4167-4178	replication	_	
24-32	4179-4181	in	_	
24-33	4182-4188	future	_	
24-34	4189-4196	studies	_	
24-35	4197-4200	and	_	
24-36	4201-4205	thus	_	
24-37	4206-4209	the	_	
24-38	4210-4223	applicability	_	
24-39	4224-4226	to	_	
24-40	4227-4232	other	_	
24-41	4233-4241	clinical	_	
24-42	4242-4249	samples	_	
24-43	4249-4250	.	_	

#Text=Unlike other machine-learning approaches previously employed to study addictions, CPM is entirely data-driven and requires no a priori selection of networks.
25-1	4251-4257	Unlike	_	
25-2	4258-4263	other	_	
25-3	4264-4280	machine-learning	_	
25-4	4281-4291	approaches	_	
25-5	4292-4302	previously	_	
25-6	4303-4311	employed	_	
25-7	4312-4314	to	_	
25-8	4315-4320	study	_	
25-9	4321-4331	addictions	_	
25-10	4331-4332	,	_	
25-11	4333-4336	CPM	_	
25-12	4337-4339	is	_	
25-13	4340-4348	entirely	_	
25-14	4349-4360	data-driven	_	
25-15	4361-4364	and	_	
25-16	4365-4373	requires	_	
25-17	4374-4376	no	_	
25-18	4377-4378	a	_	
25-19	4379-4385	priori	_	
25-20	4386-4395	selection	_	
25-21	4396-4398	of	_	
25-22	4399-4407	networks	_	
25-23	4407-4408	.	_	

#Text=It is therefore both a predictive tool as well as a method of identifying networks that subserve specific behaviors – referred to as ‘neural fingerprints’ – and thus may also be used to identify novel treatment targets.
26-1	4409-4411	It	_	
26-2	4412-4414	is	_	
26-3	4415-4424	therefore	_	
26-4	4425-4429	both	_	
26-5	4430-4431	a	_	
26-6	4432-4442	predictive	_	
26-7	4443-4447	tool	_	
26-8	4448-4450	as	_	
26-9	4451-4455	well	_	
26-10	4456-4458	as	_	
26-11	4459-4460	a	_	
26-12	4461-4467	method	_	
26-13	4468-4470	of	_	
26-14	4471-4482	identifying	_	
26-15	4483-4491	networks	_	
26-16	4492-4496	that	_	
26-17	4497-4505	subserve	_	
26-18	4506-4514	specific	_	
26-19	4515-4524	behaviors	_	
26-20	4525-4526	–	_	
26-21	4527-4535	referred	_	
26-22	4536-4538	to	_	
26-23	4539-4541	as	_	
26-24	4542-4543	‘	_	
26-25	4543-4549	neural	_	
26-26	4550-4562	fingerprints	_	
26-27	4562-4563	’	_	
26-28	4564-4565	–	_	
26-29	4566-4569	and	_	
26-30	4570-4574	thus	_	
26-31	4575-4578	may	_	
26-32	4579-4583	also	_	
26-33	4584-4586	be	_	
26-34	4587-4591	used	_	
26-35	4592-4594	to	_	
26-36	4595-4603	identify	_	
26-37	4604-4609	novel	_	
26-38	4610-4619	treatment	_	
26-39	4620-4627	targets	_	
26-40	4627-4628	.	_	

#Text=CPM has previously been used to identify neural fingerprints of IQ and attention using whole-brain functional connectivity data acquired during neurocognitive task performance, but has not been previously used to predict future behaviors or a clinical outcome.
27-1	4629-4632	CPM	_	
27-2	4633-4636	has	_	
27-3	4637-4647	previously	_	
27-4	4648-4652	been	_	
27-5	4653-4657	used	_	
27-6	4658-4660	to	_	
27-7	4661-4669	identify	_	
27-8	4670-4676	neural	_	
27-9	4677-4689	fingerprints	_	
27-10	4690-4692	of	_	
27-11	4693-4695	IQ	_	
27-12	4696-4699	and	_	
27-13	4700-4709	attention	_	
27-14	4710-4715	using	_	
27-15	4716-4727	whole-brain	_	
27-16	4728-4738	functional	_	
27-17	4739-4751	connectivity	_	
27-18	4752-4756	data	_	
27-19	4757-4765	acquired	_	
27-20	4766-4772	during	_	
27-21	4773-4787	neurocognitive	_	
27-22	4788-4792	task	_	
27-23	4793-4804	performance	_	
27-24	4804-4805	,	_	
27-25	4806-4809	but	_	
27-26	4810-4813	has	_	
27-27	4814-4817	not	_	
27-28	4818-4822	been	_	
27-29	4823-4833	previously	_	
27-30	4834-4838	used	_	
27-31	4839-4841	to	_	
27-32	4842-4849	predict	_	
27-33	4850-4856	future	_	
27-34	4857-4866	behaviors	_	
27-35	4867-4869	or	_	
27-36	4870-4871	a	_	
27-37	4872-4880	clinical	_	
27-38	4881-4888	outcome	_	
27-39	4888-4889	.	_	

#Text=Here, we use dimensional CPM to identify neural networks predictive of future abstinence from cocaine by applying CPM to fMRI reward task data acquired at the start of a 12-week treatment for cocaine-use-disorder.
28-1	4890-4894	Here	_	
28-2	4894-4895	,	_	
28-3	4896-4898	we	_	
28-4	4899-4902	use	_	
28-5	4903-4914	dimensional	_	
28-6	4915-4918	CPM	_	
28-7	4919-4921	to	_	
28-8	4922-4930	identify	_	
28-9	4931-4937	neural	_	
28-10	4938-4946	networks	_	
28-11	4947-4957	predictive	_	
28-12	4958-4960	of	_	
28-13	4961-4967	future	_	
28-14	4968-4978	abstinence	_	
28-15	4979-4983	from	_	
28-16	4984-4991	cocaine	_	
28-17	4992-4994	by	_	
28-18	4995-5003	applying	_	
28-19	5004-5007	CPM	_	
28-20	5008-5010	to	_	
28-21	5011-5015	fMRI	_	
28-22	5016-5022	reward	_	
28-23	5023-5027	task	_	
28-24	5028-5032	data	_	
28-25	5033-5041	acquired	_	
28-26	5042-5044	at	_	
28-27	5045-5048	the	_	
28-28	5049-5054	start	_	
28-29	5055-5057	of	_	
28-30	5058-5059	a	_	
28-31	5060-5062	12	_	
28-32	5062-5063	-	_	
28-33	5063-5067	week	_	
28-34	5068-5077	treatment	_	
28-35	5078-5081	for	_	
28-36	5082-5102	cocaine-use-disorder	_	
28-37	5102-5103	.	_	

#Text=We further test the stability of these networks over time and in relation to post-treatment abstinence.
29-1	5104-5106	We	_	
29-2	5107-5114	further	_	
29-3	5115-5119	test	_	
29-4	5120-5123	the	_	
29-5	5124-5133	stability	_	
29-6	5134-5136	of	_	
29-7	5137-5142	these	_	
29-8	5143-5151	networks	_	
29-9	5152-5156	over	_	
29-10	5157-5161	time	_	
29-11	5162-5165	and	_	
29-12	5166-5168	in	_	
29-13	5169-5177	relation	_	
29-14	5178-5180	to	_	
29-15	5181-5195	post-treatment	_	
29-16	5196-5206	abstinence	_	
29-17	5206-5207	.	_	

#Text=Finally, we test the ability of identified networks to predict treatment response in a heterogeneous replication sample.
30-1	5208-5215	Finally	_	
30-2	5215-5216	,	_	
30-3	5217-5219	we	_	
30-4	5220-5224	test	_	
30-5	5225-5228	the	_	
30-6	5229-5236	ability	_	
30-7	5237-5239	of	_	
30-8	5240-5250	identified	_	
30-9	5251-5259	networks	_	
30-10	5260-5262	to	_	
30-11	5263-5270	predict	_	
30-12	5271-5280	treatment	_	
30-13	5281-5289	response	_	
30-14	5290-5292	in	_	
30-15	5293-5294	a	_	
30-16	5295-5308	heterogeneous	_	
30-17	5309-5320	replication	_	
30-18	5321-5327	sample	_	
30-19	5327-5328	.	_	

#Text=Based on prior work focusing on selected networks, we hypothesized that increased connectivity within- and between medial frontal, frontoparietal and salience networks would positively predict abstinence.
31-1	5329-5334	Based	_	
31-2	5335-5337	on	_	
31-3	5338-5343	prior	_	
31-4	5344-5348	work	_	
31-5	5349-5357	focusing	_	
31-6	5358-5360	on	_	
31-7	5361-5369	selected	_	
31-8	5370-5378	networks	_	
31-9	5378-5379	,	_	
31-10	5380-5382	we	_	
31-11	5383-5395	hypothesized	_	
31-12	5396-5400	that	_	
31-13	5401-5410	increased	_	
31-14	5411-5423	connectivity	_	
31-15	5424-5430	within	_	
31-16	5430-5431	-	_	
31-17	5432-5435	and	_	
31-18	5436-5443	between	_	
31-19	5444-5450	medial	_	
31-20	5451-5458	frontal	_	
31-21	5458-5459	,	_	
31-22	5460-5474	frontoparietal	_	
31-23	5475-5478	and	_	
31-24	5479-5487	salience	_	
31-25	5488-5496	networks	_	
31-26	5497-5502	would	_	
31-27	5503-5513	positively	_	
31-28	5514-5521	predict	_	
31-29	5522-5532	abstinence	_	
31-30	5532-5533	.	_	

#Text=Methods
#Text=Participants and recruitment
#Text=Participants (n=74) were recruited from a randomized controlled trial of behavioral therapy plus galantamine or placebo treatment for cocaine-use disorder.
32-1	5534-5541	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod	
32-2	5542-5554	Participants	_	
32-3	5555-5558	and	_	
32-4	5559-5570	recruitment	_	
32-5	5571-5583	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
32-6	5584-5585	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
32-7	5585-5586	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
32-8	5586-5587	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
32-9	5587-5589	74	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
32-10	5589-5590	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
32-11	5591-5595	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
32-12	5596-5605	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
32-13	5606-5610	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
32-14	5611-5612	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
32-15	5613-5623	randomized	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
32-16	5624-5634	controlled	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
32-17	5635-5640	trial	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
32-18	5641-5643	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
32-19	5644-5654	behavioral	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
32-20	5655-5662	therapy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
32-21	5663-5667	plus	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
32-22	5668-5679	galantamine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
32-23	5680-5682	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
32-24	5683-5690	placebo	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
32-25	5691-5700	treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
32-26	5701-5704	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
32-27	5705-5716	cocaine-use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[5]	
32-28	5717-5725	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[5]	
32-29	5725-5726	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	

#Text=Demographic and clinical characteristics are shown in Table 1.
33-1	5727-5738	Demographic	_	
33-2	5739-5742	and	_	
33-3	5743-5751	clinical	_	
33-4	5752-5767	characteristics	_	
33-5	5768-5771	are	_	
33-6	5772-5777	shown	_	
33-7	5778-5780	in	_	
33-8	5781-5786	Table	_	
33-9	5787-5788	1	_	
33-10	5788-5789	.	_	

#Text=In addition to seeking treatment for cocaine, all participants were currently enrolled in methadone maintenance treatment for opioid-use disorder.
34-1	5790-5792	In	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-2	5793-5801	addition	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-3	5802-5804	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-4	5805-5812	seeking	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-5	5813-5822	treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-6	5823-5826	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-7	5827-5834	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-8	5834-5835	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-9	5836-5839	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-10	5840-5852	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-11	5853-5857	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-12	5858-5867	currently	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-13	5868-5876	enrolled	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-14	5877-5879	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-15	5880-5889	methadone	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-16	5890-5901	maintenance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-17	5902-5911	treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-18	5912-5915	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-19	5916-5926	opioid-use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-20	5927-5935	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
34-21	5935-5936	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	

#Text=Consistent with the parent trial, the fMRI sample was predominantly male (63.5%) and unemployed (73.0%), with multiple prior treatment attempts (outpatient: 2.97± 3.63, inpatient: 3.16±5.24) and legal problems (lifetime arrests: 5.46±6.29).
35-1	5937-5947	Consistent	_	
35-2	5948-5952	with	_	
35-3	5953-5956	the	_	
35-4	5957-5963	parent	_	
35-5	5964-5969	trial	_	
35-6	5969-5970	,	_	
35-7	5971-5974	the	_	
35-8	5975-5979	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
35-9	5980-5986	sample	_	
35-10	5987-5990	was	_	
35-11	5991-6004	predominantly	_	
35-12	6005-6009	male	_	
35-13	6010-6011	(	_	
35-14	6011-6016	63.5%	_	
35-15	6016-6017	)	_	
35-16	6018-6021	and	_	
35-17	6022-6032	unemployed	_	
35-18	6033-6034	(	_	
35-19	6034-6039	73.0%	_	
35-20	6039-6040	)	_	
35-21	6040-6041	,	_	
35-22	6042-6046	with	_	
35-23	6047-6055	multiple	_	
35-24	6056-6061	prior	_	
35-25	6062-6071	treatment	_	
35-26	6072-6080	attempts	_	
35-27	6081-6082	(	_	
35-28	6082-6092	outpatient	_	
35-29	6092-6093	:	_	
35-30	6094-6098	2.97	_	
35-31	6098-6099	±	_	
35-32	6100-6104	3.63	_	
35-33	6104-6105	,	_	
35-34	6106-6115	inpatient	_	
35-35	6115-6116	:	_	
35-36	6117-6121	3.16	_	
35-37	6121-6122	±	_	
35-38	6122-6126	5.24	_	
35-39	6126-6127	)	_	
35-40	6128-6131	and	_	
35-41	6132-6137	legal	_	
35-42	6138-6146	problems	_	
35-43	6147-6148	(	_	
35-44	6148-6156	lifetime	_	
35-45	6157-6164	arrests	_	
35-46	6164-6165	:	_	
35-47	6166-6170	5.46	_	
35-48	6170-6171	±	_	
35-49	6171-6175	6.29	_	
35-50	6175-6176	)	_	
35-51	6176-6177	.	_	

#Text=Following exclusion of individuals with incomplete data (n=4) or excessive motion during scanning (n=17; further details below), the final sample used for CPM analyses consisted of 53 individuals (73.6% male).
36-1	6178-6187	Following	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
36-2	6188-6197	exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
36-3	6198-6200	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
36-4	6201-6212	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
36-5	6213-6217	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
36-6	6218-6228	incomplete	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
36-7	6229-6233	data	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
36-8	6234-6235	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
36-9	6235-6236	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
36-10	6236-6237	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
36-11	6237-6238	4	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
36-12	6238-6239	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
36-13	6240-6242	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
36-14	6243-6252	excessive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
36-15	6253-6259	motion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
36-16	6260-6266	during	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
36-17	6267-6275	scanning	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
36-18	6276-6277	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
36-19	6277-6278	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
36-20	6278-6279	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
36-21	6279-6281	17	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
36-22	6281-6282	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
36-23	6283-6290	further	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
36-24	6291-6298	details	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
36-25	6299-6304	below	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
36-26	6304-6305	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
36-27	6305-6306	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
36-28	6307-6310	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
36-29	6311-6316	final	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
36-30	6317-6323	sample	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
36-31	6324-6328	used	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
36-32	6329-6332	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
36-33	6333-6336	CPM	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
36-34	6337-6345	analyses	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
36-35	6346-6355	consisted	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
36-36	6356-6358	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
36-37	6359-6361	53	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
36-38	6362-6373	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
36-39	6374-6375	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
36-40	6375-6380	73.6%	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
36-41	6381-6385	male	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
36-42	6385-6386	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
36-43	6386-6387	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	

#Text=Further details on motion controls and follow-up analyses controlling for time of scanning are provided in the Supplemental Materials.
37-1	6388-6395	Further	_	
37-2	6396-6403	details	_	
37-3	6404-6406	on	_	
37-4	6407-6413	motion	_	
37-5	6414-6422	controls	_	
37-6	6423-6426	and	_	
37-7	6427-6436	follow-up	_	
37-8	6437-6445	analyses	_	
37-9	6446-6457	controlling	_	
37-10	6458-6461	for	_	
37-11	6462-6466	time	_	
37-12	6467-6469	of	_	
37-13	6470-6478	scanning	_	
37-14	6479-6482	are	_	
37-15	6483-6491	provided	_	
37-16	6492-6494	in	_	
37-17	6495-6498	the	_	
37-18	6499-6511	Supplemental	_	
37-19	6512-6521	Materials	_	
37-20	6521-6522	.	_	

#Text=As shown in Table 1, included versus excluded participants did not differ in years of cocaine-use, treatment assignment or other clinical variables with the exception of sex (p=.004).
38-1	6523-6525	As	_	
38-2	6526-6531	shown	_	
38-3	6532-6534	in	_	
38-4	6535-6540	Table	_	
38-5	6541-6542	1	_	
38-6	6542-6543	,	_	
38-7	6544-6552	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
38-8	6553-6559	versus	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
38-9	6560-6568	excluded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
38-10	6569-6581	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
38-11	6582-6585	did	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
38-12	6586-6589	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
38-13	6590-6596	differ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
38-14	6597-6599	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
38-15	6600-6605	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
38-16	6606-6608	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
38-17	6609-6620	cocaine-use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
38-18	6620-6621	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
38-19	6622-6631	treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
38-20	6632-6642	assignment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
38-21	6643-6645	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
38-22	6646-6651	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
38-23	6652-6660	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
38-24	6661-6670	variables	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
38-25	6671-6675	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
38-26	6676-6679	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
38-27	6680-6689	exception	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
38-28	6690-6692	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
38-29	6693-6696	sex	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
38-30	6697-6698	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
38-31	6698-6699	p	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
38-32	6699-6700	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
38-33	6700-6704	.004	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
38-34	6704-6705	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
38-35	6705-6706	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	

#Text=As in our prior work, abstinence during treatment was determined based on results of biweekly urine testing and defined as the percentage of urines negative for cocaine provided during treatment.
39-1	6707-6709	As	_	
39-2	6710-6712	in	_	
39-3	6713-6716	our	_	
39-4	6717-6722	prior	_	
39-5	6723-6727	work	_	
39-6	6727-6728	,	_	
39-7	6729-6739	abstinence	_	
39-8	6740-6746	during	_	
39-9	6747-6756	treatment	_	
39-10	6757-6760	was	_	
39-11	6761-6771	determined	_	
39-12	6772-6777	based	_	
39-13	6778-6780	on	_	
39-14	6781-6788	results	_	
39-15	6789-6791	of	_	
39-16	6792-6800	biweekly	_	
39-17	6801-6806	urine	_	
39-18	6807-6814	testing	_	
39-19	6815-6818	and	_	
39-20	6819-6826	defined	_	
39-21	6827-6829	as	_	
39-22	6830-6833	the	_	
39-23	6834-6844	percentage	_	
39-24	6845-6847	of	_	
39-25	6848-6854	urines	_	
39-26	6855-6863	negative	_	
39-27	6864-6867	for	_	
39-28	6868-6875	cocaine	_	
39-29	6876-6884	provided	_	
39-30	6885-6891	during	_	
39-31	6892-6901	treatment	_	
39-32	6901-6902	.	_	

#Text=All participants provided written informed consent following a complete description of study procedures.
40-1	6903-6906	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
40-2	6907-6919	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
40-3	6920-6928	provided	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
40-4	6929-6936	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
40-5	6937-6945	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
40-6	6946-6953	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
40-7	6954-6963	following	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
40-8	6964-6965	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
40-9	6966-6974	complete	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
40-10	6975-6986	description	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
40-11	6987-6989	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
40-12	6990-6995	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
40-13	6996-7006	procedures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
40-14	7006-7007	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	

#Text=Neuroimaging data acquisition
#Text=fMRI data were acquired during performance of a well-validated Monetary Incentive Delay task (Supplemental Figure 1; details on acquisition in Supplemental Materials).
41-1	7008-7020	Neuroimaging	_	
41-2	7021-7025	data	_	
41-3	7026-7037	acquisition	_	
41-4	7038-7042	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
41-5	7043-7047	data	_	
41-6	7048-7052	were	_	
41-7	7053-7061	acquired	_	
41-8	7062-7068	during	_	
41-9	7069-7080	performance	_	
41-10	7081-7083	of	_	
41-11	7084-7085	a	_	
41-12	7086-7100	well-validated	_	
41-13	7101-7109	Monetary	_	
41-14	7110-7119	Incentive	_	
41-15	7120-7125	Delay	_	
41-16	7126-7130	task	_	
41-17	7131-7132	(	_	
41-18	7132-7144	Supplemental	_	
41-19	7145-7151	Figure	_	
41-20	7152-7153	1	_	
41-21	7153-7154	;	_	
41-22	7155-7162	details	_	
41-23	7163-7165	on	_	
41-24	7166-7177	acquisition	_	
41-25	7178-7180	in	_	
41-26	7181-7193	Supplemental	_	
41-27	7194-7203	Materials	_	
41-28	7203-7204	)	_	
41-29	7204-7205	.	_	

#Text=Preprocessing was conducted using SPM8 and the BioImage Suite and is described in the Supplemental Materials.
42-1	7206-7219	Preprocessing	_	
42-2	7220-7223	was	_	
42-3	7224-7233	conducted	_	
42-4	7234-7239	using	_	
42-5	7240-7244	SPM8	_	
42-6	7245-7248	and	_	
42-7	7249-7252	the	_	
42-8	7253-7261	BioImage	_	
42-9	7262-7267	Suite	_	
42-10	7268-7271	and	_	
42-11	7272-7274	is	_	
42-12	7275-7284	described	_	
42-13	7285-7287	in	_	
42-14	7288-7291	the	_	
42-15	7292-7304	Supplemental	_	
42-16	7305-7314	Materials	_	
42-17	7314-7315	.	_	

#Text=Functional connectivity
#Text=Whole-brain functional connectivity analyses were conducted using the BioImage suite, using previously described methods.
43-1	7316-7326	Functional	_	
43-2	7327-7339	connectivity	_	
43-3	7340-7351	Whole-brain	_	
43-4	7352-7362	functional	_	
43-5	7363-7375	connectivity	_	
43-6	7376-7384	analyses	_	
43-7	7385-7389	were	_	
43-8	7390-7399	conducted	_	
43-9	7400-7405	using	_	
43-10	7406-7409	the	_	
43-11	7410-7418	BioImage	_	
43-12	7419-7424	suite	_	
43-13	7424-7425	,	_	
43-14	7426-7431	using	_	
43-15	7432-7442	previously	_	
43-16	7443-7452	described	_	
43-17	7453-7460	methods	_	
43-18	7460-7461	.	_	

#Text=Network nodes were defined using the Shen 268-node brain atlas which includes the cortex, subcortex and cerebellum, as in other prior CPM work (further details in Supplemental Materials).
44-1	7462-7469	Network	_	
44-2	7470-7475	nodes	_	
44-3	7476-7480	were	_	
44-4	7481-7488	defined	_	
44-5	7489-7494	using	_	
44-6	7495-7498	the	_	
44-7	7499-7503	Shen	_	
44-8	7504-7507	268	_	
44-9	7507-7508	-	_	
44-10	7508-7512	node	_	
44-11	7513-7518	brain	_	
44-12	7519-7524	atlas	_	
44-13	7525-7530	which	_	
44-14	7531-7539	includes	_	
44-15	7540-7543	the	_	
44-16	7544-7550	cortex	_	
44-17	7550-7551	,	_	
44-18	7552-7561	subcortex	_	
44-19	7562-7565	and	_	
44-20	7566-7576	cerebellum	_	
44-21	7576-7577	,	_	
44-22	7578-7580	as	_	
44-23	7581-7583	in	_	
44-24	7584-7589	other	_	
44-25	7590-7595	prior	_	
44-26	7596-7599	CPM	_	
44-27	7600-7604	work	_	
44-28	7605-7606	(	_	
44-29	7606-7613	further	_	
44-30	7614-7621	details	_	
44-31	7622-7624	in	_	
44-32	7625-7637	Supplemental	_	
44-33	7638-7647	Materials	_	
44-34	7647-7648	)	_	
44-35	7648-7649	.	_	

#Text=Task connectivity was calculated based on the ‘raw’ task timecourses, with no regression of task-evoked activity.
45-1	7650-7654	Task	_	
45-2	7655-7667	connectivity	_	
45-3	7668-7671	was	_	
45-4	7672-7682	calculated	_	
45-5	7683-7688	based	_	
45-6	7689-7691	on	_	
45-7	7692-7695	the	_	
45-8	7696-7697	‘	_	
45-9	7697-7700	raw	_	
45-10	7700-7701	’	_	
45-11	7702-7706	task	_	
45-12	7707-7718	timecourses	_	
45-13	7718-7719	,	_	
45-14	7720-7724	with	_	
45-15	7725-7727	no	_	
45-16	7728-7738	regression	_	
45-17	7739-7741	of	_	
45-18	7742-7753	task-evoked	_	
45-19	7754-7762	activity	_	
45-20	7762-7763	.	_	

#Text=This involved computation of mean time courses for each of the 268 nodes (i.e., average time course of voxels within the node) for use in node-by-node pairwise Pearson’s correlations.
46-1	7764-7768	This	_	
46-2	7769-7777	involved	_	
46-3	7778-7789	computation	_	
46-4	7790-7792	of	_	
46-5	7793-7797	mean	_	
46-6	7798-7802	time	_	
46-7	7803-7810	courses	_	
46-8	7811-7814	for	_	
46-9	7815-7819	each	_	
46-10	7820-7822	of	_	
46-11	7823-7826	the	_	
46-12	7827-7830	268	_	
46-13	7831-7836	nodes	_	
46-14	7837-7838	(	_	
46-15	7838-7841	i.e	_	
46-16	7841-7842	.	_	
46-17	7842-7843	,	_	
46-18	7844-7851	average	_	
46-19	7852-7856	time	_	
46-20	7857-7863	course	_	
46-21	7864-7866	of	_	
46-22	7867-7873	voxels	_	
46-23	7874-7880	within	_	
46-24	7881-7884	the	_	
46-25	7885-7889	node	_	
46-26	7889-7890	)	_	
46-27	7891-7894	for	_	
46-28	7895-7898	use	_	
46-29	7899-7901	in	_	
46-30	7902-7914	node-by-node	_	
46-31	7915-7923	pairwise	_	
46-32	7924-7931	Pearson	_	
46-33	7931-7932	’	_	
46-34	7932-7933	s	_	
46-35	7934-7946	correlations	_	
46-36	7946-7947	.	_	

#Text=Resultant r-values were transformed using Fisher’s z-transformation to create symmetric 268x268 connectivity matrices in which each element of the matrix represents the strength of connection between two individual nodes (hereafter referred to as an edge).
47-1	7948-7957	Resultant	_	
47-2	7958-7966	r-values	_	
47-3	7967-7971	were	_	
47-4	7972-7983	transformed	_	
47-5	7984-7989	using	_	
47-6	7990-7996	Fisher	_	
47-7	7996-7997	’	_	
47-8	7997-7998	s	_	
47-9	7999-8015	z-transformation	_	
47-10	8016-8018	to	_	
47-11	8019-8025	create	_	
47-12	8026-8035	symmetric	_	
47-13	8036-8043	268x268	_	
47-14	8044-8056	connectivity	_	
47-15	8057-8065	matrices	_	
47-16	8066-8068	in	_	
47-17	8069-8074	which	_	
47-18	8075-8079	each	_	
47-19	8080-8087	element	_	
47-20	8088-8090	of	_	
47-21	8091-8094	the	_	
47-22	8095-8101	matrix	_	
47-23	8102-8112	represents	_	
47-24	8113-8116	the	_	
47-25	8117-8125	strength	_	
47-26	8126-8128	of	_	
47-27	8129-8139	connection	_	
47-28	8140-8147	between	_	
47-29	8148-8151	two	_	
47-30	8152-8162	individual	_	
47-31	8163-8168	nodes	_	
47-32	8169-8170	(	_	
47-33	8170-8179	hereafter	_	
47-34	8180-8188	referred	_	
47-35	8189-8191	to	_	
47-36	8192-8194	as	_	
47-37	8195-8197	an	_	
47-38	8198-8202	edge	_	
47-39	8202-8203	)	_	
47-40	8203-8204	.	_	

#Text=Connectome-based predictive modeling (CPM)
#Text=CPM was conducted using previously validated custom MATLAB scripts.
48-1	8205-8221	Connectome-based	_	
48-2	8222-8232	predictive	_	
48-3	8233-8241	modeling	_	
48-4	8242-8243	(	_	
48-5	8243-8246	CPM	_	
48-6	8246-8247	)	_	
48-7	8248-8251	CPM	_	
48-8	8252-8255	was	_	
48-9	8256-8265	conducted	_	
48-10	8266-8271	using	_	
48-11	8272-8282	previously	_	
48-12	8283-8292	validated	_	
48-13	8293-8299	custom	_	
48-14	8300-8306	MATLAB	_	
48-15	8307-8314	scripts	_	
48-16	8314-8315	.	_	

#Text=A schematic diagram of CPM is shown in Supplemental Figure 2.
49-1	8316-8317	A	_	
49-2	8318-8327	schematic	_	
49-3	8328-8335	diagram	_	
49-4	8336-8338	of	_	
49-5	8339-8342	CPM	_	
49-6	8343-8345	is	_	
49-7	8346-8351	shown	_	
49-8	8352-8354	in	_	
49-9	8355-8367	Supplemental	_	
49-10	8368-8374	Figure	_	
49-11	8375-8376	2	_	
49-12	8376-8377	.	_	

#Text=Briefly, CPM takes group connectivity matrices and behavioral data (in this case, percentage of cocaine-negative urines during treatment) as input to generate a predictive model of the behavioral data from connectivity matrices.
50-1	8378-8385	Briefly	_	
50-2	8385-8386	,	_	
50-3	8387-8390	CPM	_	
50-4	8391-8396	takes	_	
50-5	8397-8402	group	_	
50-6	8403-8415	connectivity	_	
50-7	8416-8424	matrices	_	
50-8	8425-8428	and	_	
50-9	8429-8439	behavioral	_	
50-10	8440-8444	data	_	
50-11	8445-8446	(	_	
50-12	8446-8448	in	_	
50-13	8449-8453	this	_	
50-14	8454-8458	case	_	
50-15	8458-8459	,	_	
50-16	8460-8470	percentage	_	
50-17	8471-8473	of	_	
50-18	8474-8490	cocaine-negative	_	
50-19	8491-8497	urines	_	
50-20	8498-8504	during	_	
50-21	8505-8514	treatment	_	
50-22	8514-8515	)	_	
50-23	8516-8518	as	_	
50-24	8519-8524	input	_	
50-25	8525-8527	to	_	
50-26	8528-8536	generate	_	
50-27	8537-8538	a	_	
50-28	8539-8549	predictive	_	
50-29	8550-8555	model	_	
50-30	8556-8558	of	_	
50-31	8559-8562	the	_	
50-32	8563-8573	behavioral	_	
50-33	8574-8578	data	_	
50-34	8579-8583	from	_	
50-35	8584-8596	connectivity	_	
50-36	8597-8605	matrices	_	
50-37	8605-8606	.	_	

#Text=Edges and behavioral data from the training dataset are correlated using regression analyses (here using either Pearson’s correlation or partial correlation) to identify positive and negative predictive networks.
51-1	8607-8612	Edges	_	
51-2	8613-8616	and	_	
51-3	8617-8627	behavioral	_	
51-4	8628-8632	data	_	
51-5	8633-8637	from	_	
51-6	8638-8641	the	_	
51-7	8642-8650	training	_	
51-8	8651-8658	dataset	_	
51-9	8659-8662	are	_	
51-10	8663-8673	correlated	_	
51-11	8674-8679	using	_	
51-12	8680-8690	regression	_	
51-13	8691-8699	analyses	_	
51-14	8700-8701	(	_	
51-15	8701-8705	here	_	
51-16	8706-8711	using	_	
51-17	8712-8718	either	_	
51-18	8719-8726	Pearson	_	
51-19	8726-8727	’	_	
51-20	8727-8728	s	_	
51-21	8729-8740	correlation	_	
51-22	8741-8743	or	_	
51-23	8744-8751	partial	_	
51-24	8752-8763	correlation	_	
51-25	8763-8764	)	_	
51-26	8765-8767	to	_	
51-27	8768-8776	identify	_	
51-28	8777-8785	positive	_	
51-29	8786-8789	and	_	
51-30	8790-8798	negative	_	
51-31	8799-8809	predictive	_	
51-32	8810-8818	networks	_	
51-33	8818-8819	.	_	

#Text=Positive networks are networks for which increased edge weights (increased connectivity) are associated with the variable of interest, whereas negative networks are networks for which decreased edge weights (decreased connectivity) are associated with the variable of interest.
52-1	8820-8828	Positive	_	
52-2	8829-8837	networks	_	
52-3	8838-8841	are	_	
52-4	8842-8850	networks	_	
52-5	8851-8854	for	_	
52-6	8855-8860	which	_	
52-7	8861-8870	increased	_	
52-8	8871-8875	edge	_	
52-9	8876-8883	weights	_	
52-10	8884-8885	(	_	
52-11	8885-8894	increased	_	
52-12	8895-8907	connectivity	_	
52-13	8907-8908	)	_	
52-14	8909-8912	are	_	
52-15	8913-8923	associated	_	
52-16	8924-8928	with	_	
52-17	8929-8932	the	_	
52-18	8933-8941	variable	_	
52-19	8942-8944	of	_	
52-20	8945-8953	interest	_	
52-21	8953-8954	,	_	
52-22	8955-8962	whereas	_	
52-23	8963-8971	negative	_	
52-24	8972-8980	networks	_	
52-25	8981-8984	are	_	
52-26	8985-8993	networks	_	
52-27	8994-8997	for	_	
52-28	8998-9003	which	_	
52-29	9004-9013	decreased	_	
52-30	9014-9018	edge	_	
52-31	9019-9026	weights	_	
52-32	9027-9028	(	_	
52-33	9028-9037	decreased	_	
52-34	9038-9050	connectivity	_	
52-35	9050-9051	)	_	
52-36	9052-9055	are	_	
52-37	9056-9066	associated	_	
52-38	9067-9071	with	_	
52-39	9072-9075	the	_	
52-40	9076-9084	variable	_	
52-41	9085-9087	of	_	
52-42	9088-9096	interest	_	
52-43	9096-9097	.	_	

#Text=While both networks are used for predicting the same variable, they are by definition independent - as a single edge cannot be both a positive and negative predictor.
53-1	9098-9103	While	_	
53-2	9104-9108	both	_	
53-3	9109-9117	networks	_	
53-4	9118-9121	are	_	
53-5	9122-9126	used	_	
53-6	9127-9130	for	_	
53-7	9131-9141	predicting	_	
53-8	9142-9145	the	_	
53-9	9146-9150	same	_	
53-10	9151-9159	variable	_	
53-11	9159-9160	,	_	
53-12	9161-9165	they	_	
53-13	9166-9169	are	_	
53-14	9170-9172	by	_	
53-15	9173-9183	definition	_	
53-16	9184-9195	independent	_	
53-17	9196-9197	-	_	
53-18	9198-9200	as	_	
53-19	9201-9202	a	_	
53-20	9203-9209	single	_	
53-21	9210-9214	edge	_	
53-22	9215-9221	cannot	_	
53-23	9222-9224	be	_	
53-24	9225-9229	both	_	
53-25	9230-9231	a	_	
53-26	9232-9240	positive	_	
53-27	9241-9244	and	_	
53-28	9245-9253	negative	_	
53-29	9254-9263	predictor	_	
53-30	9263-9264	.	_	

#Text=Single subject summary statistics are then created as the sum of the significant edge weights in each network and entered into predictive models assuming linear relationships with behavioral data.
54-1	9265-9271	Single	_	
54-2	9272-9279	subject	_	
54-3	9280-9287	summary	_	
54-4	9288-9298	statistics	_	
54-5	9299-9302	are	_	
54-6	9303-9307	then	_	
54-7	9308-9315	created	_	
54-8	9316-9318	as	_	
54-9	9319-9322	the	_	
54-10	9323-9326	sum	_	
54-11	9327-9329	of	_	
54-12	9330-9333	the	_	
54-13	9334-9345	significant	_	
54-14	9346-9350	edge	_	
54-15	9351-9358	weights	_	
54-16	9359-9361	in	_	
54-17	9362-9366	each	_	
54-18	9367-9374	network	_	
54-19	9375-9378	and	_	
54-20	9379-9386	entered	_	
54-21	9387-9391	into	_	
54-22	9392-9402	predictive	_	
54-23	9403-9409	models	_	
54-24	9410-9418	assuming	_	
54-25	9419-9425	linear	_	
54-26	9426-9439	relationships	_	
54-27	9440-9444	with	_	
54-28	9445-9455	behavioral	_	
54-29	9456-9460	data	_	
54-30	9460-9461	.	_	

#Text=Resultant polynomial coefficients (linear equation including slope and intercept) are then applied to the test dataset to predict behaviors.
55-1	9462-9471	Resultant	_	
55-2	9472-9482	polynomial	_	
55-3	9483-9495	coefficients	_	
55-4	9496-9497	(	_	
55-5	9497-9503	linear	_	
55-6	9504-9512	equation	_	
55-7	9513-9522	including	_	
55-8	9523-9528	slope	_	
55-9	9529-9532	and	_	
55-10	9533-9542	intercept	_	
55-11	9542-9543	)	_	
55-12	9544-9547	are	_	
55-13	9548-9552	then	_	
55-14	9553-9560	applied	_	
55-15	9561-9563	to	_	
55-16	9564-9567	the	_	
55-17	9568-9572	test	_	
55-18	9573-9580	dataset	_	
55-19	9581-9583	to	_	
55-20	9584-9591	predict	_	
55-21	9592-9601	behaviors	_	
55-22	9601-9602	.	_	

#Text=In the case of leave-one-out cross-validation (used here), a single participant’s predicted value (i.e., the ‘left-out’ participant) is generated by taking the data from all other participants as the training dataset in an iterative manner until all participants have a predicted value.
56-1	9603-9605	In	_	
56-2	9606-9609	the	_	
56-3	9610-9614	case	_	
56-4	9615-9617	of	_	
56-5	9618-9631	leave-one-out	_	
56-6	9632-9648	cross-validation	_	
56-7	9649-9650	(	_	
56-8	9650-9654	used	_	
56-9	9655-9659	here	_	
56-10	9659-9660	)	_	
56-11	9660-9661	,	_	
56-12	9662-9663	a	_	
56-13	9664-9670	single	_	
56-14	9671-9682	participant	_	
56-15	9682-9683	’	_	
56-16	9683-9684	s	_	
56-17	9685-9694	predicted	_	
56-18	9695-9700	value	_	
56-19	9701-9702	(	_	
56-20	9702-9705	i.e	_	
56-21	9705-9706	.	_	
56-22	9706-9707	,	_	
56-23	9708-9711	the	_	
56-24	9712-9713	‘	_	
56-25	9713-9721	left-out	_	
56-26	9721-9722	’	_	
56-27	9723-9734	participant	_	
56-28	9734-9735	)	_	
56-29	9736-9738	is	_	
56-30	9739-9748	generated	_	
56-31	9749-9751	by	_	
56-32	9752-9758	taking	_	
56-33	9759-9762	the	_	
56-34	9763-9767	data	_	
56-35	9768-9772	from	_	
56-36	9773-9776	all	_	
56-37	9777-9782	other	_	
56-38	9783-9795	participants	_	
56-39	9796-9798	as	_	
56-40	9799-9802	the	_	
56-41	9803-9811	training	_	
56-42	9812-9819	dataset	_	
56-43	9820-9822	in	_	
56-44	9823-9825	an	_	
56-45	9826-9835	iterative	_	
56-46	9836-9842	manner	_	
56-47	9843-9848	until	_	
56-48	9849-9852	all	_	
56-49	9853-9865	participants	_	
56-50	9866-9870	have	_	
56-51	9871-9872	a	_	
56-52	9873-9882	predicted	_	
56-53	9883-9888	value	_	
56-54	9888-9889	.	_	

#Text=Model performance (i.e., correspondence between predicted and actual values) was assessed using Spearman’s rho correlations.
57-1	9890-9895	Model	_	
57-2	9896-9907	performance	_	
57-3	9908-9909	(	_	
57-4	9909-9912	i.e	_	
57-5	9912-9913	.	_	
57-6	9913-9914	,	_	
57-7	9915-9929	correspondence	_	
57-8	9930-9937	between	_	
57-9	9938-9947	predicted	_	
57-10	9948-9951	and	_	
57-11	9952-9958	actual	_	
57-12	9959-9965	values	_	
57-13	9965-9966	)	_	
57-14	9967-9970	was	_	
57-15	9971-9979	assessed	_	
57-16	9980-9985	using	_	
57-17	9986-9994	Spearman	_	
57-18	9994-9995	’	_	
57-19	9995-9996	s	_	
57-20	9997-10000	rho	_	
57-21	10001-10013	correlations	_	
57-22	10013-10014	.	_	

#Text=When using leave-one-out cross-validation, analyses in the leave-one-out folds are not wholly independent and the number of degrees of freedom is thus overestimated for parametric p-values based on correlation.
58-1	10015-10019	When	_	
58-2	10020-10025	using	_	
58-3	10026-10039	leave-one-out	_	
58-4	10040-10056	cross-validation	_	
58-5	10056-10057	,	_	
58-6	10058-10066	analyses	_	
58-7	10067-10069	in	_	
58-8	10070-10073	the	_	
58-9	10074-10087	leave-one-out	_	
58-10	10088-10093	folds	_	
58-11	10094-10097	are	_	
58-12	10098-10101	not	_	
58-13	10102-10108	wholly	_	
58-14	10109-10120	independent	_	
58-15	10121-10124	and	_	
58-16	10125-10128	the	_	
58-17	10129-10135	number	_	
58-18	10136-10138	of	_	
58-19	10139-10146	degrees	_	
58-20	10147-10149	of	_	
58-21	10150-10157	freedom	_	
58-22	10158-10160	is	_	
58-23	10161-10165	thus	_	
58-24	10166-10179	overestimated	_	
58-25	10180-10183	for	_	
58-26	10184-10194	parametric	_	
58-27	10195-10203	p-values	_	
58-28	10204-10209	based	_	
58-29	10210-10212	on	_	
58-30	10213-10224	correlation	_	
58-31	10224-10225	.	_	

#Text=Instead of parametric testing, we therefore performed permutation testing.
59-1	10226-10233	Instead	_	
59-2	10234-10236	of	_	
59-3	10237-10247	parametric	_	
59-4	10248-10255	testing	_	
59-5	10255-10256	,	_	
59-6	10257-10259	we	_	
59-7	10260-10269	therefore	_	
59-8	10270-10279	performed	_	
59-9	10280-10291	permutation	_	
59-10	10292-10299	testing	_	
59-11	10299-10300	.	_	

#Text=To generate null distributions for significance testing, we randomly shuffled the correspondence between behavior variables and connectivity matrices 5,000 times and re-ran the CPM analysis with the shuffled data.
60-1	10301-10303	To	_	
60-2	10304-10312	generate	_	
60-3	10313-10317	null	_	
60-4	10318-10331	distributions	_	
60-5	10332-10335	for	_	
60-6	10336-10348	significance	_	
60-7	10349-10356	testing	_	
60-8	10356-10357	,	_	
60-9	10358-10360	we	_	
60-10	10361-10369	randomly	_	
60-11	10370-10378	shuffled	_	
60-12	10379-10382	the	_	
60-13	10383-10397	correspondence	_	
60-14	10398-10405	between	_	
60-15	10406-10414	behavior	_	
60-16	10415-10424	variables	_	
60-17	10425-10428	and	_	
60-18	10429-10441	connectivity	_	
60-19	10442-10450	matrices	_	
60-20	10451-10456	5,000	_	
60-21	10457-10462	times	_	
60-22	10463-10466	and	_	
60-23	10467-10473	re-ran	_	
60-24	10474-10477	the	_	
60-25	10478-10481	CPM	_	
60-26	10482-10490	analysis	_	
60-27	10491-10495	with	_	
60-28	10496-10499	the	_	
60-29	10500-10508	shuffled	_	
60-30	10509-10513	data	_	
60-31	10513-10514	.	_	

#Text=Based on these null distributions, the p-values for leave-one-out predictions were calculated as in prior work.
61-1	10515-10520	Based	_	
61-2	10521-10523	on	_	
61-3	10524-10529	these	_	
61-4	10530-10534	null	_	
61-5	10535-10548	distributions	_	
61-6	10548-10549	,	_	
61-7	10550-10553	the	_	
61-8	10554-10562	p-values	_	
61-9	10563-10566	for	_	
61-10	10567-10580	leave-one-out	_	
61-11	10581-10592	predictions	_	
61-12	10593-10597	were	_	
61-13	10598-10608	calculated	_	
61-14	10609-10611	as	_	
61-15	10612-10614	in	_	
61-16	10615-10620	prior	_	
61-17	10621-10625	work	_	
61-18	10625-10626	.	_	

#Text=Details on characterization of resultant network anatomy are provided in the Supplemental Materials.
62-1	10627-10634	Details	_	
62-2	10635-10637	on	_	
62-3	10638-10654	characterization	_	
62-4	10655-10657	of	_	
62-5	10658-10667	resultant	_	
62-6	10668-10675	network	_	
62-7	10676-10683	anatomy	_	
62-8	10684-10687	are	_	
62-9	10688-10696	provided	_	
62-10	10697-10699	in	_	
62-11	10700-10703	the	_	
62-12	10704-10716	Supplemental	_	
62-13	10717-10726	Materials	_	
62-14	10726-10727	.	_	

#Text=Results
#Text=Associations between baseline variables and abstinence
#Text=Spearman’s correlation analyses indicated no significant associations between baseline clinical variables (years-of-use, past-month-use, methadone dose) and within-treatment abstinence (p’s>.05).
63-1	10728-10735	Results	_	
63-2	10736-10748	Associations	_	
63-3	10749-10756	between	_	
63-4	10757-10765	baseline	_	
63-5	10766-10775	variables	_	
63-6	10776-10779	and	_	
63-7	10780-10790	abstinence	_	
63-8	10791-10799	Spearman	_	
63-9	10799-10800	’	_	
63-10	10800-10801	s	_	
63-11	10802-10813	correlation	_	
63-12	10814-10822	analyses	_	
63-13	10823-10832	indicated	_	
63-14	10833-10835	no	_	
63-15	10836-10847	significant	_	
63-16	10848-10860	associations	_	
63-17	10861-10868	between	_	
63-18	10869-10877	baseline	_	
63-19	10878-10886	clinical	_	
63-20	10887-10896	variables	_	
63-21	10897-10898	(	_	
63-22	10898-10910	years-of-use	_	
63-23	10910-10911	,	_	
63-24	10912-10926	past-month-use	_	
63-25	10926-10927	,	_	
63-26	10928-10937	methadone	_	
63-27	10938-10942	dose	_	
63-28	10942-10943	)	_	
63-29	10944-10947	and	_	
63-30	10948-10964	within-treatment	_	
63-31	10965-10975	abstinence	_	
63-32	10976-10977	(	_	
63-33	10977-10978	p	_	
63-34	10978-10979	’	_	
63-35	10979-10980	s	_	
63-36	10980-10981	>	_	
63-37	10981-10984	.05	_	
63-38	10984-10985	)	_	
63-39	10985-10986	.	_	

#Text=For comparison with CPM findings, a machine learning analysis (i.e., support vector regression; SVR) of baseline clinical data (details in Supplemental Materials) was also conducted.
64-1	10987-10990	For	_	
64-2	10991-11001	comparison	_	
64-3	11002-11006	with	_	
64-4	11007-11010	CPM	_	
64-5	11011-11019	findings	_	
64-6	11019-11020	,	_	
64-7	11021-11022	a	_	
64-8	11023-11030	machine	_	
64-9	11031-11039	learning	_	
64-10	11040-11048	analysis	_	
64-11	11049-11050	(	_	
64-12	11050-11053	i.e	_	
64-13	11053-11054	.	_	
64-14	11054-11055	,	_	
64-15	11056-11063	support	_	
64-16	11064-11070	vector	_	
64-17	11071-11081	regression	_	
64-18	11081-11082	;	_	
64-19	11083-11086	SVR	_	
64-20	11086-11087	)	_	
64-21	11088-11090	of	_	
64-22	11091-11099	baseline	_	
64-23	11100-11108	clinical	_	
64-24	11109-11113	data	_	
64-25	11114-11115	(	_	
64-26	11115-11122	details	_	
64-27	11123-11125	in	_	
64-28	11126-11138	Supplemental	_	
64-29	11139-11148	Materials	_	
64-30	11148-11149	)	_	
64-31	11150-11153	was	_	
64-32	11154-11158	also	_	
64-33	11159-11168	conducted	_	
64-34	11168-11169	.	_	

#Text=As CPM is optimized for neuroimaging data, SVR was selected over CPM for this analysis.
65-1	11170-11172	As	_	
65-2	11173-11176	CPM	_	
65-3	11177-11179	is	_	
65-4	11180-11189	optimized	_	
65-5	11190-11193	for	_	
65-6	11194-11206	neuroimaging	_	
65-7	11207-11211	data	_	
65-8	11211-11212	,	_	
65-9	11213-11216	SVR	_	
65-10	11217-11220	was	_	
65-11	11221-11229	selected	_	
65-12	11230-11234	over	_	
65-13	11235-11238	CPM	_	
65-14	11239-11242	for	_	
65-15	11243-11247	this	_	
65-16	11248-11256	analysis	_	
65-17	11256-11257	.	_	

#Text=SVR incorporating baseline clinical variables did not predict within-treatment abstinence (p>.05).
66-1	11258-11261	SVR	_	
66-2	11262-11275	incorporating	_	
66-3	11276-11284	baseline	_	
66-4	11285-11293	clinical	_	
66-5	11294-11303	variables	_	
66-6	11304-11307	did	_	
66-7	11308-11311	not	_	
66-8	11312-11319	predict	_	
66-9	11320-11336	within-treatment	_	
66-10	11337-11347	abstinence	_	
66-11	11348-11349	(	_	
66-12	11349-11350	p	_	
66-13	11350-11351	>	_	
66-14	11351-11354	.05	_	
66-15	11354-11355	)	_	
66-16	11355-11356	.	_	

#Text=Predicting within-treatment abstinence
#Text=To control for putative effects of residual motion, CPM analyses were conducted both with and without motion as a covariate.
67-1	11357-11367	Predicting	_	
67-2	11368-11384	within-treatment	_	
67-3	11385-11395	abstinence	_	
67-4	11396-11398	To	_	
67-5	11399-11406	control	_	
67-6	11407-11410	for	_	
67-7	11411-11419	putative	_	
67-8	11420-11427	effects	_	
67-9	11428-11430	of	_	
67-10	11431-11439	residual	_	
67-11	11440-11446	motion	_	
67-12	11446-11447	,	_	
67-13	11448-11451	CPM	_	
67-14	11452-11460	analyses	_	
67-15	11461-11465	were	_	
67-16	11466-11475	conducted	_	
67-17	11476-11480	both	_	
67-18	11481-11485	with	_	
67-19	11486-11489	and	_	
67-20	11490-11497	without	_	
67-21	11498-11504	motion	_	
67-22	11505-11507	as	_	
67-23	11508-11509	a	_	
67-24	11510-11519	covariate	_	
67-25	11519-11520	.	_	

#Text=Both approaches yielded similar results (further details in Supplemental Materials).
68-1	11521-11525	Both	_	
68-2	11526-11536	approaches	_	
68-3	11537-11544	yielded	_	
68-4	11545-11552	similar	_	
68-5	11553-11560	results	_	
68-6	11561-11562	(	_	
68-7	11562-11569	further	_	
68-8	11570-11577	details	_	
68-9	11578-11580	in	_	
68-10	11581-11593	Supplemental	_	
68-11	11594-11603	Materials	_	
68-12	11603-11604	)	_	
68-13	11604-11605	.	_	

#Text=For simplicity, findings including motion as a covariate are presented here unless otherwise specified.
69-1	11606-11609	For	_	
69-2	11610-11620	simplicity	_	
69-3	11620-11621	,	_	
69-4	11622-11630	findings	_	
69-5	11631-11640	including	_	
69-6	11641-11647	motion	_	
69-7	11648-11650	as	_	
69-8	11651-11652	a	_	
69-9	11653-11662	covariate	_	
69-10	11663-11666	are	_	
69-11	11667-11676	presented	_	
69-12	11677-11681	here	_	
69-13	11682-11688	unless	_	
69-14	11689-11698	otherwise	_	
69-15	11699-11708	specified	_	
69-16	11708-11709	.	_	

#Text=The overall CPM model successfully predicted abstinence (cocaine-negative urines; Figure 1A: combined: r(df=52)=0.42, p=0.001), as did connectivity within the positive (r(df=52)=0.43, p<0.001) and negative (r(df=52)=0.40 p=0.003) networks separately.
70-1	11710-11713	The	_	
70-2	11714-11721	overall	_	
70-3	11722-11725	CPM	_	
70-4	11726-11731	model	_	
70-5	11732-11744	successfully	_	
70-6	11745-11754	predicted	_	
70-7	11755-11765	abstinence	_	
70-8	11766-11767	(	_	
70-9	11767-11783	cocaine-negative	_	
70-10	11784-11790	urines	_	
70-11	11790-11791	;	_	
70-12	11792-11798	Figure	_	
70-13	11799-11801	1A	_	
70-14	11801-11802	:	_	
70-15	11803-11811	combined	_	
70-16	11811-11812	:	_	
70-17	11813-11814	r	_	
70-18	11814-11815	(	_	
70-19	11815-11817	df	_	
70-20	11817-11818	=	_	
70-21	11818-11820	52	_	
70-22	11820-11821	)	_	
70-23	11821-11822	=	_	
70-24	11822-11826	0.42	_	
70-25	11826-11827	,	_	
70-26	11828-11829	p	_	
70-27	11829-11830	=	_	
70-28	11830-11835	0.001	_	
70-29	11835-11836	)	_	
70-30	11836-11837	,	_	
70-31	11838-11840	as	_	
70-32	11841-11844	did	_	
70-33	11845-11857	connectivity	_	
70-34	11858-11864	within	_	
70-35	11865-11868	the	_	
70-36	11869-11877	positive	_	
70-37	11878-11879	(	_	
70-38	11879-11880	r	_	
70-39	11880-11881	(	_	
70-40	11881-11883	df	_	
70-41	11883-11884	=	_	
70-42	11884-11886	52	_	
70-43	11886-11887	)	_	
70-44	11887-11888	=	_	
70-45	11888-11892	0.43	_	
70-46	11892-11893	,	_	
70-47	11894-11895	p	_	
70-48	11895-11896	<	_	
70-49	11896-11901	0.001	_	
70-50	11901-11902	)	_	
70-51	11903-11906	and	_	
70-52	11907-11915	negative	_	
70-53	11916-11917	(	_	
70-54	11917-11918	r	_	
70-55	11918-11919	(	_	
70-56	11919-11921	df	_	
70-57	11921-11922	=	_	
70-58	11922-11924	52	_	
70-59	11924-11925	)	_	
70-60	11925-11926	=	_	
70-61	11926-11930	0.40	_	
70-62	11931-11932	p	_	
70-63	11932-11933	=	_	
70-64	11933-11938	0.003	_	
70-65	11938-11939	)	_	
70-66	11940-11948	networks	_	
70-67	11949-11959	separately	_	
70-68	11959-11960	.	_	

#Text=Follow-up comparisons controlling for methadone dose, medication group (galantamine/ placebo), cocaine-use history (years of use, days of past-month use), other alcohol/drug-use, smoking status, and timing of fMRI scanning with respect to treatment initiation also successfully predicted abstinence (r’s>0.400, p’s<.003) and are presented in the Supplementary Materials.
71-1	11961-11970	Follow-up	_	
71-2	11971-11982	comparisons	_	
71-3	11983-11994	controlling	_	
71-4	11995-11998	for	_	
71-5	11999-12008	methadone	_	
71-6	12009-12013	dose	_	
71-7	12013-12014	,	_	
71-8	12015-12025	medication	_	
71-9	12026-12031	group	_	
71-10	12032-12033	(	_	
71-11	12033-12044	galantamine	_	
71-12	12044-12045	/	_	
71-13	12046-12053	placebo	_	
71-14	12053-12054	)	_	
71-15	12054-12055	,	_	
71-16	12056-12067	cocaine-use	_	
71-17	12068-12075	history	_	
71-18	12076-12077	(	_	
71-19	12077-12082	years	_	
71-20	12083-12085	of	_	
71-21	12086-12089	use	_	
71-22	12089-12090	,	_	
71-23	12091-12095	days	_	
71-24	12096-12098	of	_	
71-25	12099-12109	past-month	_	
71-26	12110-12113	use	_	
71-27	12113-12114	)	_	
71-28	12114-12115	,	_	
71-29	12116-12121	other	_	
71-30	12122-12129	alcohol	_	
71-31	12129-12130	/	_	
71-32	12130-12138	drug-use	_	
71-33	12138-12139	,	_	
71-34	12140-12147	smoking	_	
71-35	12148-12154	status	_	
71-36	12154-12155	,	_	
71-37	12156-12159	and	_	
71-38	12160-12166	timing	_	
71-39	12167-12169	of	_	
71-40	12170-12174	fMRI	_	
71-41	12175-12183	scanning	_	
71-42	12184-12188	with	_	
71-43	12189-12196	respect	_	
71-44	12197-12199	to	_	
71-45	12200-12209	treatment	_	
71-46	12210-12220	initiation	_	
71-47	12221-12225	also	_	
71-48	12226-12238	successfully	_	
71-49	12239-12248	predicted	_	
71-50	12249-12259	abstinence	_	
71-51	12260-12261	(	_	
71-52	12261-12262	r	_	
71-53	12262-12263	’	_	
71-54	12263-12264	s	_	
71-55	12264-12265	>	_	
71-56	12265-12270	0.400	_	
71-57	12270-12271	,	_	
71-58	12272-12273	p	_	
71-59	12273-12274	’	_	
71-60	12274-12275	s	_	
71-61	12275-12276	<	_	
71-62	12276-12280	.003	_	
71-63	12280-12281	)	_	
71-64	12282-12285	and	_	
71-65	12286-12289	are	_	
71-66	12290-12299	presented	_	
71-67	12300-12302	in	_	
71-68	12303-12306	the	_	
71-69	12307-12320	Supplementary	_	
71-70	12321-12330	Materials	_	
71-71	12330-12331	.	_	

#Text=Post-hoc correlations indicated significant correspondence between network strengths and other abstinence indices (e.g., percent days self-reported abstinence, maximum days of consecutive abstinence) and are provided in the Supplemental Materials.
72-1	12332-12340	Post-hoc	_	
72-2	12341-12353	correlations	_	
72-3	12354-12363	indicated	_	
72-4	12364-12375	significant	_	
72-5	12376-12390	correspondence	_	
72-6	12391-12398	between	_	
72-7	12399-12406	network	_	
72-8	12407-12416	strengths	_	
72-9	12417-12420	and	_	
72-10	12421-12426	other	_	
72-11	12427-12437	abstinence	_	
72-12	12438-12445	indices	_	
72-13	12446-12447	(	_	
72-14	12447-12450	e.g	_	
72-15	12450-12451	.	_	
72-16	12451-12452	,	_	
72-17	12453-12460	percent	_	
72-18	12461-12465	days	_	
72-19	12466-12479	self-reported	_	
72-20	12480-12490	abstinence	_	
72-21	12490-12491	,	_	
72-22	12492-12499	maximum	_	
72-23	12500-12504	days	_	
72-24	12505-12507	of	_	
72-25	12508-12519	consecutive	_	
72-26	12520-12530	abstinence	_	
72-27	12530-12531	)	_	
72-28	12532-12535	and	_	
72-29	12536-12539	are	_	
72-30	12540-12548	provided	_	
72-31	12549-12551	in	_	
72-32	12552-12555	the	_	
72-33	12556-12568	Supplemental	_	
72-34	12569-12578	Materials	_	
72-35	12578-12579	.	_	

#Text=Network anatomy
#Text=Figure 2 summarizes positive and negative abstinence networks based on connectivity between macroscale brain regions (note that brain regions are presented in approximate anatomical order, such that longer range connections are represented by longer lines).
73-1	12580-12587	Network	_	
73-2	12588-12595	anatomy	_	
73-3	12596-12602	Figure	_	
73-4	12603-12604	2	_	
73-5	12605-12615	summarizes	_	
73-6	12616-12624	positive	_	
73-7	12625-12628	and	_	
73-8	12629-12637	negative	_	
73-9	12638-12648	abstinence	_	
73-10	12649-12657	networks	_	
73-11	12658-12663	based	_	
73-12	12664-12666	on	_	
73-13	12667-12679	connectivity	_	
73-14	12680-12687	between	_	
73-15	12688-12698	macroscale	_	
73-16	12699-12704	brain	_	
73-17	12705-12712	regions	_	
73-18	12713-12714	(	_	
73-19	12714-12718	note	_	
73-20	12719-12723	that	_	
73-21	12724-12729	brain	_	
73-22	12730-12737	regions	_	
73-23	12738-12741	are	_	
73-24	12742-12751	presented	_	
73-25	12752-12754	in	_	
73-26	12755-12766	approximate	_	
73-27	12767-12777	anatomical	_	
73-28	12778-12783	order	_	
73-29	12783-12784	,	_	
73-30	12785-12789	such	_	
73-31	12790-12794	that	_	
73-32	12795-12801	longer	_	
73-33	12802-12807	range	_	
73-34	12808-12819	connections	_	
73-35	12820-12823	are	_	
73-36	12824-12835	represented	_	
73-37	12836-12838	by	_	
73-38	12839-12845	longer	_	
73-39	12846-12851	lines	_	
73-40	12851-12852	)	_	
73-41	12852-12853	.	_	

#Text=Consistent with prior CPM work, network anatomies for both networks were complex and included connections between frontal, parietal, occipital and temporal lobes.
74-1	12854-12864	Consistent	_	
74-2	12865-12869	with	_	
74-3	12870-12875	prior	_	
74-4	12876-12879	CPM	_	
74-5	12880-12884	work	_	
74-6	12884-12885	,	_	
74-7	12886-12893	network	_	
74-8	12894-12903	anatomies	_	
74-9	12904-12907	for	_	
74-10	12908-12912	both	_	
74-11	12913-12921	networks	_	
74-12	12922-12926	were	_	
74-13	12927-12934	complex	_	
74-14	12935-12938	and	_	
74-15	12939-12947	included	_	
74-16	12948-12959	connections	_	
74-17	12960-12967	between	_	
74-18	12968-12975	frontal	_	
74-19	12975-12976	,	_	
74-20	12977-12985	parietal	_	
74-21	12985-12986	,	_	
74-22	12987-12996	occipital	_	
74-23	12997-13000	and	_	
74-24	13001-13009	temporal	_	
74-25	13010-13015	lobes	_	
74-26	13015-13016	.	_	

#Text=Despite this complexity, the spatial extent of both positive and negative networks together included only 539 edges (266 positive, 263 negative), or less than 1% of possible connections.
75-1	13017-13024	Despite	_	
75-2	13025-13029	this	_	
75-3	13030-13040	complexity	_	
75-4	13040-13041	,	_	
75-5	13042-13045	the	_	
75-6	13046-13053	spatial	_	
75-7	13054-13060	extent	_	
75-8	13061-13063	of	_	
75-9	13064-13068	both	_	
75-10	13069-13077	positive	_	
75-11	13078-13081	and	_	
75-12	13082-13090	negative	_	
75-13	13091-13099	networks	_	
75-14	13100-13108	together	_	
75-15	13109-13117	included	_	
75-16	13118-13122	only	_	
75-17	13123-13126	539	_	
75-18	13127-13132	edges	_	
75-19	13133-13134	(	_	
75-20	13134-13137	266	_	
75-21	13138-13146	positive	_	
75-22	13146-13147	,	_	
75-23	13148-13151	263	_	
75-24	13152-13160	negative	_	
75-25	13160-13161	)	_	
75-26	13161-13162	,	_	
75-27	13163-13165	or	_	
75-28	13166-13170	less	_	
75-29	13171-13175	than	_	
75-30	13176-13178	1%	_	
75-31	13179-13181	of	_	
75-32	13182-13190	possible	_	
75-33	13191-13202	connections	_	
75-34	13202-13203	.	_	

#Text=Highest degree nodes (i.e., nodes with the most connections) for the positive network included a prefrontal node with connections to limbic, temporal, parietal, cerebellar and other prefrontal nodes, and a temporal node with connections to limbic, parietal, motor and prefrontal nodes.
76-1	13204-13211	Highest	_	
76-2	13212-13218	degree	_	
76-3	13219-13224	nodes	_	
76-4	13225-13226	(	_	
76-5	13226-13229	i.e	_	
76-6	13229-13230	.	_	
76-7	13230-13231	,	_	
76-8	13232-13237	nodes	_	
76-9	13238-13242	with	_	
76-10	13243-13246	the	_	
76-11	13247-13251	most	_	
76-12	13252-13263	connections	_	
76-13	13263-13264	)	_	
76-14	13265-13268	for	_	
76-15	13269-13272	the	_	
76-16	13273-13281	positive	_	
76-17	13282-13289	network	_	
76-18	13290-13298	included	_	
76-19	13299-13300	a	_	
76-20	13301-13311	prefrontal	_	
76-21	13312-13316	node	_	
76-22	13317-13321	with	_	
76-23	13322-13333	connections	_	
76-24	13334-13336	to	_	
76-25	13337-13343	limbic	_	
76-26	13343-13344	,	_	
76-27	13345-13353	temporal	_	
76-28	13353-13354	,	_	
76-29	13355-13363	parietal	_	
76-30	13363-13364	,	_	
76-31	13365-13375	cerebellar	_	
76-32	13376-13379	and	_	
76-33	13380-13385	other	_	
76-34	13386-13396	prefrontal	_	
76-35	13397-13402	nodes	_	
76-36	13402-13403	,	_	
76-37	13404-13407	and	_	
76-38	13408-13409	a	_	
76-39	13410-13418	temporal	_	
76-40	13419-13423	node	_	
76-41	13424-13428	with	_	
76-42	13429-13440	connections	_	
76-43	13441-13443	to	_	
76-44	13444-13450	limbic	_	
76-45	13450-13451	,	_	
76-46	13452-13460	parietal	_	
76-47	13460-13461	,	_	
76-48	13462-13467	motor	_	
76-49	13468-13471	and	_	
76-50	13472-13482	prefrontal	_	
76-51	13483-13488	nodes	_	
76-52	13488-13489	.	_	

#Text=Highest degree nodes for the negative network also included a temporal node with connections to limbic, parietal and prefrontal nodes, as well as with connections to cerebellar and subcortical nodes.
77-1	13490-13497	Highest	_	
77-2	13498-13504	degree	_	
77-3	13505-13510	nodes	_	
77-4	13511-13514	for	_	
77-5	13515-13518	the	_	
77-6	13519-13527	negative	_	
77-7	13528-13535	network	_	
77-8	13536-13540	also	_	
77-9	13541-13549	included	_	
77-10	13550-13551	a	_	
77-11	13552-13560	temporal	_	
77-12	13561-13565	node	_	
77-13	13566-13570	with	_	
77-14	13571-13582	connections	_	
77-15	13583-13585	to	_	
77-16	13586-13592	limbic	_	
77-17	13592-13593	,	_	
77-18	13594-13602	parietal	_	
77-19	13603-13606	and	_	
77-20	13607-13617	prefrontal	_	
77-21	13618-13623	nodes	_	
77-22	13623-13624	,	_	
77-23	13625-13627	as	_	
77-24	13628-13632	well	_	
77-25	13633-13635	as	_	
77-26	13636-13640	with	_	
77-27	13641-13652	connections	_	
77-28	13653-13655	to	_	
77-29	13656-13666	cerebellar	_	
77-30	13667-13670	and	_	
77-31	13671-13682	subcortical	_	
77-32	13683-13688	nodes	_	
77-33	13688-13689	.	_	

#Text=Both abstinence networks included short- and long-range connections.
78-1	13690-13694	Both	_	
78-2	13695-13705	abstinence	_	
78-3	13706-13714	networks	_	
78-4	13715-13723	included	_	
78-5	13724-13729	short	_	
78-6	13729-13730	-	_	
78-7	13731-13734	and	_	
78-8	13735-13745	long-range	_	
78-9	13746-13757	connections	_	
78-10	13757-13758	.	_	

#Text=However, the positive network was characterized by relatively more long-range connections (56% long-range; 44% short-range), while the negative network included more short-range connections (42% long-range; 58% short-range).
79-1	13759-13766	However	_	
79-2	13766-13767	,	_	
79-3	13768-13771	the	_	
79-4	13772-13780	positive	_	
79-5	13781-13788	network	_	
79-6	13789-13792	was	_	
79-7	13793-13806	characterized	_	
79-8	13807-13809	by	_	
79-9	13810-13820	relatively	_	
79-10	13821-13825	more	_	
79-11	13826-13836	long-range	_	
79-12	13837-13848	connections	_	
79-13	13849-13850	(	_	
79-14	13850-13853	56%	_	
79-15	13854-13864	long-range	_	
79-16	13864-13865	;	_	
79-17	13866-13869	44%	_	
79-18	13870-13881	short-range	_	
79-19	13881-13882	)	_	
79-20	13882-13883	,	_	
79-21	13884-13889	while	_	
79-22	13890-13893	the	_	
79-23	13894-13902	negative	_	
79-24	13903-13910	network	_	
79-25	13911-13919	included	_	
79-26	13920-13924	more	_	
79-27	13925-13936	short-range	_	
79-28	13937-13948	connections	_	
79-29	13949-13950	(	_	
79-30	13950-13953	42%	_	
79-31	13954-13964	long-range	_	
79-32	13964-13965	;	_	
79-33	13966-13969	58%	_	
79-34	13970-13981	short-range	_	
79-35	13981-13982	)	_	
79-36	13982-13983	.	_	

#Text=Overlap with canonical neural networks
#Text=To facilitate characterization of identified abstinence networks, Figure 3 summarizes connectivity based on the number of connections within and between canonical neural networks (e.g., frontoparietal, motor/sensory) for the positive (3A) and negative (3B) networks.
80-1	13984-13991	Overlap	_	
80-2	13992-13996	with	_	
80-3	13997-14006	canonical	_	
80-4	14007-14013	neural	_	
80-5	14014-14022	networks	_	
80-6	14023-14025	To	_	
80-7	14026-14036	facilitate	_	
80-8	14037-14053	characterization	_	
80-9	14054-14056	of	_	
80-10	14057-14067	identified	_	
80-11	14068-14078	abstinence	_	
80-12	14079-14087	networks	_	
80-13	14087-14088	,	_	
80-14	14089-14095	Figure	_	
80-15	14096-14097	3	_	
80-16	14098-14108	summarizes	_	
80-17	14109-14121	connectivity	_	
80-18	14122-14127	based	_	
80-19	14128-14130	on	_	
80-20	14131-14134	the	_	
80-21	14135-14141	number	_	
80-22	14142-14144	of	_	
80-23	14145-14156	connections	_	
80-24	14157-14163	within	_	
80-25	14164-14167	and	_	
80-26	14168-14175	between	_	
80-27	14176-14185	canonical	_	
80-28	14186-14192	neural	_	
80-29	14193-14201	networks	_	
80-30	14202-14203	(	_	
80-31	14203-14206	e.g	_	
80-32	14206-14207	.	_	
80-33	14207-14208	,	_	
80-34	14209-14223	frontoparietal	_	
80-35	14223-14224	,	_	
80-36	14225-14230	motor	_	
80-37	14230-14231	/	_	
80-38	14231-14238	sensory	_	
80-39	14238-14239	)	_	
80-40	14240-14243	for	_	
80-41	14244-14247	the	_	
80-42	14248-14256	positive	_	
80-43	14257-14258	(	_	
80-44	14258-14260	3A	_	
80-45	14260-14261	)	_	
80-46	14262-14265	and	_	
80-47	14266-14274	negative	_	
80-48	14275-14276	(	_	
80-49	14276-14278	3B	_	
80-50	14278-14279	)	_	
80-51	14280-14288	networks	_	
80-52	14288-14289	.	_	

#Text=By definition, positive and negative networks do not contain overlapping connections (as a single edge cannot be both a positive and negative predictor).
81-1	14290-14292	By	_	
81-2	14293-14303	definition	_	
81-3	14303-14304	,	_	
81-4	14305-14313	positive	_	
81-5	14314-14317	and	_	
81-6	14318-14326	negative	_	
81-7	14327-14335	networks	_	
81-8	14336-14338	do	_	
81-9	14339-14342	not	_	
81-10	14343-14350	contain	_	
81-11	14351-14362	overlapping	_	
81-12	14363-14374	connections	_	
81-13	14375-14376	(	_	
81-14	14376-14378	as	_	
81-15	14379-14380	a	_	
81-16	14381-14387	single	_	
81-17	14388-14392	edge	_	
81-18	14393-14399	cannot	_	
81-19	14400-14402	be	_	
81-20	14403-14407	both	_	
81-21	14408-14409	a	_	
81-22	14410-14418	positive	_	
81-23	14419-14422	and	_	
81-24	14423-14431	negative	_	
81-25	14432-14441	predictor	_	
81-26	14441-14442	)	_	
81-27	14442-14443	.	_	

#Text=However, positive and negative abstinence networks included connections within and between similar large-scale canonical neural networks.
82-1	14444-14451	However	_	
82-2	14451-14452	,	_	
82-3	14453-14461	positive	_	
82-4	14462-14465	and	_	
82-5	14466-14474	negative	_	
82-6	14475-14485	abstinence	_	
82-7	14486-14494	networks	_	
82-8	14495-14503	included	_	
82-9	14504-14515	connections	_	
82-10	14516-14522	within	_	
82-11	14523-14526	and	_	
82-12	14527-14534	between	_	
82-13	14535-14542	similar	_	
82-14	14543-14554	large-scale	_	
82-15	14555-14564	canonical	_	
82-16	14565-14571	neural	_	
82-17	14572-14580	networks	_	
82-18	14580-14581	.	_	

#Text=Comparison of networks (Figure 3C) indicated that the positive network included relatively more connections between medial frontal and frontoparietal and default mode networks; between motor/sensory and cerebellar and salience networks; and between subcortical and motor/sensory and salience networks.
83-1	14582-14592	Comparison	_	
83-2	14593-14595	of	_	
83-3	14596-14604	networks	_	
83-4	14605-14606	(	_	
83-5	14606-14612	Figure	_	
83-6	14613-14615	3C	_	
83-7	14615-14616	)	_	
83-8	14617-14626	indicated	_	
83-9	14627-14631	that	_	
83-10	14632-14635	the	_	
83-11	14636-14644	positive	_	
83-12	14645-14652	network	_	
83-13	14653-14661	included	_	
83-14	14662-14672	relatively	_	
83-15	14673-14677	more	_	
83-16	14678-14689	connections	_	
83-17	14690-14697	between	_	
83-18	14698-14704	medial	_	
83-19	14705-14712	frontal	_	
83-20	14713-14716	and	_	
83-21	14717-14731	frontoparietal	_	
83-22	14732-14735	and	_	
83-23	14736-14743	default	_	
83-24	14744-14748	mode	_	
83-25	14749-14757	networks	_	
83-26	14757-14758	;	_	
83-27	14759-14766	between	_	
83-28	14767-14772	motor	_	
83-29	14772-14773	/	_	
83-30	14773-14780	sensory	_	
83-31	14781-14784	and	_	
83-32	14785-14795	cerebellar	_	
83-33	14796-14799	and	_	
83-34	14800-14808	salience	_	
83-35	14809-14817	networks	_	
83-36	14817-14818	;	_	
83-37	14819-14822	and	_	
83-38	14823-14830	between	_	
83-39	14831-14842	subcortical	_	
83-40	14843-14846	and	_	
83-41	14847-14852	motor	_	
83-42	14852-14853	/	_	
83-43	14853-14860	sensory	_	
83-44	14861-14864	and	_	
83-45	14865-14873	salience	_	
83-46	14874-14882	networks	_	
83-47	14882-14883	.	_	

#Text=The negative network included relatively more connections between medial frontal and salience networks; between medial frontal and subcortical networks; between medial frontal and motor/sensory networks; between default mode and salience networks; and between frontoparietal and motor/sensory networks.
84-1	14884-14887	The	_	
84-2	14888-14896	negative	_	
84-3	14897-14904	network	_	
84-4	14905-14913	included	_	
84-5	14914-14924	relatively	_	
84-6	14925-14929	more	_	
84-7	14930-14941	connections	_	
84-8	14942-14949	between	_	
84-9	14950-14956	medial	_	
84-10	14957-14964	frontal	_	
84-11	14965-14968	and	_	
84-12	14969-14977	salience	_	
84-13	14978-14986	networks	_	
84-14	14986-14987	;	_	
84-15	14988-14995	between	_	
84-16	14996-15002	medial	_	
84-17	15003-15010	frontal	_	
84-18	15011-15014	and	_	
84-19	15015-15026	subcortical	_	
84-20	15027-15035	networks	_	
84-21	15035-15036	;	_	
84-22	15037-15044	between	_	
84-23	15045-15051	medial	_	
84-24	15052-15059	frontal	_	
84-25	15060-15063	and	_	
84-26	15064-15069	motor	_	
84-27	15069-15070	/	_	
84-28	15070-15077	sensory	_	
84-29	15078-15086	networks	_	
84-30	15086-15087	;	_	
84-31	15088-15095	between	_	
84-32	15096-15103	default	_	
84-33	15104-15108	mode	_	
84-34	15109-15112	and	_	
84-35	15113-15121	salience	_	
84-36	15122-15130	networks	_	
84-37	15130-15131	;	_	
84-38	15132-15135	and	_	
84-39	15136-15143	between	_	
84-40	15144-15158	frontoparietal	_	
84-41	15159-15162	and	_	
84-42	15163-15168	motor	_	
84-43	15168-15169	/	_	
84-44	15169-15176	sensory	_	
84-45	15177-15185	networks	_	
84-46	15185-15186	.	_	

#Text=The positive network was further characterized by more within-network connections across medial frontal, frontoparietal, default mode, motor/sensory, visual association and salience networks, whereas the negative network included more within-network connections for occipital and subcortical networks.
85-1	15187-15190	The	_	
85-2	15191-15199	positive	_	
85-3	15200-15207	network	_	
85-4	15208-15211	was	_	
85-5	15212-15219	further	_	
85-6	15220-15233	characterized	_	
85-7	15234-15236	by	_	
85-8	15237-15241	more	_	
85-9	15242-15256	within-network	_	
85-10	15257-15268	connections	_	
85-11	15269-15275	across	_	
85-12	15276-15282	medial	_	
85-13	15283-15290	frontal	_	
85-14	15290-15291	,	_	
85-15	15292-15306	frontoparietal	_	
85-16	15306-15307	,	_	
85-17	15308-15315	default	_	
85-18	15316-15320	mode	_	
85-19	15320-15321	,	_	
85-20	15322-15327	motor	_	
85-21	15327-15328	/	_	
85-22	15328-15335	sensory	_	
85-23	15335-15336	,	_	
85-24	15337-15343	visual	_	
85-25	15344-15355	association	_	
85-26	15356-15359	and	_	
85-27	15360-15368	salience	_	
85-28	15369-15377	networks	_	
85-29	15377-15378	,	_	
85-30	15379-15386	whereas	_	
85-31	15387-15390	the	_	
85-32	15391-15399	negative	_	
85-33	15400-15407	network	_	
85-34	15408-15416	included	_	
85-35	15417-15421	more	_	
85-36	15422-15436	within-network	_	
85-37	15437-15448	connections	_	
85-38	15449-15452	for	_	
85-39	15453-15462	occipital	_	
85-40	15463-15466	and	_	
85-41	15467-15478	subcortical	_	
85-42	15479-15487	networks	_	
85-43	15487-15488	.	_	

#Text=Relationship to post-treatment abstinence
#Text=Individuals enrolled in the trial were also invited to participate in post-treatment fMRI scanning.
86-1	15489-15501	Relationship	_	
86-2	15502-15504	to	_	
86-3	15505-15519	post-treatment	_	
86-4	15520-15530	abstinence	_	
86-5	15531-15542	Individuals	_	
86-6	15543-15551	enrolled	_	
86-7	15552-15554	in	_	
86-8	15555-15558	the	_	
86-9	15559-15564	trial	_	
86-10	15565-15569	were	_	
86-11	15570-15574	also	_	
86-12	15575-15582	invited	_	
86-13	15583-15585	to	_	
86-14	15586-15597	participate	_	
86-15	15598-15600	in	_	
86-16	15601-15615	post-treatment	_	
86-17	15616-15620	fMRI	_	
86-18	15621-15629	scanning	_	
86-19	15629-15630	.	_	

#Text=Following exclusion for excess motion (as described above) this included 40 participants.
87-1	15631-15640	Following	_	
87-2	15641-15650	exclusion	_	
87-3	15651-15654	for	_	
87-4	15655-15661	excess	_	
87-5	15662-15668	motion	_	
87-6	15669-15670	(	_	
87-7	15670-15672	as	_	
87-8	15673-15682	described	_	
87-9	15683-15688	above	_	
87-10	15688-15689	)	_	
87-11	15690-15694	this	_	
87-12	15695-15703	included	_	
87-13	15704-15706	40	_	
87-14	15707-15719	participants	_	
87-15	15719-15720	.	_	

#Text=To determine the extension of our networks to predict abstinence following treatment, individual participant network summary scores were created as the sum of connectivity strengths within positive and negative networks (negative network values were first sign-flipped so that higher values indicated ‘better’ networks).
88-1	15721-15723	To	_	
88-2	15724-15733	determine	_	
88-3	15734-15737	the	_	
88-4	15738-15747	extension	_	
88-5	15748-15750	of	_	
88-6	15751-15754	our	_	
88-7	15755-15763	networks	_	
88-8	15764-15766	to	_	
88-9	15767-15774	predict	_	
88-10	15775-15785	abstinence	_	
88-11	15786-15795	following	_	
88-12	15796-15805	treatment	_	
88-13	15805-15806	,	_	
88-14	15807-15817	individual	_	
88-15	15818-15829	participant	_	
88-16	15830-15837	network	_	
88-17	15838-15845	summary	_	
88-18	15846-15852	scores	_	
88-19	15853-15857	were	_	
88-20	15858-15865	created	_	
88-21	15866-15868	as	_	
88-22	15869-15872	the	_	
88-23	15873-15876	sum	_	
88-24	15877-15879	of	_	
88-25	15880-15892	connectivity	_	
88-26	15893-15902	strengths	_	
88-27	15903-15909	within	_	
88-28	15910-15918	positive	_	
88-29	15919-15922	and	_	
88-30	15923-15931	negative	_	
88-31	15932-15940	networks	_	
88-32	15941-15942	(	_	
88-33	15942-15950	negative	_	
88-34	15951-15958	network	_	
88-35	15959-15965	values	_	
88-36	15966-15970	were	_	
88-37	15971-15976	first	_	
88-38	15977-15989	sign-flipped	_	
88-39	15990-15992	so	_	
88-40	15993-15997	that	_	
88-41	15998-16004	higher	_	
88-42	16005-16011	values	_	
88-43	16012-16021	indicated	_	
88-44	16022-16023	‘	_	
88-45	16023-16029	better	_	
88-46	16029-16030	’	_	
88-47	16031-16039	networks	_	
88-48	16039-16040	)	_	
88-49	16040-16041	.	_	

#Text=Resultant scores from post-treatment matrices were entered into correlation analyses with abstinence during 6month follow-up (as defined via self-report using the timeline follow-back method, assessed at monthly intervals).
89-1	16042-16051	Resultant	_	
89-2	16052-16058	scores	_	
89-3	16059-16063	from	_	
89-4	16064-16078	post-treatment	_	
89-5	16079-16087	matrices	_	
89-6	16088-16092	were	_	
89-7	16093-16100	entered	_	
89-8	16101-16105	into	_	
89-9	16106-16117	correlation	_	
89-10	16118-16126	analyses	_	
89-11	16127-16131	with	_	
89-12	16132-16142	abstinence	_	
89-13	16143-16149	during	_	
89-14	16150-16156	6month	_	
89-15	16157-16166	follow-up	_	
89-16	16167-16168	(	_	
89-17	16168-16170	as	_	
89-18	16171-16178	defined	_	
89-19	16179-16182	via	_	
89-20	16183-16194	self-report	_	
89-21	16195-16200	using	_	
89-22	16201-16204	the	_	
89-23	16205-16213	timeline	_	
89-24	16214-16225	follow-back	_	
89-25	16226-16232	method	_	
89-26	16232-16233	,	_	
89-27	16234-16242	assessed	_	
89-28	16243-16245	at	_	
89-29	16246-16253	monthly	_	
89-30	16254-16263	intervals	_	
89-31	16263-16264	)	_	
89-32	16264-16265	.	_	

#Text=Post-treatment connectivity strengths were significantly associated with abstinence during follow-up (r(df=39)=0.34, p=0.03).
90-1	16266-16280	Post-treatment	_	
90-2	16281-16293	connectivity	_	
90-3	16294-16303	strengths	_	
90-4	16304-16308	were	_	
90-5	16309-16322	significantly	_	
90-6	16323-16333	associated	_	
90-7	16334-16338	with	_	
90-8	16339-16349	abstinence	_	
90-9	16350-16356	during	_	
90-10	16357-16366	follow-up	_	
90-11	16367-16368	(	_	
90-12	16368-16369	r	_	
90-13	16369-16370	(	_	
90-14	16370-16372	df	_	
90-15	16372-16373	=	_	
90-16	16373-16375	39	_	
90-17	16375-16376	)	_	
90-18	16376-16377	=	_	
90-19	16377-16381	0.34	_	
90-20	16381-16382	,	_	
90-21	16383-16384	p	_	
90-22	16384-16385	=	_	
90-23	16385-16389	0.03	_	
90-24	16389-16390	)	_	
90-25	16390-16391	.	_	

#Text=Comparison of pre- versus post-treatment networks indicated no significant changes in connectivity strength (t(df=38)=0.81, p=0.42).
91-1	16392-16402	Comparison	_	
91-2	16403-16405	of	_	
91-3	16406-16409	pre	_	
91-4	16409-16410	-	_	
91-5	16411-16417	versus	_	
91-6	16418-16432	post-treatment	_	
91-7	16433-16441	networks	_	
91-8	16442-16451	indicated	_	
91-9	16452-16454	no	_	
91-10	16455-16466	significant	_	
91-11	16467-16474	changes	_	
91-12	16475-16477	in	_	
91-13	16478-16490	connectivity	_	
91-14	16491-16499	strength	_	
91-15	16500-16501	(	_	
91-16	16501-16502	t	_	
91-17	16502-16503	(	_	
91-18	16503-16505	df	_	
91-19	16505-16506	=	_	
91-20	16506-16508	38	_	
91-21	16508-16509	)	_	
91-22	16509-16510	=	_	
91-23	16510-16514	0.81	_	
91-24	16514-16515	,	_	
91-25	16516-16517	p	_	
91-26	16517-16518	=	_	
91-27	16518-16522	0.42	_	
91-28	16522-16523	)	_	
91-29	16523-16524	.	_	

#Text=Out-of-sample replication and binary prediction
#Text=To determine the generalizability of our findings, we tested the ability of the identified networks to predict cocaine-negative urine urine toxicology outcomes in a heterogeneous sample of cocaine-dependent individuals (n=45).
92-1	16525-16538	Out-of-sample	_	
92-2	16539-16550	replication	_	
92-3	16551-16554	and	_	
92-4	16555-16561	binary	_	
92-5	16562-16572	prediction	_	
92-6	16573-16575	To	_	
92-7	16576-16585	determine	_	
92-8	16586-16589	the	_	
92-9	16590-16606	generalizability	_	
92-10	16607-16609	of	_	
92-11	16610-16613	our	_	
92-12	16614-16622	findings	_	
92-13	16622-16623	,	_	
92-14	16624-16626	we	_	
92-15	16627-16633	tested	_	
92-16	16634-16637	the	_	
92-17	16638-16645	ability	_	
92-18	16646-16648	of	_	
92-19	16649-16652	the	_	
92-20	16653-16663	identified	_	
92-21	16664-16672	networks	_	
92-22	16673-16675	to	_	
92-23	16676-16683	predict	_	
92-24	16684-16700	cocaine-negative	_	
92-25	16701-16706	urine	_	
92-26	16707-16712	urine	_	
92-27	16713-16723	toxicology	_	
92-28	16724-16732	outcomes	_	
92-29	16733-16735	in	_	
92-30	16736-16737	a	_	
92-31	16738-16751	heterogeneous	_	
92-32	16752-16758	sample	_	
92-33	16759-16761	of	_	
92-34	16762-16779	cocaine-dependent	_	
92-35	16780-16791	individuals	_	
92-36	16792-16793	(	_	
92-37	16793-16794	n	_	
92-38	16794-16795	=	_	
92-39	16795-16797	45	_	
92-40	16797-16798	)	_	
92-41	16798-16799	.	_	

#Text=This included previously excluded individuals with excess motion during scanning (n=17; Table 1) and individuals from an independent, previously published randomized controlled trial (n=28).
93-1	16800-16804	This	_	
93-2	16805-16813	included	_	
93-3	16814-16824	previously	_	
93-4	16825-16833	excluded	_	
93-5	16834-16845	individuals	_	
93-6	16846-16850	with	_	
93-7	16851-16857	excess	_	
93-8	16858-16864	motion	_	
93-9	16865-16871	during	_	
93-10	16872-16880	scanning	_	
93-11	16881-16882	(	_	
93-12	16882-16883	n	_	
93-13	16883-16884	=	_	
93-14	16884-16886	17	_	
93-15	16886-16887	;	_	
93-16	16888-16893	Table	_	
93-17	16894-16895	1	_	
93-18	16895-16896	)	_	
93-19	16897-16900	and	_	
93-20	16901-16912	individuals	_	
93-21	16913-16917	from	_	
93-22	16918-16920	an	_	
93-23	16921-16932	independent	_	
93-24	16932-16933	,	_	
93-25	16934-16944	previously	_	
93-26	16945-16954	published	_	
93-27	16955-16965	randomized	_	
93-28	16966-16976	controlled	_	
93-29	16977-16982	trial	_	
93-30	16983-16984	(	_	
93-31	16984-16985	n	_	
93-32	16985-16986	=	_	
93-33	16986-16988	28	_	
93-34	16988-16989	)	_	
93-35	16989-16990	.	_	

#Text=As in our original analyses, residual motion was included as a covariate.
94-1	16991-16993	As	_	
94-2	16994-16996	in	_	
94-3	16997-17000	our	_	
94-4	17001-17009	original	_	
94-5	17010-17018	analyses	_	
94-6	17018-17019	,	_	
94-7	17020-17028	residual	_	
94-8	17029-17035	motion	_	
94-9	17036-17039	was	_	
94-10	17040-17048	included	_	
94-11	17049-17051	as	_	
94-12	17052-17053	a	_	
94-13	17054-17063	covariate	_	
94-14	17063-17064	.	_	

#Text=Further details on exclusion for motion and related analyses are provided in the supplemental materials.
95-1	17065-17072	Further	_	
95-2	17073-17080	details	_	
95-3	17081-17083	on	_	
95-4	17084-17093	exclusion	_	
95-5	17094-17097	for	_	
95-6	17098-17104	motion	_	
95-7	17105-17108	and	_	
95-8	17109-17116	related	_	
95-9	17117-17125	analyses	_	
95-10	17126-17129	are	_	
95-11	17130-17138	provided	_	
95-12	17139-17141	in	_	
95-13	17142-17145	the	_	
95-14	17146-17158	supplemental	_	
95-15	17159-17168	materials	_	
95-16	17168-17169	.	_	

#Text=As the practical clinical utility of biomarkers is unlikely to rely on their ability to generate continuous indices of treatment outcome, but rather on their ability to a priori identify treatment responders from non-responders in a binary manner, we further tested the ability of the identified networks to predict abstinence in a binary manner (yes/no, any drugfree urine specimens) in our replication sample.
96-1	17170-17172	As	_	
96-2	17173-17176	the	_	
96-3	17177-17186	practical	_	
96-4	17187-17195	clinical	_	
96-5	17196-17203	utility	_	
96-6	17204-17206	of	_	
96-7	17207-17217	biomarkers	_	
96-8	17218-17220	is	_	
96-9	17221-17229	unlikely	_	
96-10	17230-17232	to	_	
96-11	17233-17237	rely	_	
96-12	17238-17240	on	_	
96-13	17241-17246	their	_	
96-14	17247-17254	ability	_	
96-15	17255-17257	to	_	
96-16	17258-17266	generate	_	
96-17	17267-17277	continuous	_	
96-18	17278-17285	indices	_	
96-19	17286-17288	of	_	
96-20	17289-17298	treatment	_	
96-21	17299-17306	outcome	_	
96-22	17306-17307	,	_	
96-23	17308-17311	but	_	
96-24	17312-17318	rather	_	
96-25	17319-17321	on	_	
96-26	17322-17327	their	_	
96-27	17328-17335	ability	_	
96-28	17336-17338	to	_	
96-29	17339-17340	a	_	
96-30	17341-17347	priori	_	
96-31	17348-17356	identify	_	
96-32	17357-17366	treatment	_	
96-33	17367-17377	responders	_	
96-34	17378-17382	from	_	
96-35	17383-17397	non-responders	_	
96-36	17398-17400	in	_	
96-37	17401-17402	a	_	
96-38	17403-17409	binary	_	
96-39	17410-17416	manner	_	
96-40	17416-17417	,	_	
96-41	17418-17420	we	_	
96-42	17421-17428	further	_	
96-43	17429-17435	tested	_	
96-44	17436-17439	the	_	
96-45	17440-17447	ability	_	
96-46	17448-17450	of	_	
96-47	17451-17454	the	_	
96-48	17455-17465	identified	_	
96-49	17466-17474	networks	_	
96-50	17475-17477	to	_	
96-51	17478-17485	predict	_	
96-52	17486-17496	abstinence	_	
96-53	17497-17499	in	_	
96-54	17500-17501	a	_	
96-55	17502-17508	binary	_	
96-56	17509-17515	manner	_	
96-57	17516-17517	(	_	
96-58	17517-17520	yes	_	
96-59	17520-17521	/	_	
96-60	17521-17523	no	_	
96-61	17523-17524	,	_	
96-62	17525-17528	any	_	
96-63	17529-17537	drugfree	_	
96-64	17538-17543	urine	_	
96-65	17544-17553	specimens	_	
96-66	17553-17554	)	_	
96-67	17555-17557	in	_	
96-68	17558-17561	our	_	
96-69	17562-17573	replication	_	
96-70	17574-17580	sample	_	
96-71	17580-17581	.	_	

#Text=Individual participant summary scores were extracted from functional-connectivity matrices, as above, and entered into regression analyses with within-treatment abstinence values.
97-1	17582-17592	Individual	_	
97-2	17593-17604	participant	_	
97-3	17605-17612	summary	_	
97-4	17613-17619	scores	_	
97-5	17620-17624	were	_	
97-6	17625-17634	extracted	_	
97-7	17635-17639	from	_	
97-8	17640-17663	functional-connectivity	_	
97-9	17664-17672	matrices	_	
97-10	17672-17673	,	_	
97-11	17674-17676	as	_	
97-12	17677-17682	above	_	
97-13	17682-17683	,	_	
97-14	17684-17687	and	_	
97-15	17688-17695	entered	_	
97-16	17696-17700	into	_	
97-17	17701-17711	regression	_	
97-18	17712-17720	analyses	_	
97-19	17721-17725	with	_	
97-20	17726-17742	within-treatment	_	
97-21	17743-17753	abstinence	_	
97-22	17754-17760	values	_	
97-23	17760-17761	.	_	

#Text=Pre-treatment network strength in the independent sample predicted abstinence during treatment for both continuous (percent cocaine-negative urines during treatment; r(df=44)=0.36, p=.016) and binary (yes/no, any cocaine-negative urine; 64% accuracy, x2(df=2)=5.99, p=0.014; 82% specificity; 35% sensitivity) outcomes.
98-1	17762-17775	Pre-treatment	_	
98-2	17776-17783	network	_	
98-3	17784-17792	strength	_	
98-4	17793-17795	in	_	
98-5	17796-17799	the	_	
98-6	17800-17811	independent	_	
98-7	17812-17818	sample	_	
98-8	17819-17828	predicted	_	
98-9	17829-17839	abstinence	_	
98-10	17840-17846	during	_	
98-11	17847-17856	treatment	_	
98-12	17857-17860	for	_	
98-13	17861-17865	both	_	
98-14	17866-17876	continuous	_	
98-15	17877-17878	(	_	
98-16	17878-17885	percent	_	
98-17	17886-17902	cocaine-negative	_	
98-18	17903-17909	urines	_	
98-19	17910-17916	during	_	
98-20	17917-17926	treatment	_	
98-21	17926-17927	;	_	
98-22	17928-17929	r	_	
98-23	17929-17930	(	_	
98-24	17930-17932	df	_	
98-25	17932-17933	=	_	
98-26	17933-17935	44	_	
98-27	17935-17936	)	_	
98-28	17936-17937	=	_	
98-29	17937-17941	0.36	_	
98-30	17941-17942	,	_	
98-31	17943-17944	p	_	
98-32	17944-17945	=	_	
98-33	17945-17949	.016	_	
98-34	17949-17950	)	_	
98-35	17951-17954	and	_	
98-36	17955-17961	binary	_	
98-37	17962-17963	(	_	
98-38	17963-17966	yes	_	
98-39	17966-17967	/	_	
98-40	17967-17969	no	_	
98-41	17969-17970	,	_	
98-42	17971-17974	any	_	
98-43	17975-17991	cocaine-negative	_	
98-44	17992-17997	urine	_	
98-45	17997-17998	;	_	
98-46	17999-18002	64%	_	
98-47	18003-18011	accuracy	_	
98-48	18011-18012	,	_	
98-49	18013-18015	x2	_	
98-50	18015-18016	(	_	
98-51	18016-18018	df	_	
98-52	18018-18019	=	_	
98-53	18019-18020	2	_	
98-54	18020-18021	)	_	
98-55	18021-18022	=	_	
98-56	18022-18026	5.99	_	
98-57	18026-18027	,	_	
98-58	18028-18029	p	_	
98-59	18029-18030	=	_	
98-60	18030-18035	0.014	_	
98-61	18035-18036	;	_	
98-62	18037-18040	82%	_	
98-63	18041-18052	specificity	_	
98-64	18052-18053	;	_	
98-65	18054-18057	35%	_	
98-66	18058-18069	sensitivity	_	
98-67	18069-18070	)	_	
98-68	18071-18079	outcomes	_	
98-69	18079-18080	.	_	

#Text=For binary prediction, accuracy was increased to 71% following inclusion of baseline cocaine-use (days of use in month prior to treatment) in the model (x2(df=2)=6.20, p=0.02; 89% sensitivity; 41% specificity; Supplemental Figure 4).
99-1	18081-18084	For	_	
99-2	18085-18091	binary	_	
99-3	18092-18102	prediction	_	
99-4	18102-18103	,	_	
99-5	18104-18112	accuracy	_	
99-6	18113-18116	was	_	
99-7	18117-18126	increased	_	
99-8	18127-18129	to	_	
99-9	18130-18133	71%	_	
99-10	18134-18143	following	_	
99-11	18144-18153	inclusion	_	
99-12	18154-18156	of	_	
99-13	18157-18165	baseline	_	
99-14	18166-18177	cocaine-use	_	
99-15	18178-18179	(	_	
99-16	18179-18183	days	_	
99-17	18184-18186	of	_	
99-18	18187-18190	use	_	
99-19	18191-18193	in	_	
99-20	18194-18199	month	_	
99-21	18200-18205	prior	_	
99-22	18206-18208	to	_	
99-23	18209-18218	treatment	_	
99-24	18218-18219	)	_	
99-25	18220-18222	in	_	
99-26	18223-18226	the	_	
99-27	18227-18232	model	_	
99-28	18233-18234	(	_	
99-29	18234-18236	x2	_	
99-30	18236-18237	(	_	
99-31	18237-18239	df	_	
99-32	18239-18240	=	_	
99-33	18240-18241	2	_	
99-34	18241-18242	)	_	
99-35	18242-18243	=	_	
99-36	18243-18247	6.20	_	
99-37	18247-18248	,	_	
99-38	18249-18250	p	_	
99-39	18250-18251	=	_	
99-40	18251-18255	0.02	_	
99-41	18255-18256	;	_	
99-42	18257-18260	89%	_	
99-43	18261-18272	sensitivity	_	
99-44	18272-18273	;	_	
99-45	18274-18277	41%	_	
99-46	18278-18289	specificity	_	
99-47	18289-18290	;	_	
99-48	18291-18303	Supplemental	_	
99-49	18304-18310	Figure	_	
99-50	18311-18312	4	_	
99-51	18312-18313	)	_	
99-52	18313-18314	.	_	

#Text=As shown in Supplemental Figure 4, binarization across different levels of use (≥25% drug-free urines, ≥75% drug-free urines) decreased sensitivity (57%, 25%, respectively) but increased specificity (71%, 89%, respectively).
100-1	18315-18317	As	_	
100-2	18318-18323	shown	_	
100-3	18324-18326	in	_	
100-4	18327-18339	Supplemental	_	
100-5	18340-18346	Figure	_	
100-6	18347-18348	4	_	
100-7	18348-18349	,	_	
100-8	18350-18362	binarization	_	
100-9	18363-18369	across	_	
100-10	18370-18379	different	_	
100-11	18380-18386	levels	_	
100-12	18387-18389	of	_	
100-13	18390-18393	use	_	
100-14	18394-18395	(	_	
100-15	18395-18396	≥	_	
100-16	18396-18399	25%	_	
100-17	18400-18409	drug-free	_	
100-18	18410-18416	urines	_	
100-19	18416-18417	,	_	
100-20	18418-18419	≥	_	
100-21	18419-18422	75%	_	
100-22	18423-18432	drug-free	_	
100-23	18433-18439	urines	_	
100-24	18439-18440	)	_	
100-25	18441-18450	decreased	_	
100-26	18451-18462	sensitivity	_	
100-27	18463-18464	(	_	
100-28	18464-18467	57%	_	
100-29	18467-18468	,	_	
100-30	18469-18472	25%	_	
100-31	18472-18473	,	_	
100-32	18474-18486	respectively	_	
100-33	18486-18487	)	_	
100-34	18488-18491	but	_	
100-35	18492-18501	increased	_	
100-36	18502-18513	specificity	_	
100-37	18514-18515	(	_	
100-38	18515-18518	71%	_	
100-39	18518-18519	,	_	
100-40	18520-18523	89%	_	
100-41	18523-18524	,	_	
100-42	18525-18537	respectively	_	
100-43	18537-18538	)	_	
100-44	18538-18539	.	_	

#Text=Discussion
#Text=The translation of brain imaging findings into real-world clinical settings is one of the primary challenges of modern neuropsychiatry.
101-1	18540-18550	Discussion	_	
101-2	18551-18554	The	_	
101-3	18555-18566	translation	_	
101-4	18567-18569	of	_	
101-5	18570-18575	brain	_	
101-6	18576-18583	imaging	_	
101-7	18584-18592	findings	_	
101-8	18593-18597	into	_	
101-9	18598-18608	real-world	_	
101-10	18609-18617	clinical	_	
101-11	18618-18626	settings	_	
101-12	18627-18629	is	_	
101-13	18630-18633	one	_	
101-14	18634-18636	of	_	
101-15	18637-18640	the	_	
101-16	18641-18648	primary	_	
101-17	18649-18659	challenges	_	
101-18	18660-18662	of	_	
101-19	18663-18669	modern	_	
101-20	18670-18685	neuropsychiatry	_	
101-21	18685-18686	.	_	

#Text=Here, we demonstrate the ability of a recently developed connectome-based machine learning approach to predict treatment outcomes (abstinence from cocaine during 12-week treatment) using baseline patterns of connectivity.
102-1	18687-18691	Here	_	
102-2	18691-18692	,	_	
102-3	18693-18695	we	_	
102-4	18696-18707	demonstrate	_	
102-5	18708-18711	the	_	
102-6	18712-18719	ability	_	
102-7	18720-18722	of	_	
102-8	18723-18724	a	_	
102-9	18725-18733	recently	_	
102-10	18734-18743	developed	_	
102-11	18744-18760	connectome-based	_	
102-12	18761-18768	machine	_	
102-13	18769-18777	learning	_	
102-14	18778-18786	approach	_	
102-15	18787-18789	to	_	
102-16	18790-18797	predict	_	
102-17	18798-18807	treatment	_	
102-18	18808-18816	outcomes	_	
102-19	18817-18818	(	_	
102-20	18818-18828	abstinence	_	
102-21	18829-18833	from	_	
102-22	18834-18841	cocaine	_	
102-23	18842-18848	during	_	
102-24	18849-18851	12	_	
102-25	18851-18852	-	_	
102-26	18852-18856	week	_	
102-27	18857-18866	treatment	_	
102-28	18866-18867	)	_	
102-29	18868-18873	using	_	
102-30	18874-18882	baseline	_	
102-31	18883-18891	patterns	_	
102-32	18892-18894	of	_	
102-33	18895-18907	connectivity	_	
102-34	18907-18908	.	_	

#Text=We further demonstrate that post-treatment patterns of connectivity within these networks predict abstinence during six-month follow-up.
103-1	18909-18911	We	_	
103-2	18912-18919	further	_	
103-3	18920-18931	demonstrate	_	
103-4	18932-18936	that	_	
103-5	18937-18951	post-treatment	_	
103-6	18952-18960	patterns	_	
103-7	18961-18963	of	_	
103-8	18964-18976	connectivity	_	
103-9	18977-18983	within	_	
103-10	18984-18989	these	_	
103-11	18990-18998	networks	_	
103-12	18999-19006	predict	_	
103-13	19007-19017	abstinence	_	
103-14	19018-19024	during	_	
103-15	19025-19034	six-month	_	
103-16	19035-19044	follow-up	_	
103-17	19044-19045	.	_	

#Text=Finally, we demonstrate that the same networks can be used to predict treatment response in an independent, heterogeneous sample.
104-1	19046-19053	Finally	_	
104-2	19053-19054	,	_	
104-3	19055-19057	we	_	
104-4	19058-19069	demonstrate	_	
104-5	19070-19074	that	_	
104-6	19075-19078	the	_	
104-7	19079-19083	same	_	
104-8	19084-19092	networks	_	
104-9	19093-19096	can	_	
104-10	19097-19099	be	_	
104-11	19100-19104	used	_	
104-12	19105-19107	to	_	
104-13	19108-19115	predict	_	
104-14	19116-19125	treatment	_	
104-15	19126-19134	response	_	
104-16	19135-19137	in	_	
104-17	19138-19140	an	_	
104-18	19141-19152	independent	_	
104-19	19152-19153	,	_	
104-20	19154-19167	heterogeneous	_	
104-21	19168-19174	sample	_	
104-22	19174-19175	.	_	

#Text=Despite this predictive ability, identified networks could be considered potential treatment targets, and further replication and model refinement is needed prior to direct application of findings to clinical decision-making.
105-1	19176-19183	Despite	_	
105-2	19184-19188	this	_	
105-3	19189-19199	predictive	_	
105-4	19200-19207	ability	_	
105-5	19207-19208	,	_	
105-6	19209-19219	identified	_	
105-7	19220-19228	networks	_	
105-8	19229-19234	could	_	
105-9	19235-19237	be	_	
105-10	19238-19248	considered	_	
105-11	19249-19258	potential	_	
105-12	19259-19268	treatment	_	
105-13	19269-19276	targets	_	
105-14	19276-19277	,	_	
105-15	19278-19281	and	_	
105-16	19282-19289	further	_	
105-17	19290-19301	replication	_	
105-18	19302-19305	and	_	
105-19	19306-19311	model	_	
105-20	19312-19322	refinement	_	
105-21	19323-19325	is	_	
105-22	19326-19332	needed	_	
105-23	19333-19338	prior	_	
105-24	19339-19341	to	_	
105-25	19342-19348	direct	_	
105-26	19349-19360	application	_	
105-27	19361-19363	of	_	
105-28	19364-19372	findings	_	
105-29	19373-19375	to	_	
105-30	19376-19384	clinical	_	
105-31	19385-19400	decision-making	_	
105-32	19400-19401	.	_	

#Text=Consistent with the connectome-based approach, abstinence networks were complex and included connections between multiple well-established neural networks.
106-1	19402-19412	Consistent	_	
106-2	19413-19417	with	_	
106-3	19418-19421	the	_	
106-4	19422-19438	connectome-based	_	
106-5	19439-19447	approach	_	
106-6	19447-19448	,	_	
106-7	19449-19459	abstinence	_	
106-8	19460-19468	networks	_	
106-9	19469-19473	were	_	
106-10	19474-19481	complex	_	
106-11	19482-19485	and	_	
106-12	19486-19494	included	_	
106-13	19495-19506	connections	_	
106-14	19507-19514	between	_	
106-15	19515-19523	multiple	_	
106-16	19524-19540	well-established	_	
106-17	19541-19547	neural	_	
106-18	19548-19556	networks	_	
106-19	19556-19557	.	_	

#Text=The positive network included more frontoparietal-medial frontal-default mode connections as well as more salience-subcortical-motor/sensory-connections.
107-1	19558-19561	The	_	
107-2	19562-19570	positive	_	
107-3	19571-19578	network	_	
107-4	19579-19587	included	_	
107-5	19588-19592	more	_	
107-6	19593-19614	frontoparietal-medial	_	
107-7	19615-19630	frontal-default	_	
107-8	19631-19635	mode	_	
107-9	19636-19647	connections	_	
107-10	19648-19650	as	_	
107-11	19651-19655	well	_	
107-12	19656-19658	as	_	
107-13	19659-19663	more	_	
107-14	19664-19690	salience-subcortical-motor	_	
107-15	19690-19691	/	_	
107-16	19691-19710	sensory-connections	_	
107-17	19710-19711	.	_	

#Text=In contrast, the negative network (network for which increased connectivity is negatively associated with abstinence) included more connections between the medial frontal network and salience, subcortical, and motor/sensory networks, as well as more salience-default mode connections.
108-1	19712-19714	In	_	
108-2	19715-19723	contrast	_	
108-3	19723-19724	,	_	
108-4	19725-19728	the	_	
108-5	19729-19737	negative	_	
108-6	19738-19745	network	_	
108-7	19746-19747	(	_	
108-8	19747-19754	network	_	
108-9	19755-19758	for	_	
108-10	19759-19764	which	_	
108-11	19765-19774	increased	_	
108-12	19775-19787	connectivity	_	
108-13	19788-19790	is	_	
108-14	19791-19801	negatively	_	
108-15	19802-19812	associated	_	
108-16	19813-19817	with	_	
108-17	19818-19828	abstinence	_	
108-18	19828-19829	)	_	
108-19	19830-19838	included	_	
108-20	19839-19843	more	_	
108-21	19844-19855	connections	_	
108-22	19856-19863	between	_	
108-23	19864-19867	the	_	
108-24	19868-19874	medial	_	
108-25	19875-19882	frontal	_	
108-26	19883-19890	network	_	
108-27	19891-19894	and	_	
108-28	19895-19903	salience	_	
108-29	19903-19904	,	_	
108-30	19905-19916	subcortical	_	
108-31	19916-19917	,	_	
108-32	19918-19921	and	_	
108-33	19922-19927	motor	_	
108-34	19927-19928	/	_	
108-35	19928-19935	sensory	_	
108-36	19936-19944	networks	_	
108-37	19944-19945	,	_	
108-38	19946-19948	as	_	
108-39	19949-19953	well	_	
108-40	19954-19956	as	_	
108-41	19957-19961	more	_	
108-42	19962-19978	salience-default	_	
108-43	19979-19983	mode	_	
108-44	19984-19995	connections	_	
108-45	19995-19996	.	_	

#Text=Based on these findings, Figure 4 presents a theoretical network model of abstinence.
109-1	19997-20002	Based	_	
109-2	20003-20005	on	_	
109-3	20006-20011	these	_	
109-4	20012-20020	findings	_	
109-5	20020-20021	,	_	
109-6	20022-20028	Figure	_	
109-7	20029-20030	4	_	
109-8	20031-20039	presents	_	
109-9	20040-20041	a	_	
109-10	20042-20053	theoretical	_	
109-11	20054-20061	network	_	
109-12	20062-20067	model	_	
109-13	20068-20070	of	_	
109-14	20071-20081	abstinence	_	
109-15	20081-20082	.	_	

#Text=We propose that abstinence is: (i) positively predicted by integration of an cognitive/executive control system involving increased connectivity between frontoparietal and medial frontal networks; (ii) by integration of a reward responsiveness system involving increased connectivity between salience, motor/sensory and subcortical networks; and (iii) by segregation (decreased connectivity) between these two systems.
110-1	20083-20085	We	_	
110-2	20086-20093	propose	_	
110-3	20094-20098	that	_	
110-4	20099-20109	abstinence	_	
110-5	20110-20112	is	_	
110-6	20112-20113	:	_	
110-7	20114-20115	(	_	
110-8	20115-20116	i	_	
110-9	20116-20117	)	_	
110-10	20118-20128	positively	_	
110-11	20129-20138	predicted	_	
110-12	20139-20141	by	_	
110-13	20142-20153	integration	_	
110-14	20154-20156	of	_	
110-15	20157-20159	an	_	
110-16	20160-20169	cognitive	_	
110-17	20169-20170	/	_	
110-18	20170-20179	executive	_	
110-19	20180-20187	control	_	
110-20	20188-20194	system	_	
110-21	20195-20204	involving	_	
110-22	20205-20214	increased	_	
110-23	20215-20227	connectivity	_	
110-24	20228-20235	between	_	
110-25	20236-20250	frontoparietal	_	
110-26	20251-20254	and	_	
110-27	20255-20261	medial	_	
110-28	20262-20269	frontal	_	
110-29	20270-20278	networks	_	
110-30	20278-20279	;	_	
110-31	20280-20281	(	_	
110-32	20281-20283	ii	_	
110-33	20283-20284	)	_	
110-34	20285-20287	by	_	
110-35	20288-20299	integration	_	
110-36	20300-20302	of	_	
110-37	20303-20304	a	_	
110-38	20305-20311	reward	_	
110-39	20312-20326	responsiveness	_	
110-40	20327-20333	system	_	
110-41	20334-20343	involving	_	
110-42	20344-20353	increased	_	
110-43	20354-20366	connectivity	_	
110-44	20367-20374	between	_	
110-45	20375-20383	salience	_	
110-46	20383-20384	,	_	
110-47	20385-20390	motor	_	
110-48	20390-20391	/	_	
110-49	20391-20398	sensory	_	
110-50	20399-20402	and	_	
110-51	20403-20414	subcortical	_	
110-52	20415-20423	networks	_	
110-53	20423-20424	;	_	
110-54	20425-20428	and	_	
110-55	20429-20430	(	_	
110-56	20430-20433	iii	_	
110-57	20433-20434	)	_	
110-58	20435-20437	by	_	
110-59	20438-20449	segregation	_	
110-60	20450-20451	(	_	
110-61	20451-20460	decreased	_	
110-62	20461-20473	connectivity	_	
110-63	20473-20474	)	_	
110-64	20475-20482	between	_	
110-65	20483-20488	these	_	
110-66	20489-20492	two	_	
110-67	20493-20500	systems	_	
110-68	20500-20501	.	_	

#Text=This model builds on prior models of addiction emphasizing separation of frontoparietal and salience networks but also incorporates medial frontal, motor/sensory and subcortical networks to provide a theoretical framework for future research.
111-1	20502-20506	This	_	
111-2	20507-20512	model	_	
111-3	20513-20519	builds	_	
111-4	20520-20522	on	_	
111-5	20523-20528	prior	_	
111-6	20529-20535	models	_	
111-7	20536-20538	of	_	
111-8	20539-20548	addiction	_	
111-9	20549-20560	emphasizing	_	
111-10	20561-20571	separation	_	
111-11	20572-20574	of	_	
111-12	20575-20589	frontoparietal	_	
111-13	20590-20593	and	_	
111-14	20594-20602	salience	_	
111-15	20603-20611	networks	_	
111-16	20612-20615	but	_	
111-17	20616-20620	also	_	
111-18	20621-20633	incorporates	_	
111-19	20634-20640	medial	_	
111-20	20641-20648	frontal	_	
111-21	20648-20649	,	_	
111-22	20650-20655	motor	_	
111-23	20655-20656	/	_	
111-24	20656-20663	sensory	_	
111-25	20664-20667	and	_	
111-26	20668-20679	subcortical	_	
111-27	20680-20688	networks	_	
111-28	20689-20691	to	_	
111-29	20692-20699	provide	_	
111-30	20700-20701	a	_	
111-31	20702-20713	theoretical	_	
111-32	20714-20723	framework	_	
111-33	20724-20727	for	_	
111-34	20728-20734	future	_	
111-35	20735-20743	research	_	
111-36	20743-20744	.	_	

#Text=Within the above context, cognitive/executive control networks are theorized to contribute to abstinence via coordination of top-down processes necessary for treatment engagement (e.g., acquisition of new skills, enhanced control over impulsive behavior), whereas integration of reward networks may support motivational processes relevant to treatment (e.g., willingness to change, attending to alternate rewards).
112-1	20745-20751	Within	_	
112-2	20752-20755	the	_	
112-3	20756-20761	above	_	
112-4	20762-20769	context	_	
112-5	20769-20770	,	_	
112-6	20771-20780	cognitive	_	
112-7	20780-20781	/	_	
112-8	20781-20790	executive	_	
112-9	20791-20798	control	_	
112-10	20799-20807	networks	_	
112-11	20808-20811	are	_	
112-12	20812-20821	theorized	_	
112-13	20822-20824	to	_	
112-14	20825-20835	contribute	_	
112-15	20836-20838	to	_	
112-16	20839-20849	abstinence	_	
112-17	20850-20853	via	_	
112-18	20854-20866	coordination	_	
112-19	20867-20869	of	_	
112-20	20870-20878	top-down	_	
112-21	20879-20888	processes	_	
112-22	20889-20898	necessary	_	
112-23	20899-20902	for	_	
112-24	20903-20912	treatment	_	
112-25	20913-20923	engagement	_	
112-26	20924-20925	(	_	
112-27	20925-20928	e.g	_	
112-28	20928-20929	.	_	
112-29	20929-20930	,	_	
112-30	20931-20942	acquisition	_	
112-31	20943-20945	of	_	
112-32	20946-20949	new	_	
112-33	20950-20956	skills	_	
112-34	20956-20957	,	_	
112-35	20958-20966	enhanced	_	
112-36	20967-20974	control	_	
112-37	20975-20979	over	_	
112-38	20980-20989	impulsive	_	
112-39	20990-20998	behavior	_	
112-40	20998-20999	)	_	
112-41	20999-21000	,	_	
112-42	21001-21008	whereas	_	
112-43	21009-21020	integration	_	
112-44	21021-21023	of	_	
112-45	21024-21030	reward	_	
112-46	21031-21039	networks	_	
112-47	21040-21043	may	_	
112-48	21044-21051	support	_	
112-49	21052-21064	motivational	_	
112-50	21065-21074	processes	_	
112-51	21075-21083	relevant	_	
112-52	21084-21086	to	_	
112-53	21087-21096	treatment	_	
112-54	21097-21098	(	_	
112-55	21098-21101	e.g	_	
112-56	21101-21102	.	_	
112-57	21102-21103	,	_	
112-58	21104-21115	willingness	_	
112-59	21116-21118	to	_	
112-60	21119-21125	change	_	
112-61	21125-21126	,	_	
112-62	21127-21136	attending	_	
112-63	21137-21139	to	_	
112-64	21140-21149	alternate	_	
112-65	21150-21157	rewards	_	
112-66	21157-21158	)	_	
112-67	21158-21159	.	_	

#Text=In addition, based on prior resting state work in cocaine-use disorder, appropriate separation between these two systems is theorized to relate to greater behavioral flexibility (or to decreased compulsivity), as would be required for behavior change during treatment.
113-1	21160-21162	In	_	
113-2	21163-21171	addition	_	
113-3	21171-21172	,	_	
113-4	21173-21178	based	_	
113-5	21179-21181	on	_	
113-6	21182-21187	prior	_	
113-7	21188-21195	resting	_	
113-8	21196-21201	state	_	
113-9	21202-21206	work	_	
113-10	21207-21209	in	_	
113-11	21210-21221	cocaine-use	_	
113-12	21222-21230	disorder	_	
113-13	21230-21231	,	_	
113-14	21232-21243	appropriate	_	
113-15	21244-21254	separation	_	
113-16	21255-21262	between	_	
113-17	21263-21268	these	_	
113-18	21269-21272	two	_	
113-19	21273-21280	systems	_	
113-20	21281-21283	is	_	
113-21	21284-21293	theorized	_	
113-22	21294-21296	to	_	
113-23	21297-21303	relate	_	
113-24	21304-21306	to	_	
113-25	21307-21314	greater	_	
113-26	21315-21325	behavioral	_	
113-27	21326-21337	flexibility	_	
113-28	21338-21339	(	_	
113-29	21339-21341	or	_	
113-30	21342-21344	to	_	
113-31	21345-21354	decreased	_	
113-32	21355-21367	compulsivity	_	
113-33	21367-21368	)	_	
113-34	21368-21369	,	_	
113-35	21370-21372	as	_	
113-36	21373-21378	would	_	
113-37	21379-21381	be	_	
113-38	21382-21390	required	_	
113-39	21391-21394	for	_	
113-40	21395-21403	behavior	_	
113-41	21404-21410	change	_	
113-42	21411-21417	during	_	
113-43	21418-21427	treatment	_	
113-44	21427-21428	.	_	

#Text=While we did not model specific events-of-interest but rather used ‘raw’ time courses, our findings are nonetheless intuitive when considered within the context of reward task performance - which requires coordination of both attentional and cognitive control processes as well as of salience encoding and reward response behaviors.
114-1	21429-21434	While	_	
114-2	21435-21437	we	_	
114-3	21438-21441	did	_	
114-4	21442-21445	not	_	
114-5	21446-21451	model	_	
114-6	21452-21460	specific	_	
114-7	21461-21479	events-of-interest	_	
114-8	21480-21483	but	_	
114-9	21484-21490	rather	_	
114-10	21491-21495	used	_	
114-11	21496-21497	‘	_	
114-12	21497-21500	raw	_	
114-13	21500-21501	’	_	
114-14	21502-21506	time	_	
114-15	21507-21514	courses	_	
114-16	21514-21515	,	_	
114-17	21516-21519	our	_	
114-18	21520-21528	findings	_	
114-19	21529-21532	are	_	
114-20	21533-21544	nonetheless	_	
114-21	21545-21554	intuitive	_	
114-22	21555-21559	when	_	
114-23	21560-21570	considered	_	
114-24	21571-21577	within	_	
114-25	21578-21581	the	_	
114-26	21582-21589	context	_	
114-27	21590-21592	of	_	
114-28	21593-21599	reward	_	
114-29	21600-21604	task	_	
114-30	21605-21616	performance	_	
114-31	21617-21618	-	_	
114-32	21619-21624	which	_	
114-33	21625-21633	requires	_	
114-34	21634-21646	coordination	_	
114-35	21647-21649	of	_	
114-36	21650-21654	both	_	
114-37	21655-21666	attentional	_	
114-38	21667-21670	and	_	
114-39	21671-21680	cognitive	_	
114-40	21681-21688	control	_	
114-41	21689-21698	processes	_	
114-42	21699-21701	as	_	
114-43	21702-21706	well	_	
114-44	21707-21709	as	_	
114-45	21710-21712	of	_	
114-46	21713-21721	salience	_	
114-47	21722-21730	encoding	_	
114-48	21731-21734	and	_	
114-49	21735-21741	reward	_	
114-50	21742-21750	response	_	
114-51	21751-21760	behaviors	_	
114-52	21760-21761	.	_	

#Text=Findings are further consistent with recent data prospectively linking medial prefrontal, frontoparietal and salience networks to cocaine relapse, as well as with data from activation-based studies linking individual differences in brain reward responses to treatment outcomes in addiction.
115-1	21762-21770	Findings	_	
115-2	21771-21774	are	_	
115-3	21775-21782	further	_	
115-4	21783-21793	consistent	_	
115-5	21794-21798	with	_	
115-6	21799-21805	recent	_	
115-7	21806-21810	data	_	
115-8	21811-21824	prospectively	_	
115-9	21825-21832	linking	_	
115-10	21833-21839	medial	_	
115-11	21840-21850	prefrontal	_	
115-12	21850-21851	,	_	
115-13	21852-21866	frontoparietal	_	
115-14	21867-21870	and	_	
115-15	21871-21879	salience	_	
115-16	21880-21888	networks	_	
115-17	21889-21891	to	_	
115-18	21892-21899	cocaine	_	
115-19	21900-21907	relapse	_	
115-20	21907-21908	,	_	
115-21	21909-21911	as	_	
115-22	21912-21916	well	_	
115-23	21917-21919	as	_	
115-24	21920-21924	with	_	
115-25	21925-21929	data	_	
115-26	21930-21934	from	_	
115-27	21935-21951	activation-based	_	
115-28	21952-21959	studies	_	
115-29	21960-21967	linking	_	
115-30	21968-21978	individual	_	
115-31	21979-21990	differences	_	
115-32	21991-21993	in	_	
115-33	21994-21999	brain	_	
115-34	22000-22006	reward	_	
115-35	22007-22016	responses	_	
115-36	22017-22019	to	_	
115-37	22020-22029	treatment	_	
115-38	22030-22038	outcomes	_	
115-39	22039-22041	in	_	
115-40	22042-22051	addiction	_	
115-41	22051-22052	.	_	

#Text=They further suggest that segregation of executive control/attention and salience/reward response systems within the context of MID task performance may be optimal for achieving abstinence from cocaine.
116-1	22053-22057	They	_	
116-2	22058-22065	further	_	
116-3	22066-22073	suggest	_	
116-4	22074-22078	that	_	
116-5	22079-22090	segregation	_	
116-6	22091-22093	of	_	
116-7	22094-22103	executive	_	
116-8	22104-22111	control	_	
116-9	22111-22112	/	_	
116-10	22112-22121	attention	_	
116-11	22122-22125	and	_	
116-12	22126-22134	salience	_	
116-13	22134-22135	/	_	
116-14	22135-22141	reward	_	
116-15	22142-22150	response	_	
116-16	22151-22158	systems	_	
116-17	22159-22165	within	_	
116-18	22166-22169	the	_	
116-19	22170-22177	context	_	
116-20	22178-22180	of	_	
116-21	22181-22184	MID	_	
116-22	22185-22189	task	_	
116-23	22190-22201	performance	_	
116-24	22202-22205	may	_	
116-25	22206-22208	be	_	
116-26	22209-22216	optimal	_	
116-27	22217-22220	for	_	
116-28	22221-22230	achieving	_	
116-29	22231-22241	abstinence	_	
116-30	22242-22246	from	_	
116-31	22247-22254	cocaine	_	
116-32	22254-22255	.	_	

#Text=More generally, these data add to emerging evidence that manipulation of brain states (e.g., via reward task performance) may be helpful in detecting individual differences in brain-behavior relationships.
117-1	22256-22260	More	_	
117-2	22261-22270	generally	_	
117-3	22270-22271	,	_	
117-4	22272-22277	these	_	
117-5	22278-22282	data	_	
117-6	22283-22286	add	_	
117-7	22287-22289	to	_	
117-8	22290-22298	emerging	_	
117-9	22299-22307	evidence	_	
117-10	22308-22312	that	_	
117-11	22313-22325	manipulation	_	
117-12	22326-22328	of	_	
117-13	22329-22334	brain	_	
117-14	22335-22341	states	_	
117-15	22342-22343	(	_	
117-16	22343-22346	e.g	_	
117-17	22346-22347	.	_	
117-18	22347-22348	,	_	
117-19	22349-22352	via	_	
117-20	22353-22359	reward	_	
117-21	22360-22364	task	_	
117-22	22365-22376	performance	_	
117-23	22376-22377	)	_	
117-24	22378-22381	may	_	
117-25	22382-22384	be	_	
117-26	22385-22392	helpful	_	
117-27	22393-22395	in	_	
117-28	22396-22405	detecting	_	
117-29	22406-22416	individual	_	
117-30	22417-22428	differences	_	
117-31	22429-22431	in	_	
117-32	22432-22446	brain-behavior	_	
117-33	22447-22460	relationships	_	
117-34	22460-22461	.	_	

#Text=For example, CPMs derived from task-based data have consistently out-performed those derived from resting state data in non-addicted populations.
118-1	22462-22465	For	_	
118-2	22466-22473	example	_	
118-3	22473-22474	,	_	
118-4	22475-22479	CPMs	_	
118-5	22480-22487	derived	_	
118-6	22488-22492	from	_	
118-7	22493-22503	task-based	_	
118-8	22504-22508	data	_	
118-9	22509-22513	have	_	
118-10	22514-22526	consistently	_	
118-11	22527-22540	out-performed	_	
118-12	22541-22546	those	_	
118-13	22547-22554	derived	_	
118-14	22555-22559	from	_	
118-15	22560-22567	resting	_	
118-16	22568-22573	state	_	
118-17	22574-22578	data	_	
118-18	22579-22581	in	_	
118-19	22582-22594	non-addicted	_	
118-20	22595-22606	populations	_	
118-21	22606-22607	.	_	

#Text=However, further work across different brain states and in relation to diverse substance-use behaviors is needed to test this hypothesis within the specific context of addictions.
119-1	22608-22615	However	_	
119-2	22615-22616	,	_	
119-3	22617-22624	further	_	
119-4	22625-22629	work	_	
119-5	22630-22636	across	_	
119-6	22637-22646	different	_	
119-7	22647-22652	brain	_	
119-8	22653-22659	states	_	
119-9	22660-22663	and	_	
119-10	22664-22666	in	_	
119-11	22667-22675	relation	_	
119-12	22676-22678	to	_	
119-13	22679-22686	diverse	_	
119-14	22687-22700	substance-use	_	
119-15	22701-22710	behaviors	_	
119-16	22711-22713	is	_	
119-17	22714-22720	needed	_	
119-18	22721-22723	to	_	
119-19	22724-22728	test	_	
119-20	22729-22733	this	_	
119-21	22734-22744	hypothesis	_	
119-22	22745-22751	within	_	
119-23	22752-22755	the	_	
119-24	22756-22764	specific	_	
119-25	22765-22772	context	_	
119-26	22773-22775	of	_	
119-27	22776-22786	addictions	_	
119-28	22786-22787	.	_	

#Text=Connectivity strength within abstinence networks did not differ from pre- to posttreatment.
120-1	22788-22800	Connectivity	_	
120-2	22801-22809	strength	_	
120-3	22810-22816	within	_	
120-4	22817-22827	abstinence	_	
120-5	22828-22836	networks	_	
120-6	22837-22840	did	_	
120-7	22841-22844	not	_	
120-8	22845-22851	differ	_	
120-9	22852-22856	from	_	
120-10	22857-22860	pre	_	
120-11	22860-22861	-	_	
120-12	22862-22864	to	_	
120-13	22865-22878	posttreatment	_	
120-14	22878-22879	.	_	

#Text=Prior activation-based studies have demonstrated changes in neural responses following substance-use treatments; however, comparatively little is known about network-level changes with treatment.
121-1	22880-22885	Prior	_	
121-2	22886-22902	activation-based	_	
121-3	22903-22910	studies	_	
121-4	22911-22915	have	_	
121-5	22916-22928	demonstrated	_	
121-6	22929-22936	changes	_	
121-7	22937-22939	in	_	
121-8	22940-22946	neural	_	
121-9	22947-22956	responses	_	
121-10	22957-22966	following	_	
121-11	22967-22980	substance-use	_	
121-12	22981-22991	treatments	_	
121-13	22991-22992	;	_	
121-14	22993-23000	however	_	
121-15	23000-23001	,	_	
121-16	23002-23015	comparatively	_	
121-17	23016-23022	little	_	
121-18	23023-23025	is	_	
121-19	23026-23031	known	_	
121-20	23032-23037	about	_	
121-21	23038-23051	network-level	_	
121-22	23052-23059	changes	_	
121-23	23060-23064	with	_	
121-24	23065-23074	treatment	_	
121-25	23074-23075	.	_	

#Text=For example, individual differences in connectivity have been found to predict subsequent relapse to cocaine, yet no prior study has compared connectivity before and after treatment for cocaine-use-disorder.
122-1	23076-23079	For	_	
122-2	23080-23087	example	_	
122-3	23087-23088	,	_	
122-4	23089-23099	individual	_	
122-5	23100-23111	differences	_	
122-6	23112-23114	in	_	
122-7	23115-23127	connectivity	_	
122-8	23128-23132	have	_	
122-9	23133-23137	been	_	
122-10	23138-23143	found	_	
122-11	23144-23146	to	_	
122-12	23147-23154	predict	_	
122-13	23155-23165	subsequent	_	
122-14	23166-23173	relapse	_	
122-15	23174-23176	to	_	
122-16	23177-23184	cocaine	_	
122-17	23184-23185	,	_	
122-18	23186-23189	yet	_	
122-19	23190-23192	no	_	
122-20	23193-23198	prior	_	
122-21	23199-23204	study	_	
122-22	23205-23208	has	_	
122-23	23209-23217	compared	_	
122-24	23218-23230	connectivity	_	
122-25	23231-23237	before	_	
122-26	23238-23241	and	_	
122-27	23242-23247	after	_	
122-28	23248-23257	treatment	_	
122-29	23258-23261	for	_	
122-30	23262-23282	cocaine-use-disorder	_	
122-31	23282-23283	.	_	

#Text=Our findings suggest relative stability of identified networks over 12-week treatment, raising the possibility that abstinence may be more closely linked to pre-treatment neural function than to within-treatment neuroplasticity.
123-1	23284-23287	Our	_	
123-2	23288-23296	findings	_	
123-3	23297-23304	suggest	_	
123-4	23305-23313	relative	_	
123-5	23314-23323	stability	_	
123-6	23324-23326	of	_	
123-7	23327-23337	identified	_	
123-8	23338-23346	networks	_	
123-9	23347-23351	over	_	
123-10	23352-23354	12	_	
123-11	23354-23355	-	_	
123-12	23355-23359	week	_	
123-13	23360-23369	treatment	_	
123-14	23369-23370	,	_	
123-15	23371-23378	raising	_	
123-16	23379-23382	the	_	
123-17	23383-23394	possibility	_	
123-18	23395-23399	that	_	
123-19	23400-23410	abstinence	_	
123-20	23411-23414	may	_	
123-21	23415-23417	be	_	
123-22	23418-23422	more	_	
123-23	23423-23430	closely	_	
123-24	23431-23437	linked	_	
123-25	23438-23440	to	_	
123-26	23441-23454	pre-treatment	_	
123-27	23455-23461	neural	_	
123-28	23462-23470	function	_	
123-29	23471-23475	than	_	
123-30	23476-23478	to	_	
123-31	23479-23495	within-treatment	_	
123-32	23496-23511	neuroplasticity	_	
123-33	23511-23512	.	_	

#Text=Within this context, it is possible that pre-treatment interventions influencing connectivity within the identified networks (e.g., cognitive training, targeted pharmacotherapies) may be helpful in promoting abstinence during treatment.
124-1	23513-23519	Within	_	
124-2	23520-23524	this	_	
124-3	23525-23532	context	_	
124-4	23532-23533	,	_	
124-5	23534-23536	it	_	
124-6	23537-23539	is	_	
124-7	23540-23548	possible	_	
124-8	23549-23553	that	_	
124-9	23554-23567	pre-treatment	_	
124-10	23568-23581	interventions	_	
124-11	23582-23593	influencing	_	
124-12	23594-23606	connectivity	_	
124-13	23607-23613	within	_	
124-14	23614-23617	the	_	
124-15	23618-23628	identified	_	
124-16	23629-23637	networks	_	
124-17	23638-23639	(	_	
124-18	23639-23642	e.g	_	
124-19	23642-23643	.	_	
124-20	23643-23644	,	_	
124-21	23645-23654	cognitive	_	
124-22	23655-23663	training	_	
124-23	23663-23664	,	_	
124-24	23665-23673	targeted	_	
124-25	23674-23691	pharmacotherapies	_	
124-26	23691-23692	)	_	
124-27	23693-23696	may	_	
124-28	23697-23699	be	_	
124-29	23700-23707	helpful	_	
124-30	23708-23710	in	_	
124-31	23711-23720	promoting	_	
124-32	23721-23731	abstinence	_	
124-33	23732-23738	during	_	
124-34	23739-23748	treatment	_	
124-35	23748-23749	.	_	

#Text=For example, prior CPM work has demonstrated that connectivity strength within networks predictive of ADHD symptoms is changed following methylphenidate administration.
125-1	23750-23753	For	_	
125-2	23754-23761	example	_	
125-3	23761-23762	,	_	
125-4	23763-23768	prior	_	
125-5	23769-23772	CPM	_	
125-6	23773-23777	work	_	
125-7	23778-23781	has	_	
125-8	23782-23794	demonstrated	_	
125-9	23795-23799	that	_	
125-10	23800-23812	connectivity	_	
125-11	23813-23821	strength	_	
125-12	23822-23828	within	_	
125-13	23829-23837	networks	_	
125-14	23838-23848	predictive	_	
125-15	23849-23851	of	_	
125-16	23852-23856	ADHD	_	
125-17	23857-23865	symptoms	_	
125-18	23866-23868	is	_	
125-19	23869-23876	changed	_	
125-20	23877-23886	following	_	
125-21	23887-23902	methylphenidate	_	
125-22	23903-23917	administration	_	
125-23	23917-23918	.	_	

#Text=Thus it is possible that effective treatments for addictions might also influence connectivity within complex networks.
126-1	23919-23923	Thus	_	
126-2	23924-23926	it	_	
126-3	23927-23929	is	_	
126-4	23930-23938	possible	_	
126-5	23939-23943	that	_	
126-6	23944-23953	effective	_	
126-7	23954-23964	treatments	_	
126-8	23965-23968	for	_	
126-9	23969-23979	addictions	_	
126-10	23980-23985	might	_	
126-11	23986-23990	also	_	
126-12	23991-24000	influence	_	
126-13	24001-24013	connectivity	_	
126-14	24014-24020	within	_	
126-15	24021-24028	complex	_	
126-16	24029-24037	networks	_	
126-17	24037-24038	.	_	

#Text=It is further possible that networks contributing to treatment response are distinct from those directly implicated in disease pathology or that change with treatment.
127-1	24039-24041	It	_	
127-2	24042-24044	is	_	
127-3	24045-24052	further	_	
127-4	24053-24061	possible	_	
127-5	24062-24066	that	_	
127-6	24067-24075	networks	_	
127-7	24076-24088	contributing	_	
127-8	24089-24091	to	_	
127-9	24092-24101	treatment	_	
127-10	24102-24110	response	_	
127-11	24111-24114	are	_	
127-12	24115-24123	distinct	_	
127-13	24124-24128	from	_	
127-14	24129-24134	those	_	
127-15	24135-24143	directly	_	
127-16	24144-24154	implicated	_	
127-17	24155-24157	in	_	
127-18	24158-24165	disease	_	
127-19	24166-24175	pathology	_	
127-20	24176-24178	or	_	
127-21	24179-24183	that	_	
127-22	24184-24190	change	_	
127-23	24191-24195	with	_	
127-24	24196-24205	treatment	_	
127-25	24205-24206	.	_	

#Text=Brain regions predictive of treatment responses in other disorders often have limited overlap with regions consistently found to differentiate patients from controls.
128-1	24207-24212	Brain	_	
128-2	24213-24220	regions	_	
128-3	24221-24231	predictive	_	
128-4	24232-24234	of	_	
128-5	24235-24244	treatment	_	
128-6	24245-24254	responses	_	
128-7	24255-24257	in	_	
128-8	24258-24263	other	_	
128-9	24264-24273	disorders	_	
128-10	24274-24279	often	_	
128-11	24280-24284	have	_	
128-12	24285-24292	limited	_	
128-13	24293-24300	overlap	_	
128-14	24301-24305	with	_	
128-15	24306-24313	regions	_	
128-16	24314-24326	consistently	_	
128-17	24327-24332	found	_	
128-18	24333-24335	to	_	
128-19	24336-24349	differentiate	_	
128-20	24350-24358	patients	_	
128-21	24359-24363	from	_	
128-22	24364-24372	controls	_	
128-23	24372-24373	.	_	

#Text=Clinically, factors that predict treatment response (e.g., motivation to change) may be distinct from those that change with treatment (e.g., acquisition of new skills).
129-1	24374-24384	Clinically	_	
129-2	24384-24385	,	_	
129-3	24386-24393	factors	_	
129-4	24394-24398	that	_	
129-5	24399-24406	predict	_	
129-6	24407-24416	treatment	_	
129-7	24417-24425	response	_	
129-8	24426-24427	(	_	
129-9	24427-24430	e.g	_	
129-10	24430-24431	.	_	
129-11	24431-24432	,	_	
129-12	24433-24443	motivation	_	
129-13	24444-24446	to	_	
129-14	24447-24453	change	_	
129-15	24453-24454	)	_	
129-16	24455-24458	may	_	
129-17	24459-24461	be	_	
129-18	24462-24470	distinct	_	
129-19	24471-24475	from	_	
129-20	24476-24481	those	_	
129-21	24482-24486	that	_	
129-22	24487-24493	change	_	
129-23	24494-24498	with	_	
129-24	24499-24508	treatment	_	
129-25	24509-24510	(	_	
129-26	24510-24513	e.g	_	
129-27	24513-24514	.	_	
129-28	24514-24515	,	_	
129-29	24516-24527	acquisition	_	
129-30	24528-24530	of	_	
129-31	24531-24534	new	_	
129-32	24535-24541	skills	_	
129-33	24541-24542	)	_	
129-34	24542-24543	.	_	

#Text=Thus, the same may be true for neural networks.
130-1	24544-24548	Thus	_	
130-2	24548-24549	,	_	
130-3	24550-24553	the	_	
130-4	24554-24558	same	_	
130-5	24559-24562	may	_	
130-6	24563-24565	be	_	
130-7	24566-24570	true	_	
130-8	24571-24574	for	_	
130-9	24575-24581	neural	_	
130-10	24582-24590	networks	_	
130-11	24590-24591	.	_	

#Text=Further, it is possible that changes within abstinence networks may take time to emerge and thus may only be detectable following treatment, as would be consistent with data indicating protracted emergence of treatment effects.
131-1	24592-24599	Further	_	
131-2	24599-24600	,	_	
131-3	24601-24603	it	_	
131-4	24604-24606	is	_	
131-5	24607-24615	possible	_	
131-6	24616-24620	that	_	
131-7	24621-24628	changes	_	
131-8	24629-24635	within	_	
131-9	24636-24646	abstinence	_	
131-10	24647-24655	networks	_	
131-11	24656-24659	may	_	
131-12	24660-24664	take	_	
131-13	24665-24669	time	_	
131-14	24670-24672	to	_	
131-15	24673-24679	emerge	_	
131-16	24680-24683	and	_	
131-17	24684-24688	thus	_	
131-18	24689-24692	may	_	
131-19	24693-24697	only	_	
131-20	24698-24700	be	_	
131-21	24701-24711	detectable	_	
131-22	24712-24721	following	_	
131-23	24722-24731	treatment	_	
131-24	24731-24732	,	_	
131-25	24733-24735	as	_	
131-26	24736-24741	would	_	
131-27	24742-24744	be	_	
131-28	24745-24755	consistent	_	
131-29	24756-24760	with	_	
131-30	24761-24765	data	_	
131-31	24766-24776	indicating	_	
131-32	24777-24787	protracted	_	
131-33	24788-24797	emergence	_	
131-34	24798-24800	of	_	
131-35	24801-24810	treatment	_	
131-36	24811-24818	effects	_	
131-37	24818-24819	.	_	

#Text=Additional work is therefore needed to characterize network-level changes over time and in relation to addiction pathology, per se.
132-1	24820-24830	Additional	_	
132-2	24831-24835	work	_	
132-3	24836-24838	is	_	
132-4	24839-24848	therefore	_	
132-5	24849-24855	needed	_	
132-6	24856-24858	to	_	
132-7	24859-24871	characterize	_	
132-8	24872-24885	network-level	_	
132-9	24886-24893	changes	_	
132-10	24894-24898	over	_	
132-11	24899-24903	time	_	
132-12	24904-24907	and	_	
132-13	24908-24910	in	_	
132-14	24911-24919	relation	_	
132-15	24920-24922	to	_	
132-16	24923-24932	addiction	_	
132-17	24933-24942	pathology	_	
132-18	24942-24943	,	_	
132-19	24944-24947	per	_	
132-20	24948-24950	se	_	
132-21	24950-24951	.	_	

#Text=Similarly, future studies should consider how ‘positive’ versus ‘negative’ networks might change over the course of treatment.
133-1	24952-24961	Similarly	_	
133-2	24961-24962	,	_	
133-3	24963-24969	future	_	
133-4	24970-24977	studies	_	
133-5	24978-24984	should	_	
133-6	24985-24993	consider	_	
133-7	24994-24997	how	_	
133-8	24998-24999	‘	_	
133-9	24999-25007	positive	_	
133-10	25007-25008	’	_	
133-11	25009-25015	versus	_	
133-12	25016-25017	‘	_	
133-13	25017-25025	negative	_	
133-14	25025-25026	’	_	
133-15	25027-25035	networks	_	
133-16	25036-25041	might	_	
133-17	25042-25048	change	_	
133-18	25049-25053	over	_	
133-19	25054-25057	the	_	
133-20	25058-25064	course	_	
133-21	25065-25067	of	_	
133-22	25068-25077	treatment	_	
133-23	25077-25078	.	_	

#Text=While continuous prediction approaches, which maximize individual differences, are optimal for feature selection in heterogeneous clinical samples, the practical value of predictive modeling within a clinical context will likely involve binary prediction (e.g., treatment responder versus non-responder).
134-1	25079-25084	While	_	
134-2	25085-25095	continuous	_	
134-3	25096-25106	prediction	_	
134-4	25107-25117	approaches	_	
134-5	25117-25118	,	_	
134-6	25119-25124	which	_	
134-7	25125-25133	maximize	_	
134-8	25134-25144	individual	_	
134-9	25145-25156	differences	_	
134-10	25156-25157	,	_	
134-11	25158-25161	are	_	
134-12	25162-25169	optimal	_	
134-13	25170-25173	for	_	
134-14	25174-25181	feature	_	
134-15	25182-25191	selection	_	
134-16	25192-25194	in	_	
134-17	25195-25208	heterogeneous	_	
134-18	25209-25217	clinical	_	
134-19	25218-25225	samples	_	
134-20	25225-25226	,	_	
134-21	25227-25230	the	_	
134-22	25231-25240	practical	_	
134-23	25241-25246	value	_	
134-24	25247-25249	of	_	
134-25	25250-25260	predictive	_	
134-26	25261-25269	modeling	_	
134-27	25270-25276	within	_	
134-28	25277-25278	a	_	
134-29	25279-25287	clinical	_	
134-30	25288-25295	context	_	
134-31	25296-25300	will	_	
134-32	25301-25307	likely	_	
134-33	25308-25315	involve	_	
134-34	25316-25322	binary	_	
134-35	25323-25333	prediction	_	
134-36	25334-25335	(	_	
134-37	25335-25338	e.g	_	
134-38	25338-25339	.	_	
134-39	25339-25340	,	_	
134-40	25341-25350	treatment	_	
134-41	25351-25360	responder	_	
134-42	25361-25367	versus	_	
134-43	25368-25381	non-responder	_	
134-44	25381-25382	)	_	
134-45	25382-25383	.	_	

#Text=We therefore tested the ability of the identified networks to predict categorical outcomes (yes/no, drug negative urine), as well as to predict dimensional (percent drug negative urines) within-treatment abstinence in an independent, heterogeneous sample of individuals with cocaine-use disorder with and without concurrent methadone treatment.
135-1	25384-25386	We	_	
135-2	25387-25396	therefore	_	
135-3	25397-25403	tested	_	
135-4	25404-25407	the	_	
135-5	25408-25415	ability	_	
135-6	25416-25418	of	_	
135-7	25419-25422	the	_	
135-8	25423-25433	identified	_	
135-9	25434-25442	networks	_	
135-10	25443-25445	to	_	
135-11	25446-25453	predict	_	
135-12	25454-25465	categorical	_	
135-13	25466-25474	outcomes	_	
135-14	25475-25476	(	_	
135-15	25476-25479	yes	_	
135-16	25479-25480	/	_	
135-17	25480-25482	no	_	
135-18	25482-25483	,	_	
135-19	25484-25488	drug	_	
135-20	25489-25497	negative	_	
135-21	25498-25503	urine	_	
135-22	25503-25504	)	_	
135-23	25504-25505	,	_	
135-24	25506-25508	as	_	
135-25	25509-25513	well	_	
135-26	25514-25516	as	_	
135-27	25517-25519	to	_	
135-28	25520-25527	predict	_	
135-29	25528-25539	dimensional	_	
135-30	25540-25541	(	_	
135-31	25541-25548	percent	_	
135-32	25549-25553	drug	_	
135-33	25554-25562	negative	_	
135-34	25563-25569	urines	_	
135-35	25569-25570	)	_	
135-36	25571-25587	within-treatment	_	
135-37	25588-25598	abstinence	_	
135-38	25599-25601	in	_	
135-39	25602-25604	an	_	
135-40	25605-25616	independent	_	
135-41	25616-25617	,	_	
135-42	25618-25631	heterogeneous	_	
135-43	25632-25638	sample	_	
135-44	25639-25641	of	_	
135-45	25642-25653	individuals	_	
135-46	25654-25658	with	_	
135-47	25659-25670	cocaine-use	_	
135-48	25671-25679	disorder	_	
135-49	25680-25684	with	_	
135-50	25685-25688	and	_	
135-51	25689-25696	without	_	
135-52	25697-25707	concurrent	_	
135-53	25708-25717	methadone	_	
135-54	25718-25727	treatment	_	
135-55	25727-25728	.	_	

#Text=Connectivity within the identified networks successfully predicted both categorical and dimensional treatment response in our replication sample.
136-1	25729-25741	Connectivity	_	
136-2	25742-25748	within	_	
136-3	25749-25752	the	_	
136-4	25753-25763	identified	_	
136-5	25764-25772	networks	_	
136-6	25773-25785	successfully	_	
136-7	25786-25795	predicted	_	
136-8	25796-25800	both	_	
136-9	25801-25812	categorical	_	
136-10	25813-25816	and	_	
136-11	25817-25828	dimensional	_	
136-12	25829-25838	treatment	_	
136-13	25839-25847	response	_	
136-14	25848-25850	in	_	
136-15	25851-25854	our	_	
136-16	25855-25866	replication	_	
136-17	25867-25873	sample	_	
136-18	25873-25874	.	_	

#Text=In our replication sample, our model had high sensitivity but low specificity.
137-1	25875-25877	In	_	
137-2	25878-25881	our	_	
137-3	25882-25893	replication	_	
137-4	25894-25900	sample	_	
137-5	25900-25901	,	_	
137-6	25902-25905	our	_	
137-7	25906-25911	model	_	
137-8	25912-25915	had	_	
137-9	25916-25920	high	_	
137-10	25921-25932	sensitivity	_	
137-11	25933-25936	but	_	
137-12	25937-25940	low	_	
137-13	25941-25952	specificity	_	
137-14	25952-25953	.	_	

#Text=In this instance, low sensitivity would translate to under identification of responders (and thus under assignment of individuals to effective treatment), whereas low specificity would translate to under identification of non-responders (over-assignment to ineffective treatment).
138-1	25954-25956	In	_	
138-2	25957-25961	this	_	
138-3	25962-25970	instance	_	
138-4	25970-25971	,	_	
138-5	25972-25975	low	_	
138-6	25976-25987	sensitivity	_	
138-7	25988-25993	would	_	
138-8	25994-26003	translate	_	
138-9	26004-26006	to	_	
138-10	26007-26012	under	_	
138-11	26013-26027	identification	_	
138-12	26028-26030	of	_	
138-13	26031-26041	responders	_	
138-14	26042-26043	(	_	
138-15	26043-26046	and	_	
138-16	26047-26051	thus	_	
138-17	26052-26057	under	_	
138-18	26058-26068	assignment	_	
138-19	26069-26071	of	_	
138-20	26072-26083	individuals	_	
138-21	26084-26086	to	_	
138-22	26087-26096	effective	_	
138-23	26097-26106	treatment	_	
138-24	26106-26107	)	_	
138-25	26107-26108	,	_	
138-26	26109-26116	whereas	_	
138-27	26117-26120	low	_	
138-28	26121-26132	specificity	_	
138-29	26133-26138	would	_	
138-30	26139-26148	translate	_	
138-31	26149-26151	to	_	
138-32	26152-26157	under	_	
138-33	26158-26172	identification	_	
138-34	26173-26175	of	_	
138-35	26176-26190	non-responders	_	
138-36	26191-26192	(	_	
138-37	26192-26207	over-assignment	_	
138-38	26208-26210	to	_	
138-39	26211-26222	ineffective	_	
138-40	26223-26232	treatment	_	
138-41	26232-26233	)	_	
138-42	26233-26234	.	_	

#Text=Given that multiple failed treatment attempts are common in addictions – and that only resources are lost in the instance of over assignment to ineffective treatment – maximizing sensitivity in this instance appears paramount.
139-1	26235-26240	Given	_	
139-2	26241-26245	that	_	
139-3	26246-26254	multiple	_	
139-4	26255-26261	failed	_	
139-5	26262-26271	treatment	_	
139-6	26272-26280	attempts	_	
139-7	26281-26284	are	_	
139-8	26285-26291	common	_	
139-9	26292-26294	in	_	
139-10	26295-26305	addictions	_	
139-11	26306-26307	–	_	
139-12	26308-26311	and	_	
139-13	26312-26316	that	_	
139-14	26317-26321	only	_	
139-15	26322-26331	resources	_	
139-16	26332-26335	are	_	
139-17	26336-26340	lost	_	
139-18	26341-26343	in	_	
139-19	26344-26347	the	_	
139-20	26348-26356	instance	_	
139-21	26357-26359	of	_	
139-22	26360-26364	over	_	
139-23	26365-26375	assignment	_	
139-24	26376-26378	to	_	
139-25	26379-26390	ineffective	_	
139-26	26391-26400	treatment	_	
139-27	26401-26402	–	_	
139-28	26403-26413	maximizing	_	
139-29	26414-26425	sensitivity	_	
139-30	26426-26428	in	_	
139-31	26429-26433	this	_	
139-32	26434-26442	instance	_	
139-33	26443-26450	appears	_	
139-34	26451-26460	paramount	_	
139-35	26460-26461	.	_	

#Text=Strengths and limitations
#Text=This study has several strengths, including use of a recently developed whole-brain predictive modeling approach, multiple time point fMRI data (pre- and post-treatment) and out-of-sample replication.
140-1	26462-26471	Strengths	_	
140-2	26472-26475	and	_	
140-3	26476-26487	limitations	_	
140-4	26488-26492	This	_	
140-5	26493-26498	study	_	
140-6	26499-26502	has	_	
140-7	26503-26510	several	_	
140-8	26511-26520	strengths	_	
140-9	26520-26521	,	_	
140-10	26522-26531	including	_	
140-11	26532-26535	use	_	
140-12	26536-26538	of	_	
140-13	26539-26540	a	_	
140-14	26541-26549	recently	_	
140-15	26550-26559	developed	_	
140-16	26560-26571	whole-brain	_	
140-17	26572-26582	predictive	_	
140-18	26583-26591	modeling	_	
140-19	26592-26600	approach	_	
140-20	26600-26601	,	_	
140-21	26602-26610	multiple	_	
140-22	26611-26615	time	_	
140-23	26616-26621	point	_	
140-24	26622-26626	fMRI	_	
140-25	26627-26631	data	_	
140-26	26632-26633	(	_	
140-27	26633-26636	pre	_	
140-28	26636-26637	-	_	
140-29	26638-26641	and	_	
140-30	26642-26656	post-treatment	_	
140-31	26656-26657	)	_	
140-32	26658-26661	and	_	
140-33	26662-26675	out-of-sample	_	
140-34	26676-26687	replication	_	
140-35	26687-26688	.	_	

#Text=However, several limitations should be noted.
141-1	26689-26696	However	_	
141-2	26696-26697	,	_	
141-3	26698-26705	several	_	
141-4	26706-26717	limitations	_	
141-5	26718-26724	should	_	
141-6	26725-26727	be	_	
141-7	26728-26733	noted	_	
141-8	26733-26734	.	_	

#Text=Some participants were excluded for missing data or excess motion during scanning, resulting in a relatively modest sample size for our primary analysis (N=53); thus, further work in larger samples is warranted, as noted above.
142-1	26735-26739	Some	_	
142-2	26740-26752	participants	_	
142-3	26753-26757	were	_	
142-4	26758-26766	excluded	_	
142-5	26767-26770	for	_	
142-6	26771-26778	missing	_	
142-7	26779-26783	data	_	
142-8	26784-26786	or	_	
142-9	26787-26793	excess	_	
142-10	26794-26800	motion	_	
142-11	26801-26807	during	_	
142-12	26808-26816	scanning	_	
142-13	26816-26817	,	_	
142-14	26818-26827	resulting	_	
142-15	26828-26830	in	_	
142-16	26831-26832	a	_	
142-17	26833-26843	relatively	_	
142-18	26844-26850	modest	_	
142-19	26851-26857	sample	_	
142-20	26858-26862	size	_	
142-21	26863-26866	for	_	
142-22	26867-26870	our	_	
142-23	26871-26878	primary	_	
142-24	26879-26887	analysis	_	
142-25	26888-26889	(	_	
142-26	26889-26890	N	_	
142-27	26890-26891	=	_	
142-28	26891-26893	53	_	
142-29	26893-26894	)	_	
142-30	26894-26895	;	_	
142-31	26896-26900	thus	_	
142-32	26900-26901	,	_	
142-33	26902-26909	further	_	
142-34	26910-26914	work	_	
142-35	26915-26917	in	_	
142-36	26918-26924	larger	_	
142-37	26925-26932	samples	_	
142-38	26933-26935	is	_	
142-39	26936-26945	warranted	_	
142-40	26945-26946	,	_	
142-41	26947-26949	as	_	
142-42	26950-26955	noted	_	
142-43	26956-26961	above	_	
142-44	26961-26962	.	_	

#Text=In addition, the functional significance of the identified networks in relation to other aspects of substance-use pathology remains to be determined.
143-1	26963-26965	In	_	
143-2	26966-26974	addition	_	
143-3	26974-26975	,	_	
143-4	26976-26979	the	_	
143-5	26980-26990	functional	_	
143-6	26991-27003	significance	_	
143-7	27004-27006	of	_	
143-8	27007-27010	the	_	
143-9	27011-27021	identified	_	
143-10	27022-27030	networks	_	
143-11	27031-27033	in	_	
143-12	27034-27042	relation	_	
143-13	27043-27045	to	_	
143-14	27046-27051	other	_	
143-15	27052-27059	aspects	_	
143-16	27060-27062	of	_	
143-17	27063-27076	substance-use	_	
143-18	27077-27086	pathology	_	
143-19	27087-27094	remains	_	
143-20	27095-27097	to	_	
143-21	27098-27100	be	_	
143-22	27101-27111	determined	_	
143-23	27111-27112	.	_	

#Text=While networks were relatively robust and not significantly changed in follow-up analyses controlling for other factors, we cannot entirely exclude the effects of other clinical variables, such as concurrent use of other substances or even acute intoxication, on connectivity strength.
144-1	27113-27118	While	_	
144-2	27119-27127	networks	_	
144-3	27128-27132	were	_	
144-4	27133-27143	relatively	_	
144-5	27144-27150	robust	_	
144-6	27151-27154	and	_	
144-7	27155-27158	not	_	
144-8	27159-27172	significantly	_	
144-9	27173-27180	changed	_	
144-10	27181-27183	in	_	
144-11	27184-27193	follow-up	_	
144-12	27194-27202	analyses	_	
144-13	27203-27214	controlling	_	
144-14	27215-27218	for	_	
144-15	27219-27224	other	_	
144-16	27225-27232	factors	_	
144-17	27232-27233	,	_	
144-18	27234-27236	we	_	
144-19	27237-27243	cannot	_	
144-20	27244-27252	entirely	_	
144-21	27253-27260	exclude	_	
144-22	27261-27264	the	_	
144-23	27265-27272	effects	_	
144-24	27273-27275	of	_	
144-25	27276-27281	other	_	
144-26	27282-27290	clinical	_	
144-27	27291-27300	variables	_	
144-28	27300-27301	,	_	
144-29	27302-27306	such	_	
144-30	27307-27309	as	_	
144-31	27310-27320	concurrent	_	
144-32	27321-27324	use	_	
144-33	27325-27327	of	_	
144-34	27328-27333	other	_	
144-35	27334-27344	substances	_	
144-36	27345-27347	or	_	
144-37	27348-27352	even	_	
144-38	27353-27358	acute	_	
144-39	27359-27371	intoxication	_	
144-40	27371-27372	,	_	
144-41	27373-27375	on	_	
144-42	27376-27388	connectivity	_	
144-43	27389-27397	strength	_	
144-44	27397-27398	.	_	

#Text=Given the relatively limited temporal specificity of urine toxicology analyses, future studies should consider incorporation of salivary testing for acute drug effects.
145-1	27399-27404	Given	_	
145-2	27405-27408	the	_	
145-3	27409-27419	relatively	_	
145-4	27420-27427	limited	_	
145-5	27428-27436	temporal	_	
145-6	27437-27448	specificity	_	
145-7	27449-27451	of	_	
145-8	27452-27457	urine	_	
145-9	27458-27468	toxicology	_	
145-10	27469-27477	analyses	_	
145-11	27477-27478	,	_	
145-12	27479-27485	future	_	
145-13	27486-27493	studies	_	
145-14	27494-27500	should	_	
145-15	27501-27509	consider	_	
145-16	27510-27523	incorporation	_	
145-17	27524-27526	of	_	
145-18	27527-27535	salivary	_	
145-19	27536-27543	testing	_	
145-20	27544-27547	for	_	
145-21	27548-27553	acute	_	
145-22	27554-27558	drug	_	
145-23	27559-27566	effects	_	
145-24	27566-27567	.	_	

#Text=In addition, further work will be needed to determine generalizability of these findings to fMRI data acquired during performance of different tasks and/or while the brain is ‘at-rest’.
146-1	27568-27570	In	_	
146-2	27571-27579	addition	_	
146-3	27579-27580	,	_	
146-4	27581-27588	further	_	
146-5	27589-27593	work	_	
146-6	27594-27598	will	_	
146-7	27599-27601	be	_	
146-8	27602-27608	needed	_	
146-9	27609-27611	to	_	
146-10	27612-27621	determine	_	
146-11	27622-27638	generalizability	_	
146-12	27639-27641	of	_	
146-13	27642-27647	these	_	
146-14	27648-27656	findings	_	
146-15	27657-27659	to	_	
146-16	27660-27664	fMRI	_	
146-17	27665-27669	data	_	
146-18	27670-27678	acquired	_	
146-19	27679-27685	during	_	
146-20	27686-27697	performance	_	
146-21	27698-27700	of	_	
146-22	27701-27710	different	_	
146-23	27711-27716	tasks	_	
146-24	27717-27720	and	_	
146-25	27720-27721	/	_	
146-26	27721-27723	or	_	
146-27	27724-27729	while	_	
146-28	27730-27733	the	_	
146-29	27734-27739	brain	_	
146-30	27740-27742	is	_	
146-31	27743-27744	‘	_	
146-32	27744-27751	at-rest	_	
146-33	27751-27752	’	_	
146-34	27752-27753	.	_	

#Text=To avoid circularity, we did not test the ability of pre-treatment data to predict abstinence during follow-up; however, this will be an important next step for future studies.
147-1	27754-27756	To	_	
147-2	27757-27762	avoid	_	
147-3	27763-27774	circularity	_	
147-4	27774-27775	,	_	
147-5	27776-27778	we	_	
147-6	27779-27782	did	_	
147-7	27783-27786	not	_	
147-8	27787-27791	test	_	
147-9	27792-27795	the	_	
147-10	27796-27803	ability	_	
147-11	27804-27806	of	_	
147-12	27807-27820	pre-treatment	_	
147-13	27821-27825	data	_	
147-14	27826-27828	to	_	
147-15	27829-27836	predict	_	
147-16	27837-27847	abstinence	_	
147-17	27848-27854	during	_	
147-18	27855-27864	follow-up	_	
147-19	27864-27865	;	_	
147-20	27866-27873	however	_	
147-21	27873-27874	,	_	
147-22	27875-27879	this	_	
147-23	27880-27884	will	_	
147-24	27885-27887	be	_	
147-25	27888-27890	an	_	
147-26	27891-27900	important	_	
147-27	27901-27905	next	_	
147-28	27906-27910	step	_	
147-29	27911-27914	for	_	
147-30	27915-27921	future	_	
147-31	27922-27929	studies	_	
147-32	27929-27930	.	_	

#Text=To facilitate replication, we have made the positive and negative abstinence network masks publicly available at our website (to be posted upon manuscript publication).
148-1	27931-27933	To	_	
148-2	27934-27944	facilitate	_	
148-3	27945-27956	replication	_	
148-4	27956-27957	,	_	
148-5	27958-27960	we	_	
148-6	27961-27965	have	_	
148-7	27966-27970	made	_	
148-8	27971-27974	the	_	
148-9	27975-27983	positive	_	
148-10	27984-27987	and	_	
148-11	27988-27996	negative	_	
148-12	27997-28007	abstinence	_	
148-13	28008-28015	network	_	
148-14	28016-28021	masks	_	
148-15	28022-28030	publicly	_	
148-16	28031-28040	available	_	
148-17	28041-28043	at	_	
148-18	28044-28047	our	_	
148-19	28048-28055	website	_	
148-20	28056-28057	(	_	
148-21	28057-28059	to	_	
148-22	28060-28062	be	_	
148-23	28063-28069	posted	_	
148-24	28070-28074	upon	_	
148-25	28075-28085	manuscript	_	
148-26	28086-28097	publication	_	
148-27	28097-28098	)	_	
148-28	28098-28099	.	_	

#Text=Identified networks accounted for just under 20% of the variance in within treatment abstinence for novel subjects.
149-1	28100-28110	Identified	_	
149-2	28111-28119	networks	_	
149-3	28120-28129	accounted	_	
149-4	28130-28133	for	_	
149-5	28134-28138	just	_	
149-6	28139-28144	under	_	
149-7	28145-28148	20%	_	
149-8	28149-28151	of	_	
149-9	28152-28155	the	_	
149-10	28156-28164	variance	_	
149-11	28165-28167	in	_	
149-12	28168-28174	within	_	
149-13	28175-28184	treatment	_	
149-14	28185-28195	abstinence	_	
149-15	28196-28199	for	_	
149-16	28200-28205	novel	_	
149-17	28206-28214	subjects	_	
149-18	28214-28215	.	_	

#Text=While arguably somewhat modest, it is important to note that effect sizes estimates derived from ‘traditional’ statistical approaches – i.e., statistics applied to test explanatory hypotheses – are typically larger than those derived from machine learning approaches – i.e., statistics applied to predict unknown information.
150-1	28216-28221	While	_	
150-2	28222-28230	arguably	_	
150-3	28231-28239	somewhat	_	
150-4	28240-28246	modest	_	
150-5	28246-28247	,	_	
150-6	28248-28250	it	_	
150-7	28251-28253	is	_	
150-8	28254-28263	important	_	
150-9	28264-28266	to	_	
150-10	28267-28271	note	_	
150-11	28272-28276	that	_	
150-12	28277-28283	effect	_	
150-13	28284-28289	sizes	_	
150-14	28290-28299	estimates	_	
150-15	28300-28307	derived	_	
150-16	28308-28312	from	_	
150-17	28313-28314	‘	_	
150-18	28314-28325	traditional	_	
150-19	28325-28326	’	_	
150-20	28327-28338	statistical	_	
150-21	28339-28349	approaches	_	
150-22	28350-28351	–	_	
150-23	28352-28355	i.e	_	
150-24	28355-28356	.	_	
150-25	28356-28357	,	_	
150-26	28358-28368	statistics	_	
150-27	28369-28376	applied	_	
150-28	28377-28379	to	_	
150-29	28380-28384	test	_	
150-30	28385-28396	explanatory	_	
150-31	28397-28407	hypotheses	_	
150-32	28408-28409	–	_	
150-33	28410-28413	are	_	
150-34	28414-28423	typically	_	
150-35	28424-28430	larger	_	
150-36	28431-28435	than	_	
150-37	28436-28441	those	_	
150-38	28442-28449	derived	_	
150-39	28450-28454	from	_	
150-40	28455-28462	machine	_	
150-41	28463-28471	learning	_	
150-42	28472-28482	approaches	_	
150-43	28483-28484	–	_	
150-44	28485-28488	i.e	_	
150-45	28488-28489	.	_	
150-46	28489-28490	,	_	
150-47	28491-28501	statistics	_	
150-48	28502-28509	applied	_	
150-49	28510-28512	to	_	
150-50	28513-28520	predict	_	
150-51	28521-28528	unknown	_	
150-52	28529-28540	information	_	
150-53	28540-28541	.	_	

#Text=Predictive models are less likely to overfit a specific dataset, leading to both increased likelihood of outof-sample-replication as well as typically decreased (more realistic) effect size estimates.
151-1	28542-28552	Predictive	_	
151-2	28553-28559	models	_	
151-3	28560-28563	are	_	
151-4	28564-28568	less	_	
151-5	28569-28575	likely	_	
151-6	28576-28578	to	_	
151-7	28579-28586	overfit	_	
151-8	28587-28588	a	_	
151-9	28589-28597	specific	_	
151-10	28598-28605	dataset	_	
151-11	28605-28606	,	_	
151-12	28607-28614	leading	_	
151-13	28615-28617	to	_	
151-14	28618-28622	both	_	
151-15	28623-28632	increased	_	
151-16	28633-28643	likelihood	_	
151-17	28644-28646	of	_	
151-18	28647-28671	outof-sample-replication	_	
151-19	28672-28674	as	_	
151-20	28675-28679	well	_	
151-21	28680-28682	as	_	
151-22	28683-28692	typically	_	
151-23	28693-28702	decreased	_	
151-24	28703-28704	(	_	
151-25	28704-28708	more	_	
151-26	28709-28718	realistic	_	
151-27	28718-28719	)	_	
151-28	28720-28726	effect	_	
151-29	28727-28731	size	_	
151-30	28732-28741	estimates	_	
151-31	28741-28742	.	_	

#Text=Similarly, small effect sizes are found in mega-analyses with ~10,000 subjects (e.g., findings from the EGINMA project).
152-1	28743-28752	Similarly	_	
152-2	28752-28753	,	_	
152-3	28754-28759	small	_	
152-4	28760-28766	effect	_	
152-5	28767-28772	sizes	_	
152-6	28773-28776	are	_	
152-7	28777-28782	found	_	
152-8	28783-28785	in	_	
152-9	28786-28799	mega-analyses	_	
152-10	28800-28804	with	_	
152-11	28805-28806	~	_	
152-12	28806-28812	10,000	_	
152-13	28813-28821	subjects	_	
152-14	28822-28823	(	_	
152-15	28823-28826	e.g	_	
152-16	28826-28827	.	_	
152-17	28827-28828	,	_	
152-18	28829-28837	findings	_	
152-19	28838-28842	from	_	
152-20	28843-28846	the	_	
152-21	28847-28853	EGINMA	_	
152-22	28854-28861	project	_	
152-23	28861-28862	)	_	
152-24	28862-28863	.	_	

#Text=Conclusions
#Text=This study demonstrates that baseline patterns of whole-brain connectivity can predict a complex clinical outcome – in this case, cocaine abstinence.
153-1	28864-28875	Conclusions	_	
153-2	28876-28880	This	_	
153-3	28881-28886	study	_	
153-4	28887-28899	demonstrates	_	
153-5	28900-28904	that	_	
153-6	28905-28913	baseline	_	
153-7	28914-28922	patterns	_	
153-8	28923-28925	of	_	
153-9	28926-28937	whole-brain	_	
153-10	28938-28950	connectivity	_	
153-11	28951-28954	can	_	
153-12	28955-28962	predict	_	
153-13	28963-28964	a	_	
153-14	28965-28972	complex	_	
153-15	28973-28981	clinical	_	
153-16	28982-28989	outcome	_	
153-17	28990-28991	–	_	
153-18	28992-28994	in	_	
153-19	28995-28999	this	_	
153-20	29000-29004	case	_	
153-21	29004-29005	,	_	
153-22	29006-29013	cocaine	_	
153-23	29014-29024	abstinence	_	
153-24	29024-29025	.	_	

#Text=Consistent with the parent randomized controlled trial, participants had significant addiction histories including multiple prior quit-attempts, legal problems and concurrent methadone treatment for opioid-use disorder.
154-1	29026-29036	Consistent	_	
154-2	29037-29041	with	_	
154-3	29042-29045	the	_	
154-4	29046-29052	parent	_	
154-5	29053-29063	randomized	_	
154-6	29064-29074	controlled	_	
154-7	29075-29080	trial	_	
154-8	29080-29081	,	_	
154-9	29082-29094	participants	_	
154-10	29095-29098	had	_	
154-11	29099-29110	significant	_	
154-12	29111-29120	addiction	_	
154-13	29121-29130	histories	_	
154-14	29131-29140	including	_	
154-15	29141-29149	multiple	_	
154-16	29150-29155	prior	_	
154-17	29156-29169	quit-attempts	_	
154-18	29169-29170	,	_	
154-19	29171-29176	legal	_	
154-20	29177-29185	problems	_	
154-21	29186-29189	and	_	
154-22	29190-29200	concurrent	_	
154-23	29201-29210	methadone	_	
154-24	29211-29220	treatment	_	
154-25	29221-29224	for	_	
154-26	29225-29235	opioid-use	_	
154-27	29236-29244	disorder	_	
154-28	29244-29245	.	_	

#Text=Despite this clinically rich profile, baseline connectivity within the identified networks successfully predicted within-treatment abstinence, even after controlling for other baseline variables including other drug-use history and treatment assignment.
155-1	29246-29253	Despite	_	
155-2	29254-29258	this	_	
155-3	29259-29269	clinically	_	
155-4	29270-29274	rich	_	
155-5	29275-29282	profile	_	
155-6	29282-29283	,	_	
155-7	29284-29292	baseline	_	
155-8	29293-29305	connectivity	_	
155-9	29306-29312	within	_	
155-10	29313-29316	the	_	
155-11	29317-29327	identified	_	
155-12	29328-29336	networks	_	
155-13	29337-29349	successfully	_	
155-14	29350-29359	predicted	_	
155-15	29360-29376	within-treatment	_	
155-16	29377-29387	abstinence	_	
155-17	29387-29388	,	_	
155-18	29389-29393	even	_	
155-19	29394-29399	after	_	
155-20	29400-29411	controlling	_	
155-21	29412-29415	for	_	
155-22	29416-29421	other	_	
155-23	29422-29430	baseline	_	
155-24	29431-29440	variables	_	
155-25	29441-29450	including	_	
155-26	29451-29456	other	_	
155-27	29457-29465	drug-use	_	
155-28	29466-29473	history	_	
155-29	29474-29477	and	_	
155-30	29478-29487	treatment	_	
155-31	29488-29498	assignment	_	
155-32	29498-29499	.	_	

#Text=The predictive ability of these networks translated to a separate, heterogeneous sample of individuals (including non-methadone maintained individuals with cocaine-use disorder scanned prior to enrollment in a different treatment trial).
156-1	29500-29503	The	_	
156-2	29504-29514	predictive	_	
156-3	29515-29522	ability	_	
156-4	29523-29525	of	_	
156-5	29526-29531	these	_	
156-6	29532-29540	networks	_	
156-7	29541-29551	translated	_	
156-8	29552-29554	to	_	
156-9	29555-29556	a	_	
156-10	29557-29565	separate	_	
156-11	29565-29566	,	_	
156-12	29567-29580	heterogeneous	_	
156-13	29581-29587	sample	_	
156-14	29588-29590	of	_	
156-15	29591-29602	individuals	_	
156-16	29603-29604	(	_	
156-17	29604-29613	including	_	
156-18	29614-29627	non-methadone	_	
156-19	29628-29638	maintained	_	
156-20	29639-29650	individuals	_	
156-21	29651-29655	with	_	
156-22	29656-29667	cocaine-use	_	
156-23	29668-29676	disorder	_	
156-24	29677-29684	scanned	_	
156-25	29685-29690	prior	_	
156-26	29691-29693	to	_	
156-27	29694-29704	enrollment	_	
156-28	29705-29707	in	_	
156-29	29708-29709	a	_	
156-30	29710-29719	different	_	
156-31	29720-29729	treatment	_	
156-32	29730-29735	trial	_	
156-33	29735-29736	)	_	
156-34	29736-29737	.	_	

#Text=These data demonstrate that individual differences in connectivity within large-scale neural networks implicated in cognitive/executive control and reward responsiveness processes contribute to variability in cocaine-use outcomes.
157-1	29738-29743	These	_	
157-2	29744-29748	data	_	
157-3	29749-29760	demonstrate	_	
157-4	29761-29765	that	_	
157-5	29766-29776	individual	_	
157-6	29777-29788	differences	_	
157-7	29789-29791	in	_	
157-8	29792-29804	connectivity	_	
157-9	29805-29811	within	_	
157-10	29812-29823	large-scale	_	
157-11	29824-29830	neural	_	
157-12	29831-29839	networks	_	
157-13	29840-29850	implicated	_	
157-14	29851-29853	in	_	
157-15	29854-29863	cognitive	_	
157-16	29863-29864	/	_	
157-17	29864-29873	executive	_	
157-18	29874-29881	control	_	
157-19	29882-29885	and	_	
157-20	29886-29892	reward	_	
157-21	29893-29907	responsiveness	_	
157-22	29908-29917	processes	_	
157-23	29918-29928	contribute	_	
157-24	29929-29931	to	_	
157-25	29932-29943	variability	_	
157-26	29944-29946	in	_	
157-27	29947-29958	cocaine-use	_	
157-28	29959-29967	outcomes	_	
157-29	29967-29968	.	_	

#Text=As such, these ‘neural fingerprints’ may be an appropriate target for future intervention efforts.
158-1	29969-29971	As	_	
158-2	29972-29976	such	_	
158-3	29976-29977	,	_	
158-4	29978-29983	these	_	
158-5	29984-29985	‘	_	
158-6	29985-29991	neural	_	
158-7	29992-30004	fingerprints	_	
158-8	30004-30005	’	_	
158-9	30006-30009	may	_	
158-10	30010-30012	be	_	
158-11	30013-30015	an	_	
158-12	30016-30027	appropriate	_	
158-13	30028-30034	target	_	
158-14	30035-30038	for	_	
158-15	30039-30045	future	_	
158-16	30046-30058	intervention	_	
158-17	30059-30066	efforts	_	
158-18	30066-30067	.	_	

#Text=Supplementary Material
#Text=References
#Text=Individual differences in anterior cingulate activation associated with attentional bias predict cocaine use after treatment
#Text=Neurofunctional Reward Processing Changes in Cocaine Dependence During Recovery
#Text=Functional brain networks associated with cognitive control, cocaine dependence, and treatment outcome
#Text=Anticipatory reward processing among cocaine-dependent individuals with and without concurrent methadone-maintenance treatment: Relationship to treatment response
#Text=Salience and default mode network dysregulation in chronic cocaine users predict treatment outcome
#Text=Toward biomarkers of the addicted human brain: Using neuroimaging to predict relapse and sustained abstinence in substance use disorder
#Text=
#Text=The neurobiology of successful abstinence
#Text=Brain connectomics predict response to treatment in social anxiety disorder
#Text=Brain mechanisms of Change in Addictions Treatment: Models, Methods, and Emerging Findings
#Text=Prediction as a Humanitarian and Pragmatic Contribution from Human Cognitive Neuroscience
#Text=When Optimism Hurts: Inflated Predictions in Psychiatric Neuroimaging
#Text=Using connectome-based predictive modeling to predict individual behavior from brain connectivity
#Text=Puzzlingly High Correlations in fMRI Studies of Emotion, Personality, and Social Cognition
#Text=The potential of neuroimaging for identifying predictors of adolescent alcohol use initiation and misuse
#Text=Executive control network connectivity strength protects against relapse to cocaine use
#Text=Functional connectome fingerprinting: identifying individuals using patterns of brain connectivity
#Text=A neuromarker of sustained attention from whole-brain functional connectivity
#Text=Methylphenidate Modulates Functional Network Connectivity to Enhance Attention
#Text=Galantamine and Computerized Cognitive Behavioral Therapy for Cocaine Dependence: A Randomized Clinical Trial
#Text=Individuals Family History Positive for Alcoholism Show Functional Magnetic Resonance Imaging Differences in Reward Sensitivity That Are Related to Impulsivity Factors
#Text=Groupwise whole-brain parcellation from resting-state fMRI data for network node identification
#Text=Can brain state be manipulated to emphasize individual differences in functional connectivity?
159-1	30068-30081	Supplementary	_	
159-2	30082-30090	Material	_	
159-3	30091-30101	References	_	
159-4	30102-30112	Individual	_	
159-5	30113-30124	differences	_	
159-6	30125-30127	in	_	
159-7	30128-30136	anterior	_	
159-8	30137-30146	cingulate	_	
159-9	30147-30157	activation	_	
159-10	30158-30168	associated	_	
159-11	30169-30173	with	_	
159-12	30174-30185	attentional	_	
159-13	30186-30190	bias	_	
159-14	30191-30198	predict	_	
159-15	30199-30206	cocaine	_	
159-16	30207-30210	use	_	
159-17	30211-30216	after	_	
159-18	30217-30226	treatment	_	
159-19	30227-30242	Neurofunctional	_	
159-20	30243-30249	Reward	_	
159-21	30250-30260	Processing	_	
159-22	30261-30268	Changes	_	
159-23	30269-30271	in	_	
159-24	30272-30279	Cocaine	_	
159-25	30280-30290	Dependence	_	
159-26	30291-30297	During	_	
159-27	30298-30306	Recovery	_	
159-28	30307-30317	Functional	_	
159-29	30318-30323	brain	_	
159-30	30324-30332	networks	_	
159-31	30333-30343	associated	_	
159-32	30344-30348	with	_	
159-33	30349-30358	cognitive	_	
159-34	30359-30366	control	_	
159-35	30366-30367	,	_	
159-36	30368-30375	cocaine	_	
159-37	30376-30386	dependence	_	
159-38	30386-30387	,	_	
159-39	30388-30391	and	_	
159-40	30392-30401	treatment	_	
159-41	30402-30409	outcome	_	
159-42	30410-30422	Anticipatory	_	
159-43	30423-30429	reward	_	
159-44	30430-30440	processing	_	
159-45	30441-30446	among	_	
159-46	30447-30464	cocaine-dependent	_	
159-47	30465-30476	individuals	_	
159-48	30477-30481	with	_	
159-49	30482-30485	and	_	
159-50	30486-30493	without	_	
159-51	30494-30504	concurrent	_	
159-52	30505-30526	methadone-maintenance	_	
159-53	30527-30536	treatment	_	
159-54	30536-30537	:	_	
159-55	30538-30550	Relationship	_	
159-56	30551-30553	to	_	
159-57	30554-30563	treatment	_	
159-58	30564-30572	response	_	
159-59	30573-30581	Salience	_	
159-60	30582-30585	and	_	
159-61	30586-30593	default	_	
159-62	30594-30598	mode	_	
159-63	30599-30606	network	_	
159-64	30607-30620	dysregulation	_	
159-65	30621-30623	in	_	
159-66	30624-30631	chronic	_	
159-67	30632-30639	cocaine	_	
159-68	30640-30645	users	_	
159-69	30646-30653	predict	_	
159-70	30654-30663	treatment	_	
159-71	30664-30671	outcome	_	
159-72	30672-30678	Toward	_	
159-73	30679-30689	biomarkers	_	
159-74	30690-30692	of	_	
159-75	30693-30696	the	_	
159-76	30697-30705	addicted	_	
159-77	30706-30711	human	_	
159-78	30712-30717	brain	_	
159-79	30717-30718	:	_	
159-80	30719-30724	Using	_	
159-81	30725-30737	neuroimaging	_	
159-82	30738-30740	to	_	
159-83	30741-30748	predict	_	
159-84	30749-30756	relapse	_	
159-85	30757-30760	and	_	
159-86	30761-30770	sustained	_	
159-87	30771-30781	abstinence	_	
159-88	30782-30784	in	_	
159-89	30785-30794	substance	_	
159-90	30795-30798	use	_	
159-91	30799-30807	disorder	_	
159-92	30809-30812	The	_	
159-93	30813-30825	neurobiology	_	
159-94	30826-30828	of	_	
159-95	30829-30839	successful	_	
159-96	30840-30850	abstinence	_	
159-97	30851-30856	Brain	_	
159-98	30857-30869	connectomics	_	
159-99	30870-30877	predict	_	
159-100	30878-30886	response	_	
159-101	30887-30889	to	_	
159-102	30890-30899	treatment	_	
159-103	30900-30902	in	_	
159-104	30903-30909	social	_	
159-105	30910-30917	anxiety	_	
159-106	30918-30926	disorder	_	
159-107	30927-30932	Brain	_	
159-108	30933-30943	mechanisms	_	
159-109	30944-30946	of	_	
159-110	30947-30953	Change	_	
159-111	30954-30956	in	_	
159-112	30957-30967	Addictions	_	
159-113	30968-30977	Treatment	_	
159-114	30977-30978	:	_	
159-115	30979-30985	Models	_	
159-116	30985-30986	,	_	
159-117	30987-30994	Methods	_	
159-118	30994-30995	,	_	
159-119	30996-30999	and	_	
159-120	31000-31008	Emerging	_	
159-121	31009-31017	Findings	_	
159-122	31018-31028	Prediction	_	
159-123	31029-31031	as	_	
159-124	31032-31033	a	_	
159-125	31034-31046	Humanitarian	_	
159-126	31047-31050	and	_	
159-127	31051-31060	Pragmatic	_	
159-128	31061-31073	Contribution	_	
159-129	31074-31078	from	_	
159-130	31079-31084	Human	_	
159-131	31085-31094	Cognitive	_	
159-132	31095-31107	Neuroscience	_	
159-133	31108-31112	When	_	
159-134	31113-31121	Optimism	_	
159-135	31122-31127	Hurts	_	
159-136	31127-31128	:	_	
159-137	31129-31137	Inflated	_	
159-138	31138-31149	Predictions	_	
159-139	31150-31152	in	_	
159-140	31153-31164	Psychiatric	_	
159-141	31165-31177	Neuroimaging	_	
159-142	31178-31183	Using	_	
159-143	31184-31200	connectome-based	_	
159-144	31201-31211	predictive	_	
159-145	31212-31220	modeling	_	
159-146	31221-31223	to	_	
159-147	31224-31231	predict	_	
159-148	31232-31242	individual	_	
159-149	31243-31251	behavior	_	
159-150	31252-31256	from	_	
159-151	31257-31262	brain	_	
159-152	31263-31275	connectivity	_	
159-153	31276-31286	Puzzlingly	_	
159-154	31287-31291	High	_	
159-155	31292-31304	Correlations	_	
159-156	31305-31307	in	_	
159-157	31308-31312	fMRI	_	
159-158	31313-31320	Studies	_	
159-159	31321-31323	of	_	
159-160	31324-31331	Emotion	_	
159-161	31331-31332	,	_	
159-162	31333-31344	Personality	_	
159-163	31344-31345	,	_	
159-164	31346-31349	and	_	
159-165	31350-31356	Social	_	
159-166	31357-31366	Cognition	_	
159-167	31367-31370	The	_	
159-168	31371-31380	potential	_	
159-169	31381-31383	of	_	
159-170	31384-31396	neuroimaging	_	
159-171	31397-31400	for	_	
159-172	31401-31412	identifying	_	
159-173	31413-31423	predictors	_	
159-174	31424-31426	of	_	
159-175	31427-31437	adolescent	_	
159-176	31438-31445	alcohol	_	
159-177	31446-31449	use	_	
159-178	31450-31460	initiation	_	
159-179	31461-31464	and	_	
159-180	31465-31471	misuse	_	
159-181	31472-31481	Executive	_	
159-182	31482-31489	control	_	
159-183	31490-31497	network	_	
159-184	31498-31510	connectivity	_	
159-185	31511-31519	strength	_	
159-186	31520-31528	protects	_	
159-187	31529-31536	against	_	
159-188	31537-31544	relapse	_	
159-189	31545-31547	to	_	
159-190	31548-31555	cocaine	_	
159-191	31556-31559	use	_	
159-192	31560-31570	Functional	_	
159-193	31571-31581	connectome	_	
159-194	31582-31596	fingerprinting	_	
159-195	31596-31597	:	_	
159-196	31598-31609	identifying	_	
159-197	31610-31621	individuals	_	
159-198	31622-31627	using	_	
159-199	31628-31636	patterns	_	
159-200	31637-31639	of	_	
159-201	31640-31645	brain	_	
159-202	31646-31658	connectivity	_	
159-203	31659-31660	A	_	
159-204	31661-31672	neuromarker	_	
159-205	31673-31675	of	_	
159-206	31676-31685	sustained	_	
159-207	31686-31695	attention	_	
159-208	31696-31700	from	_	
159-209	31701-31712	whole-brain	_	
159-210	31713-31723	functional	_	
159-211	31724-31736	connectivity	_	
159-212	31737-31752	Methylphenidate	_	
159-213	31753-31762	Modulates	_	
159-214	31763-31773	Functional	_	
159-215	31774-31781	Network	_	
159-216	31782-31794	Connectivity	_	
159-217	31795-31797	to	_	
159-218	31798-31805	Enhance	_	
159-219	31806-31815	Attention	_	
159-220	31816-31827	Galantamine	_	
159-221	31828-31831	and	_	
159-222	31832-31844	Computerized	_	
159-223	31845-31854	Cognitive	_	
159-224	31855-31865	Behavioral	_	
159-225	31866-31873	Therapy	_	
159-226	31874-31877	for	_	
159-227	31878-31885	Cocaine	_	
159-228	31886-31896	Dependence	_	
159-229	31896-31897	:	_	
159-230	31898-31899	A	_	
159-231	31900-31910	Randomized	_	
159-232	31911-31919	Clinical	_	
159-233	31920-31925	Trial	_	
159-234	31926-31937	Individuals	_	
159-235	31938-31944	Family	_	
159-236	31945-31952	History	_	
159-237	31953-31961	Positive	_	
159-238	31962-31965	for	_	
159-239	31966-31976	Alcoholism	_	
159-240	31977-31981	Show	_	
159-241	31982-31992	Functional	_	
159-242	31993-32001	Magnetic	_	
159-243	32002-32011	Resonance	_	
159-244	32012-32019	Imaging	_	
159-245	32020-32031	Differences	_	
159-246	32032-32034	in	_	
159-247	32035-32041	Reward	_	
159-248	32042-32053	Sensitivity	_	
159-249	32054-32058	That	_	
159-250	32059-32062	Are	_	
159-251	32063-32070	Related	_	
159-252	32071-32073	to	_	
159-253	32074-32085	Impulsivity	_	
159-254	32086-32093	Factors	_	
159-255	32094-32103	Groupwise	_	
159-256	32104-32115	whole-brain	_	
159-257	32116-32128	parcellation	_	
159-258	32129-32133	from	_	
159-259	32134-32147	resting-state	_	
159-260	32148-32152	fMRI	_	
159-261	32153-32157	data	_	
159-262	32158-32161	for	_	
159-263	32162-32169	network	_	
159-264	32170-32174	node	_	
159-265	32175-32189	identification	_	
159-266	32190-32193	Can	_	
159-267	32194-32199	brain	_	
159-268	32200-32205	state	_	
159-269	32206-32208	be	_	
159-270	32209-32220	manipulated	_	
159-271	32221-32223	to	_	
159-272	32224-32233	emphasize	_	
159-273	32234-32244	individual	_	
159-274	32245-32256	differences	_	
159-275	32257-32259	in	_	
159-276	32260-32270	functional	_	
159-277	32271-32283	connectivity	_	
159-278	32283-32284	?	_	

#Text=Prediction as a humanitarian and pragmatic contribution from human cognitive neuroscience
#Text=Resting State Functional Connectivity in Addiction: Lessons Learned and a Road Ahead
#Text=
#Text=
#Text=Impaired functional connectivity within and between frontostriatal circuits and its association with compulsive drug use and trait impulsivity in cocaine addiction
#Text=Anticipatory Reward Processing in Addicted Populations: A Focus on the Monetary Incentive Delay Task
#Text=Dissociation of reward anticipation and outcome with event-related fMRI
#Text=Enhanced midbrain response at 6-month follow-up in cocaine addiction, association with reduced drug-related choice
#Text=Task-induced brain state manipulation improves prediction of individual traits
#Text=CorticoAmygdala Coupling as a Marker of Early Relapse Risk in Cocaine-Addicted Individuals
#Text=Effects of chronic and acute stimulants on brain functional connectivity hubs
#Text=Cognitive enhancement as a treatment for drug addictions
#Text=Performance-Based Contingency Management in Cognitive Remediation Training: A Pilot Study
#Text=Remember the future: working memory training decreases delay discounting among stimulant addicts
#Text=Predicting treatment response in social anxiety disorder from functional magnetic resonance imaging
#Text=One year follow-up of disulfiram and psychotherapy for cocaine-alcohol abusers: Sustained effects of treatment
#Text=Building better biomarkers: brain models in translational neuroimaging
#Text=To Explain or to Predict?
160-1	32285-32295	Prediction	_	
160-2	32296-32298	as	_	
160-3	32299-32300	a	_	
160-4	32301-32313	humanitarian	_	
160-5	32314-32317	and	_	
160-6	32318-32327	pragmatic	_	
160-7	32328-32340	contribution	_	
160-8	32341-32345	from	_	
160-9	32346-32351	human	_	
160-10	32352-32361	cognitive	_	
160-11	32362-32374	neuroscience	_	
160-12	32375-32382	Resting	_	
160-13	32383-32388	State	_	
160-14	32389-32399	Functional	_	
160-15	32400-32412	Connectivity	_	
160-16	32413-32415	in	_	
160-17	32416-32425	Addiction	_	
160-18	32425-32426	:	_	
160-19	32427-32434	Lessons	_	
160-20	32435-32442	Learned	_	
160-21	32443-32446	and	_	
160-22	32447-32448	a	_	
160-23	32449-32453	Road	_	
160-24	32454-32459	Ahead	_	
160-25	32462-32470	Impaired	_	
160-26	32471-32481	functional	_	
160-27	32482-32494	connectivity	_	
160-28	32495-32501	within	_	
160-29	32502-32505	and	_	
160-30	32506-32513	between	_	
160-31	32514-32528	frontostriatal	_	
160-32	32529-32537	circuits	_	
160-33	32538-32541	and	_	
160-34	32542-32545	its	_	
160-35	32546-32557	association	_	
160-36	32558-32562	with	_	
160-37	32563-32573	compulsive	_	
160-38	32574-32578	drug	_	
160-39	32579-32582	use	_	
160-40	32583-32586	and	_	
160-41	32587-32592	trait	_	
160-42	32593-32604	impulsivity	_	
160-43	32605-32607	in	_	
160-44	32608-32615	cocaine	_	
160-45	32616-32625	addiction	_	
160-46	32626-32638	Anticipatory	_	
160-47	32639-32645	Reward	_	
160-48	32646-32656	Processing	_	
160-49	32657-32659	in	_	
160-50	32660-32668	Addicted	_	
160-51	32669-32680	Populations	_	
160-52	32680-32681	:	_	
160-53	32682-32683	A	_	
160-54	32684-32689	Focus	_	
160-55	32690-32692	on	_	
160-56	32693-32696	the	_	
160-57	32697-32705	Monetary	_	
160-58	32706-32715	Incentive	_	
160-59	32716-32721	Delay	_	
160-60	32722-32726	Task	_	
160-61	32727-32739	Dissociation	_	
160-62	32740-32742	of	_	
160-63	32743-32749	reward	_	
160-64	32750-32762	anticipation	_	
160-65	32763-32766	and	_	
160-66	32767-32774	outcome	_	
160-67	32775-32779	with	_	
160-68	32780-32793	event-related	_	
160-69	32794-32798	fMRI	_	
160-70	32799-32807	Enhanced	_	
160-71	32808-32816	midbrain	_	
160-72	32817-32825	response	_	
160-73	32826-32828	at	_	
160-74	32829-32830	6	_	
160-75	32830-32831	-	_	
160-76	32831-32836	month	_	
160-77	32837-32846	follow-up	_	
160-78	32847-32849	in	_	
160-79	32850-32857	cocaine	_	
160-80	32858-32867	addiction	_	
160-81	32867-32868	,	_	
160-82	32869-32880	association	_	
160-83	32881-32885	with	_	
160-84	32886-32893	reduced	_	
160-85	32894-32906	drug-related	_	
160-86	32907-32913	choice	_	
160-87	32914-32926	Task-induced	_	
160-88	32927-32932	brain	_	
160-89	32933-32938	state	_	
160-90	32939-32951	manipulation	_	
160-91	32952-32960	improves	_	
160-92	32961-32971	prediction	_	
160-93	32972-32974	of	_	
160-94	32975-32985	individual	_	
160-95	32986-32992	traits	_	
160-96	32993-33008	CorticoAmygdala	_	
160-97	33009-33017	Coupling	_	
160-98	33018-33020	as	_	
160-99	33021-33022	a	_	
160-100	33023-33029	Marker	_	
160-101	33030-33032	of	_	
160-102	33033-33038	Early	_	
160-103	33039-33046	Relapse	_	
160-104	33047-33051	Risk	_	
160-105	33052-33054	in	_	
160-106	33055-33071	Cocaine-Addicted	_	
160-107	33072-33083	Individuals	_	
160-108	33084-33091	Effects	_	
160-109	33092-33094	of	_	
160-110	33095-33102	chronic	_	
160-111	33103-33106	and	_	
160-112	33107-33112	acute	_	
160-113	33113-33123	stimulants	_	
160-114	33124-33126	on	_	
160-115	33127-33132	brain	_	
160-116	33133-33143	functional	_	
160-117	33144-33156	connectivity	_	
160-118	33157-33161	hubs	_	
160-119	33162-33171	Cognitive	_	
160-120	33172-33183	enhancement	_	
160-121	33184-33186	as	_	
160-122	33187-33188	a	_	
160-123	33189-33198	treatment	_	
160-124	33199-33202	for	_	
160-125	33203-33207	drug	_	
160-126	33208-33218	addictions	_	
160-127	33219-33236	Performance-Based	_	
160-128	33237-33248	Contingency	_	
160-129	33249-33259	Management	_	
160-130	33260-33262	in	_	
160-131	33263-33272	Cognitive	_	
160-132	33273-33284	Remediation	_	
160-133	33285-33293	Training	_	
160-134	33293-33294	:	_	
160-135	33295-33296	A	_	
160-136	33297-33302	Pilot	_	
160-137	33303-33308	Study	_	
160-138	33309-33317	Remember	_	
160-139	33318-33321	the	_	
160-140	33322-33328	future	_	
160-141	33328-33329	:	_	
160-142	33330-33337	working	_	
160-143	33338-33344	memory	_	
160-144	33345-33353	training	_	
160-145	33354-33363	decreases	_	
160-146	33364-33369	delay	_	
160-147	33370-33381	discounting	_	
160-148	33382-33387	among	_	
160-149	33388-33397	stimulant	_	
160-150	33398-33405	addicts	_	
160-151	33406-33416	Predicting	_	
160-152	33417-33426	treatment	_	
160-153	33427-33435	response	_	
160-154	33436-33438	in	_	
160-155	33439-33445	social	_	
160-156	33446-33453	anxiety	_	
160-157	33454-33462	disorder	_	
160-158	33463-33467	from	_	
160-159	33468-33478	functional	_	
160-160	33479-33487	magnetic	_	
160-161	33488-33497	resonance	_	
160-162	33498-33505	imaging	_	
160-163	33506-33509	One	_	
160-164	33510-33514	year	_	
160-165	33515-33524	follow-up	_	
160-166	33525-33527	of	_	
160-167	33528-33538	disulfiram	_	
160-168	33539-33542	and	_	
160-169	33543-33556	psychotherapy	_	
160-170	33557-33560	for	_	
160-171	33561-33576	cocaine-alcohol	_	
160-172	33577-33584	abusers	_	
160-173	33584-33585	:	_	
160-174	33586-33595	Sustained	_	
160-175	33596-33603	effects	_	
160-176	33604-33606	of	_	
160-177	33607-33616	treatment	_	
160-178	33617-33625	Building	_	
160-179	33626-33632	better	_	
160-180	33633-33643	biomarkers	_	
160-181	33643-33644	:	_	
160-182	33645-33650	brain	_	
160-183	33651-33657	models	_	
160-184	33658-33660	in	_	
160-185	33661-33674	translational	_	
160-186	33675-33687	neuroimaging	_	
160-187	33688-33690	To	_	
160-188	33691-33698	Explain	_	
160-189	33699-33701	or	_	
160-190	33702-33704	to	_	
160-191	33705-33712	Predict	_	
160-192	33712-33713	?	_	

#Text=When optimism hurts: inflated predictions in psychiatric neuroimaging
#Text=Choosing Prediction Over Explanation in Psychology: Lessons From Machine Learning
#Text=The relation between statistical power and inference in fMRI
#Text=CPM model performance and positive and negative abstinence networks
#Text=Figure 1A shows positive (red) and negative (blue) abstinence networks.
161-1	33714-33718	When	_	
161-2	33719-33727	optimism	_	
161-3	33728-33733	hurts	_	
161-4	33733-33734	:	_	
161-5	33735-33743	inflated	_	
161-6	33744-33755	predictions	_	
161-7	33756-33758	in	_	
161-8	33759-33770	psychiatric	_	
161-9	33771-33783	neuroimaging	_	
161-10	33784-33792	Choosing	_	
161-11	33793-33803	Prediction	_	
161-12	33804-33808	Over	_	
161-13	33809-33820	Explanation	_	
161-14	33821-33823	in	_	
161-15	33824-33834	Psychology	_	
161-16	33834-33835	:	_	
161-17	33836-33843	Lessons	_	
161-18	33844-33848	From	_	
161-19	33849-33856	Machine	_	
161-20	33857-33865	Learning	_	
161-21	33866-33869	The	_	
161-22	33870-33878	relation	_	
161-23	33879-33886	between	_	
161-24	33887-33898	statistical	_	
161-25	33899-33904	power	_	
161-26	33905-33908	and	_	
161-27	33909-33918	inference	_	
161-28	33919-33921	in	_	
161-29	33922-33926	fMRI	_	
161-30	33927-33930	CPM	_	
161-31	33931-33936	model	_	
161-32	33937-33948	performance	_	
161-33	33949-33952	and	_	
161-34	33953-33961	positive	_	
161-35	33962-33965	and	_	
161-36	33966-33974	negative	_	
161-37	33975-33985	abstinence	_	
161-38	33986-33994	networks	_	
161-39	33995-34001	Figure	_	
161-40	34002-34004	1A	_	
161-41	34005-34010	shows	_	
161-42	34011-34019	positive	_	
161-43	34020-34021	(	_	
161-44	34021-34024	red	_	
161-45	34024-34025	)	_	
161-46	34026-34029	and	_	
161-47	34030-34038	negative	_	
161-48	34039-34040	(	_	
161-49	34040-34044	blue	_	
161-50	34044-34045	)	_	
161-51	34046-34056	abstinence	_	
161-52	34057-34065	networks	_	
161-53	34065-34066	.	_	

#Text=For the positive network, increased edge weights (i.e., increased functional connectivity) predict more within-treatment abstinence.
162-1	34067-34070	For	_	
162-2	34071-34074	the	_	
162-3	34075-34083	positive	_	
162-4	34084-34091	network	_	
162-5	34091-34092	,	_	
162-6	34093-34102	increased	_	
162-7	34103-34107	edge	_	
162-8	34108-34115	weights	_	
162-9	34116-34117	(	_	
162-10	34117-34120	i.e	_	
162-11	34120-34121	.	_	
162-12	34121-34122	,	_	
162-13	34123-34132	increased	_	
162-14	34133-34143	functional	_	
162-15	34144-34156	connectivity	_	
162-16	34156-34157	)	_	
162-17	34158-34165	predict	_	
162-18	34166-34170	more	_	
162-19	34171-34187	within-treatment	_	
162-20	34188-34198	abstinence	_	
162-21	34198-34199	.	_	

#Text=For the negative network, decreased edge weights (i.e., decreased functional connectivity) predict more within-treatment abstinence.
163-1	34200-34203	For	_	
163-2	34204-34207	the	_	
163-3	34208-34216	negative	_	
163-4	34217-34224	network	_	
163-5	34224-34225	,	_	
163-6	34226-34235	decreased	_	
163-7	34236-34240	edge	_	
163-8	34241-34248	weights	_	
163-9	34249-34250	(	_	
163-10	34250-34253	i.e	_	
163-11	34253-34254	.	_	
163-12	34254-34255	,	_	
163-13	34256-34265	decreased	_	
163-14	34266-34276	functional	_	
163-15	34277-34289	connectivity	_	
163-16	34289-34290	)	_	
163-17	34291-34298	predict	_	
163-18	34299-34303	more	_	
163-19	34304-34320	within-treatment	_	
163-20	34321-34331	abstinence	_	
163-21	34331-34332	.	_	

#Text=Larger (smaller) spheres indicate nodes with more (less) edges.
164-1	34333-34339	Larger	_	
164-2	34340-34341	(	_	
164-3	34341-34348	smaller	_	
164-4	34348-34349	)	_	
164-5	34350-34357	spheres	_	
164-6	34358-34366	indicate	_	
164-7	34367-34372	nodes	_	
164-8	34373-34377	with	_	
164-9	34378-34382	more	_	
164-10	34383-34384	(	_	
164-11	34384-34388	less	_	
164-12	34388-34389	)	_	
164-13	34390-34395	edges	_	
164-14	34395-34396	.	_	

#Text=Figure 1B shows the correspondence between actual (x-axis) and predicted (y-axis) abstinence values generated using CPM.
165-1	34397-34403	Figure	_	
165-2	34404-34406	1B	_	
165-3	34407-34412	shows	_	
165-4	34413-34416	the	_	
165-5	34417-34431	correspondence	_	
165-6	34432-34439	between	_	
165-7	34440-34446	actual	_	
165-8	34447-34448	(	_	
165-9	34448-34454	x-axis	_	
165-10	34454-34455	)	_	
165-11	34456-34459	and	_	
165-12	34460-34469	predicted	_	
165-13	34470-34471	(	_	
165-14	34471-34477	y-axis	_	
165-15	34477-34478	)	_	
165-16	34479-34489	abstinence	_	
165-17	34490-34496	values	_	
165-18	34497-34506	generated	_	
165-19	34507-34512	using	_	
165-20	34513-34516	CPM	_	
165-21	34516-34517	.	_	

#Text=Abstinence values correspond to the percentage of urines negative for cocaine provided during treatment.
166-1	34518-34528	Abstinence	_	
166-2	34529-34535	values	_	
166-3	34536-34546	correspond	_	
166-4	34547-34549	to	_	
166-5	34550-34553	the	_	
166-6	34554-34564	percentage	_	
166-7	34565-34567	of	_	
166-8	34568-34574	urines	_	
166-9	34575-34583	negative	_	
166-10	34584-34587	for	_	
166-11	34588-34595	cocaine	_	
166-12	34596-34604	provided	_	
166-13	34605-34611	during	_	
166-14	34612-34621	treatment	_	
166-15	34621-34622	.	_	

#Text=Despite the clinical complexity of the population (Table 1), CPM successfully predicted within-treatment abstinence (p’s<.005).
167-1	34623-34630	Despite	_	
167-2	34631-34634	the	_	
167-3	34635-34643	clinical	_	
167-4	34644-34654	complexity	_	
167-5	34655-34657	of	_	
167-6	34658-34661	the	_	
167-7	34662-34672	population	_	
167-8	34673-34674	(	_	
167-9	34674-34679	Table	_	
167-10	34680-34681	1	_	
167-11	34681-34682	)	_	
167-12	34682-34683	,	_	
167-13	34684-34687	CPM	_	
167-14	34688-34700	successfully	_	
167-15	34701-34710	predicted	_	
167-16	34711-34727	within-treatment	_	
167-17	34728-34738	abstinence	_	
167-18	34739-34740	(	_	
167-19	34740-34741	p	_	
167-20	34741-34742	’	_	
167-21	34742-34743	s	_	
167-22	34743-34744	<	_	
167-23	34744-34748	.005	_	
167-24	34748-34749	)	_	
167-25	34749-34750	.	_	

#Text=Predictions remained significant in follow-up analyses controlling for clinical variables including years-of-cocaine-use and treatment retention (Supplementary Materials).
168-1	34751-34762	Predictions	_	
168-2	34763-34771	remained	_	
168-3	34772-34783	significant	_	
168-4	34784-34786	in	_	
168-5	34787-34796	follow-up	_	
168-6	34797-34805	analyses	_	
168-7	34806-34817	controlling	_	
168-8	34818-34821	for	_	
168-9	34822-34830	clinical	_	
168-10	34831-34840	variables	_	
168-11	34841-34850	including	_	
168-12	34851-34871	years-of-cocaine-use	_	
168-13	34872-34875	and	_	
168-14	34876-34885	treatment	_	
168-15	34886-34895	retention	_	
168-16	34896-34897	(	_	
168-17	34897-34910	Supplementary	_	
168-18	34911-34920	Materials	_	
168-19	34920-34921	)	_	
168-20	34921-34922	.	_	

#Text=Positive and negative abstinence networks summarized by connectivity between macroscale brain regions
#Text=Figure 2 summarizes positive and negative abstinence networks based on connectivity between macroscale brain regions.
169-1	34923-34931	Positive	_	
169-2	34932-34935	and	_	
169-3	34936-34944	negative	_	
169-4	34945-34955	abstinence	_	
169-5	34956-34964	networks	_	
169-6	34965-34975	summarized	_	
169-7	34976-34978	by	_	
169-8	34979-34991	connectivity	_	
169-9	34992-34999	between	_	
169-10	35000-35010	macroscale	_	
169-11	35011-35016	brain	_	
169-12	35017-35024	regions	_	
169-13	35025-35031	Figure	_	
169-14	35032-35033	2	_	
169-15	35034-35044	summarizes	_	
169-16	35045-35053	positive	_	
169-17	35054-35057	and	_	
169-18	35058-35066	negative	_	
169-19	35067-35077	abstinence	_	
169-20	35078-35086	networks	_	
169-21	35087-35092	based	_	
169-22	35093-35095	on	_	
169-23	35096-35108	connectivity	_	
169-24	35109-35116	between	_	
169-25	35117-35127	macroscale	_	
169-26	35128-35133	brain	_	
169-27	35134-35141	regions	_	
169-28	35141-35142	.	_	

#Text=From top, brain regions are presented in approximate anatomical order, such that longer range connections are represented by longer lines.
170-1	35143-35147	From	_	
170-2	35148-35151	top	_	
170-3	35151-35152	,	_	
170-4	35153-35158	brain	_	
170-5	35159-35166	regions	_	
170-6	35167-35170	are	_	
170-7	35171-35180	presented	_	
170-8	35181-35183	in	_	
170-9	35184-35195	approximate	_	
170-10	35196-35206	anatomical	_	
170-11	35207-35212	order	_	
170-12	35212-35213	,	_	
170-13	35214-35218	such	_	
170-14	35219-35223	that	_	
170-15	35224-35230	longer	_	
170-16	35231-35236	range	_	
170-17	35237-35248	connections	_	
170-18	35249-35252	are	_	
170-19	35253-35264	represented	_	
170-20	35265-35267	by	_	
170-21	35268-35274	longer	_	
170-22	35275-35280	lines	_	
170-23	35280-35281	.	_	

#Text=Positive and negative abstinence networks summarized by overlap with canonical neural networks
#Text=Within- and between-network connectivity for the positive network (A), negative network (B) and for positive – negative networks (C) are summarized based on overlap with canonical neural networks.
171-1	35282-35290	Positive	_	
171-2	35291-35294	and	_	
171-3	35295-35303	negative	_	
171-4	35304-35314	abstinence	_	
171-5	35315-35323	networks	_	
171-6	35324-35334	summarized	_	
171-7	35335-35337	by	_	
171-8	35338-35345	overlap	_	
171-9	35346-35350	with	_	
171-10	35351-35360	canonical	_	
171-11	35361-35367	neural	_	
171-12	35368-35376	networks	_	
171-13	35377-35383	Within	_	
171-14	35383-35384	-	_	
171-15	35385-35388	and	_	
171-16	35389-35404	between-network	_	
171-17	35405-35417	connectivity	_	
171-18	35418-35421	for	_	
171-19	35422-35425	the	_	
171-20	35426-35434	positive	_	
171-21	35435-35442	network	_	
171-22	35443-35444	(	_	
171-23	35444-35445	A	_	
171-24	35445-35446	)	_	
171-25	35446-35447	,	_	
171-26	35448-35456	negative	_	
171-27	35457-35464	network	_	
171-28	35465-35466	(	_	
171-29	35466-35467	B	_	
171-30	35467-35468	)	_	
171-31	35469-35472	and	_	
171-32	35473-35476	for	_	
171-33	35477-35485	positive	_	
171-34	35486-35487	–	_	
171-35	35488-35496	negative	_	
171-36	35497-35505	networks	_	
171-37	35506-35507	(	_	
171-38	35507-35508	C	_	
171-39	35508-35509	)	_	
171-40	35510-35513	are	_	
171-41	35514-35524	summarized	_	
171-42	35525-35530	based	_	
171-43	35531-35533	on	_	
171-44	35534-35541	overlap	_	
171-45	35542-35546	with	_	
171-46	35547-35556	canonical	_	
171-47	35557-35563	neural	_	
171-48	35564-35572	networks	_	
171-49	35572-35573	.	_	

#Text=For A and B, cells represent the total number of edges connecting nodes within (and between) each network with darker colors indicating a greater number of edges.
172-1	35574-35577	For	_	
172-2	35578-35579	A	_	
172-3	35580-35583	and	_	
172-4	35584-35585	B	_	
172-5	35585-35586	,	_	
172-6	35587-35592	cells	_	
172-7	35593-35602	represent	_	
172-8	35603-35606	the	_	
172-9	35607-35612	total	_	
172-10	35613-35619	number	_	
172-11	35620-35622	of	_	
172-12	35623-35628	edges	_	
172-13	35629-35639	connecting	_	
172-14	35640-35645	nodes	_	
172-15	35646-35652	within	_	
172-16	35653-35654	(	_	
172-17	35654-35657	and	_	
172-18	35658-35665	between	_	
172-19	35665-35666	)	_	
172-20	35667-35671	each	_	
172-21	35672-35679	network	_	
172-22	35680-35684	with	_	
172-23	35685-35691	darker	_	
172-24	35692-35698	colors	_	
172-25	35699-35709	indicating	_	
172-26	35710-35711	a	_	
172-27	35712-35719	greater	_	
172-28	35720-35726	number	_	
172-29	35727-35729	of	_	
172-30	35730-35735	edges	_	
172-31	35735-35736	.	_	

#Text=For C, cells represent the number of positive versus negative edges connecting nodes within (and between) each network with warmer colors (orange/yellow) indicating more edges in the positive network and cooler colors (blue/green) indicating more edges in the negative network.
173-1	35737-35740	For	_	
173-2	35741-35742	C	_	
173-3	35742-35743	,	_	
173-4	35744-35749	cells	_	
173-5	35750-35759	represent	_	
173-6	35760-35763	the	_	
173-7	35764-35770	number	_	
173-8	35771-35773	of	_	
173-9	35774-35782	positive	_	
173-10	35783-35789	versus	_	
173-11	35790-35798	negative	_	
173-12	35799-35804	edges	_	
173-13	35805-35815	connecting	_	
173-14	35816-35821	nodes	_	
173-15	35822-35828	within	_	
173-16	35829-35830	(	_	
173-17	35830-35833	and	_	
173-18	35834-35841	between	_	
173-19	35841-35842	)	_	
173-20	35843-35847	each	_	
173-21	35848-35855	network	_	
173-22	35856-35860	with	_	
173-23	35861-35867	warmer	_	
173-24	35868-35874	colors	_	
173-25	35875-35876	(	_	
173-26	35876-35882	orange	_	
173-27	35882-35883	/	_	
173-28	35883-35889	yellow	_	
173-29	35889-35890	)	_	
173-30	35891-35901	indicating	_	
173-31	35902-35906	more	_	
173-32	35907-35912	edges	_	
173-33	35913-35915	in	_	
173-34	35916-35919	the	_	
173-35	35920-35928	positive	_	
173-36	35929-35936	network	_	
173-37	35937-35940	and	_	
173-38	35941-35947	cooler	_	
173-39	35948-35954	colors	_	
173-40	35955-35956	(	_	
173-41	35956-35960	blue	_	
173-42	35960-35961	/	_	
173-43	35961-35966	green	_	
173-44	35966-35967	)	_	
173-45	35968-35978	indicating	_	
173-46	35979-35983	more	_	
173-47	35984-35989	edges	_	
173-48	35990-35992	in	_	
173-49	35993-35996	the	_	
173-50	35997-36005	negative	_	
173-51	36006-36013	network	_	
173-52	36013-36014	.	_	

#Text=Despite this visual simplification, it is important to note that, by definition positive and negative networks do not contain overlapping edges (for further information on network definitions, see Supplemental Materials).
174-1	36015-36022	Despite	_	
174-2	36023-36027	this	_	
174-3	36028-36034	visual	_	
174-4	36035-36049	simplification	_	
174-5	36049-36050	,	_	
174-6	36051-36053	it	_	
174-7	36054-36056	is	_	
174-8	36057-36066	important	_	
174-9	36067-36069	to	_	
174-10	36070-36074	note	_	
174-11	36075-36079	that	_	
174-12	36079-36080	,	_	
174-13	36081-36083	by	_	
174-14	36084-36094	definition	_	
174-15	36095-36103	positive	_	
174-16	36104-36107	and	_	
174-17	36108-36116	negative	_	
174-18	36117-36125	networks	_	
174-19	36126-36128	do	_	
174-20	36129-36132	not	_	
174-21	36133-36140	contain	_	
174-22	36141-36152	overlapping	_	
174-23	36153-36158	edges	_	
174-24	36159-36160	(	_	
174-25	36160-36163	for	_	
174-26	36164-36171	further	_	
174-27	36172-36183	information	_	
174-28	36184-36186	on	_	
174-29	36187-36194	network	_	
174-30	36195-36206	definitions	_	
174-31	36206-36207	,	_	
174-32	36208-36211	see	_	
174-33	36212-36224	Supplemental	_	
174-34	36225-36234	Materials	_	
174-35	36234-36235	)	_	
174-36	36235-36236	.	_	

#Text=Five network model of abstinence
#Text=Large-scale patterns of between-network connectivity for abstinence networks identified using CPM are summarized based on relative number of connections within positive (red) versus negative (blue) networks.
175-1	36237-36241	Five	_	
175-2	36242-36249	network	_	
175-3	36250-36255	model	_	
175-4	36256-36258	of	_	
175-5	36259-36269	abstinence	_	
175-6	36270-36281	Large-scale	_	
175-7	36282-36290	patterns	_	
175-8	36291-36293	of	_	
175-9	36294-36309	between-network	_	
175-10	36310-36322	connectivity	_	
175-11	36323-36326	for	_	
175-12	36327-36337	abstinence	_	
175-13	36338-36346	networks	_	
175-14	36347-36357	identified	_	
175-15	36358-36363	using	_	
175-16	36364-36367	CPM	_	
175-17	36368-36371	are	_	
175-18	36372-36382	summarized	_	
175-19	36383-36388	based	_	
175-20	36389-36391	on	_	
175-21	36392-36400	relative	_	
175-22	36401-36407	number	_	
175-23	36408-36410	of	_	
175-24	36411-36422	connections	_	
175-25	36423-36429	within	_	
175-26	36430-36438	positive	_	
175-27	36439-36440	(	_	
175-28	36440-36443	red	_	
175-29	36443-36444	)	_	
175-30	36445-36451	versus	_	
175-31	36452-36460	negative	_	
175-32	36461-36462	(	_	
175-33	36462-36466	blue	_	
175-34	36466-36467	)	_	
175-35	36468-36476	networks	_	
175-36	36476-36477	.	_	

#Text=Stronger connectivity (i.e., network integration) between frontoparietal and medial-frontal networks (top) and between sensory-motor, salience and subcortical networks (bottom) positively predicted within treatment abstinence.
176-1	36478-36486	Stronger	_	
176-2	36487-36499	connectivity	_	
176-3	36500-36501	(	_	
176-4	36501-36504	i.e	_	
176-5	36504-36505	.	_	
176-6	36505-36506	,	_	
176-7	36507-36514	network	_	
176-8	36515-36526	integration	_	
176-9	36526-36527	)	_	
176-10	36528-36535	between	_	
176-11	36536-36550	frontoparietal	_	
176-12	36551-36554	and	_	
176-13	36555-36569	medial-frontal	_	
176-14	36570-36578	networks	_	
176-15	36579-36580	(	_	
176-16	36580-36583	top	_	
176-17	36583-36584	)	_	
176-18	36585-36588	and	_	
176-19	36589-36596	between	_	
176-20	36597-36610	sensory-motor	_	
176-21	36610-36611	,	_	
176-22	36612-36620	salience	_	
176-23	36621-36624	and	_	
176-24	36625-36636	subcortical	_	
176-25	36637-36645	networks	_	
176-26	36646-36647	(	_	
176-27	36647-36653	bottom	_	
176-28	36653-36654	)	_	
176-29	36655-36665	positively	_	
176-30	36666-36675	predicted	_	
176-31	36676-36682	within	_	
176-32	36683-36692	treatment	_	
176-33	36693-36703	abstinence	_	
176-34	36703-36704	.	_	

#Text=Weaker connectivity between these two systems (i.e., network segregation) also predicted more within treatment abstinence.
177-1	36705-36711	Weaker	_	
177-2	36712-36724	connectivity	_	
177-3	36725-36732	between	_	
177-4	36733-36738	these	_	
177-5	36739-36742	two	_	
177-6	36743-36750	systems	_	
177-7	36751-36752	(	_	
177-8	36752-36755	i.e	_	
177-9	36755-36756	.	_	
177-10	36756-36757	,	_	
177-11	36758-36765	network	_	
177-12	36766-36777	segregation	_	
177-13	36777-36778	)	_	
177-14	36779-36783	also	_	
177-15	36784-36793	predicted	_	
177-16	36794-36798	more	_	
177-17	36799-36805	within	_	
177-18	36806-36815	treatment	_	
177-19	36816-36826	abstinence	_	
177-20	36826-36827	.	_	

#Text=Demographic and clinical characteristics of methadone-maintained, cocaine-dependent participants (N=74)
#Text=\t\tfMRI data included in CPM*\t\t\t \tVariable\tTotal (N=74)\tYes (n=53)\tNo (n=21)\tF or X2\tp-value\t \tFemale, No. (%)\t27\t36.5\t14\t26.4\t13\t61.9\t8.18\t0.004\t \tMethadone dose at baseline (mg), mean (SD)\t73\t24.4\t74.7\t23.1\t69\t27.5\t0.81\t0.37\t \tDays in treatment at fMRI scan, mean (SD)\t1.9\t7.3\t1.5\t6.7\t2.9\t8.6\t0.55\t0.46\t \tCompleted High School, No. (%)\t53\t71.6\t37\t69.8\t16\t76.2\t0.3\t0.58\t \tUnemployed, No. (%)\t54\t73\t36\t71.7\t16\t76.2\t0.15\t0.7\t \tAge, mean (SD)\t36.3\t9.4\t35.2\t9.4\t39.3\t9.1\t2.95\t0.09\t \tDays opioid use, past 28, mean (SD)\t3.6\t5.8\t3.8\t6.1\t3.1\t5\t0.23\t0.63\t \tDays marijuana use, past 28, mean (SD)\t2\t5.5\t1.9\t5.9\t2.2\t4.2\t0.04\t0.85\t \tDays cocaine use, past 28, mean (SD)\t16.2\t8.1\t16.9\t8.3\t14.5\t7.4\t1.33\t0.25\t \tDays cigarette use, past 28, mean (SD)\t26.1\t6.6\t25.6\t7.6\t27.4\t2.8\t1.06\t0.31\t \tDays alcohol use, past 28, mean (SD)\t2.4\t5.9\t2.1\t5.1\t3.2\t7.7\t0.56\t0.46\t \tYears of regular cocaine use, mean (SD)\t9\t7.8\t8.1\t6.5\t11.3\t10.2\t2.6\t0.11\t \tNo. prior outpatient drug treatments, mean (SD)\t3\t3.6\t3\t3.8\t2.9\t3.4\t0.01\t0.92\t \tNo. prior inpatient drug treatments, mean (SD)\t3.2\t5.2\t3\t4.7\t3.6\t6.6\t0.18\t0.68\t \tLifetime No. of arrests, mean (SD)\t5.5\t6.3\t5.3\t6.1\t5.8\t6.9\t0.07\t0.8\t \tEstimated IQ (Shipley), mean (SD)\t90.5\t12.8\t90.1\t12.8\t91.2\t13.2\t0.11\t0.74\t \tRoute of Cocaine Use\t \t    Smoke, No. (%)\t52\t70.3\t37\t69.8\t15\t71.4\t0.5\t0.92\t \t    Snort, No. (%)\t15\t20.3\t11\t20.8\t4\t19\t\t\t \t    IV, No. (%)\t6\t8.1\t4\t7.5\t2\t9.5\t\t\t \t    Speedball, No. (%)\t1\t1.4\t1\t1.9\t0\t0\t\t\t \tPercent cocaine negative urines, mean (SD)\t21.6\t28.9\t23\t28\t18\t31.5\t0.46\t0.5\t \t
#Text=4 individuals were excluded due to incomplete or missing data; 17 were excluded due to excessive motion during scannin
178-1	36828-36839	Demographic	_	
178-2	36840-36843	and	_	
178-3	36844-36852	clinical	_	
178-4	36853-36868	characteristics	_	
178-5	36869-36871	of	_	
178-6	36872-36892	methadone-maintained	_	
178-7	36892-36893	,	_	
178-8	36894-36911	cocaine-dependent	_	
178-9	36912-36924	participants	_	
178-10	36925-36926	(	_	
178-11	36926-36927	N	_	
178-12	36927-36928	=	_	
178-13	36928-36930	74	_	
178-14	36930-36931	)	_	
178-15	36934-36938	fMRI	_	
178-16	36939-36943	data	_	
178-17	36944-36952	included	_	
178-18	36953-36955	in	_	
178-19	36956-36959	CPM	_	
178-20	36959-36960	*	_	
178-21	36965-36973	Variable	_	
178-22	36974-36979	Total	_	
178-23	36980-36981	(	_	
178-24	36981-36982	N	_	
178-25	36982-36983	=	_	
178-26	36983-36985	74	_	
178-27	36985-36986	)	_	
178-28	36987-36990	Yes	_	
178-29	36991-36992	(	_	
178-30	36992-36993	n	_	
178-31	36993-36994	=	_	
178-32	36994-36996	53	_	
178-33	36996-36997	)	_	
178-34	36998-37000	No	_	
178-35	37001-37002	(	_	
178-36	37002-37003	n	_	
178-37	37003-37004	=	_	
178-38	37004-37006	21	_	
178-39	37006-37007	)	_	
178-40	37008-37009	F	_	
178-41	37010-37012	or	_	
178-42	37013-37015	X2	_	
178-43	37016-37023	p-value	_	
178-44	37026-37032	Female	_	
178-45	37032-37033	,	_	
178-46	37034-37036	No	_	
178-47	37036-37037	.	_	
178-48	37038-37039	(	_	
178-49	37039-37040	%	_	
178-50	37040-37041	)	_	
178-51	37042-37044	27	_	
178-52	37045-37049	36.5	_	
178-53	37050-37052	14	_	
178-54	37053-37057	26.4	_	
178-55	37058-37060	13	_	
178-56	37061-37065	61.9	_	
178-57	37066-37070	8.18	_	
178-58	37071-37076	0.004	_	
178-59	37079-37088	Methadone	_	
178-60	37089-37093	dose	_	
178-61	37094-37096	at	_	
178-62	37097-37105	baseline	_	
178-63	37106-37107	(	_	
178-64	37107-37109	mg	_	
178-65	37109-37110	)	_	
178-66	37110-37111	,	_	
178-67	37112-37116	mean	_	
178-68	37117-37118	(	_	
178-69	37118-37120	SD	_	
178-70	37120-37121	)	_	
178-71	37122-37124	73	_	
178-72	37125-37129	24.4	_	
178-73	37130-37134	74.7	_	
178-74	37135-37139	23.1	_	
178-75	37140-37142	69	_	
178-76	37143-37147	27.5	_	
178-77	37148-37152	0.81	_	
178-78	37153-37157	0.37	_	
178-79	37160-37164	Days	_	
178-80	37165-37167	in	_	
178-81	37168-37177	treatment	_	
178-82	37178-37180	at	_	
178-83	37181-37185	fMRI	_	
178-84	37186-37190	scan	_	
178-85	37190-37191	,	_	
178-86	37192-37196	mean	_	
178-87	37197-37198	(	_	
178-88	37198-37200	SD	_	
178-89	37200-37201	)	_	
178-90	37202-37205	1.9	_	
178-91	37206-37209	7.3	_	
178-92	37210-37213	1.5	_	
178-93	37214-37217	6.7	_	
178-94	37218-37221	2.9	_	
178-95	37222-37225	8.6	_	
178-96	37226-37230	0.55	_	
178-97	37231-37235	0.46	_	
178-98	37238-37247	Completed	_	
178-99	37248-37252	High	_	
178-100	37253-37259	School	_	
178-101	37259-37260	,	_	
178-102	37261-37263	No	_	
178-103	37263-37264	.	_	
178-104	37265-37266	(	_	
178-105	37266-37267	%	_	
178-106	37267-37268	)	_	
178-107	37269-37271	53	_	
178-108	37272-37276	71.6	_	
178-109	37277-37279	37	_	
178-110	37280-37284	69.8	_	
178-111	37285-37287	16	_	
178-112	37288-37292	76.2	_	
178-113	37293-37296	0.3	_	
178-114	37297-37301	0.58	_	
178-115	37304-37314	Unemployed	_	
178-116	37314-37315	,	_	
178-117	37316-37318	No	_	
178-118	37318-37319	.	_	
178-119	37320-37321	(	_	
178-120	37321-37322	%	_	
178-121	37322-37323	)	_	
178-122	37324-37326	54	_	
178-123	37327-37329	73	_	
178-124	37330-37332	36	_	
178-125	37333-37337	71.7	_	
178-126	37338-37340	16	_	
178-127	37341-37345	76.2	_	
178-128	37346-37350	0.15	_	
178-129	37351-37354	0.7	_	
178-130	37357-37360	Age	_	
178-131	37360-37361	,	_	
178-132	37362-37366	mean	_	
178-133	37367-37368	(	_	
178-134	37368-37370	SD	_	
178-135	37370-37371	)	_	
178-136	37372-37376	36.3	_	
178-137	37377-37380	9.4	_	
178-138	37381-37385	35.2	_	
178-139	37386-37389	9.4	_	
178-140	37390-37394	39.3	_	
178-141	37395-37398	9.1	_	
178-142	37399-37403	2.95	_	
178-143	37404-37408	0.09	_	
178-144	37411-37415	Days	_	
178-145	37416-37422	opioid	_	
178-146	37423-37426	use	_	
178-147	37426-37427	,	_	
178-148	37428-37432	past	_	
178-149	37433-37435	28	_	
178-150	37435-37436	,	_	
178-151	37437-37441	mean	_	
178-152	37442-37443	(	_	
178-153	37443-37445	SD	_	
178-154	37445-37446	)	_	
178-155	37447-37450	3.6	_	
178-156	37451-37454	5.8	_	
178-157	37455-37458	3.8	_	
178-158	37459-37462	6.1	_	
178-159	37463-37466	3.1	_	
178-160	37467-37468	5	_	
178-161	37469-37473	0.23	_	
178-162	37474-37478	0.63	_	
178-163	37481-37485	Days	_	
178-164	37486-37495	marijuana	_	
178-165	37496-37499	use	_	
178-166	37499-37500	,	_	
178-167	37501-37505	past	_	
178-168	37506-37508	28	_	
178-169	37508-37509	,	_	
178-170	37510-37514	mean	_	
178-171	37515-37516	(	_	
178-172	37516-37518	SD	_	
178-173	37518-37519	)	_	
178-174	37520-37521	2	_	
178-175	37522-37525	5.5	_	
178-176	37526-37529	1.9	_	
178-177	37530-37533	5.9	_	
178-178	37534-37537	2.2	_	
178-179	37538-37541	4.2	_	
178-180	37542-37546	0.04	_	
178-181	37547-37551	0.85	_	
178-182	37554-37558	Days	_	
178-183	37559-37566	cocaine	_	
178-184	37567-37570	use	_	
178-185	37570-37571	,	_	
178-186	37572-37576	past	_	
178-187	37577-37579	28	_	
178-188	37579-37580	,	_	
178-189	37581-37585	mean	_	
178-190	37586-37587	(	_	
178-191	37587-37589	SD	_	
178-192	37589-37590	)	_	
178-193	37591-37595	16.2	_	
178-194	37596-37599	8.1	_	
178-195	37600-37604	16.9	_	
178-196	37605-37608	8.3	_	
178-197	37609-37613	14.5	_	
178-198	37614-37617	7.4	_	
178-199	37618-37622	1.33	_	
178-200	37623-37627	0.25	_	
178-201	37630-37634	Days	_	
178-202	37635-37644	cigarette	_	
178-203	37645-37648	use	_	
178-204	37648-37649	,	_	
178-205	37650-37654	past	_	
178-206	37655-37657	28	_	
178-207	37657-37658	,	_	
178-208	37659-37663	mean	_	
178-209	37664-37665	(	_	
178-210	37665-37667	SD	_	
178-211	37667-37668	)	_	
178-212	37669-37673	26.1	_	
178-213	37674-37677	6.6	_	
178-214	37678-37682	25.6	_	
178-215	37683-37686	7.6	_	
178-216	37687-37691	27.4	_	
178-217	37692-37695	2.8	_	
178-218	37696-37700	1.06	_	
178-219	37701-37705	0.31	_	
178-220	37708-37712	Days	_	
178-221	37713-37720	alcohol	_	
178-222	37721-37724	use	_	
178-223	37724-37725	,	_	
178-224	37726-37730	past	_	
178-225	37731-37733	28	_	
178-226	37733-37734	,	_	
178-227	37735-37739	mean	_	
178-228	37740-37741	(	_	
178-229	37741-37743	SD	_	
178-230	37743-37744	)	_	
178-231	37745-37748	2.4	_	
178-232	37749-37752	5.9	_	
178-233	37753-37756	2.1	_	
178-234	37757-37760	5.1	_	
178-235	37761-37764	3.2	_	
178-236	37765-37768	7.7	_	
178-237	37769-37773	0.56	_	
178-238	37774-37778	0.46	_	
178-239	37781-37786	Years	_	
178-240	37787-37789	of	_	
178-241	37790-37797	regular	_	
178-242	37798-37805	cocaine	_	
178-243	37806-37809	use	_	
178-244	37809-37810	,	_	
178-245	37811-37815	mean	_	
178-246	37816-37817	(	_	
178-247	37817-37819	SD	_	
178-248	37819-37820	)	_	
178-249	37821-37822	9	_	
178-250	37823-37826	7.8	_	
178-251	37827-37830	8.1	_	
178-252	37831-37834	6.5	_	
178-253	37835-37839	11.3	_	
178-254	37840-37844	10.2	_	
178-255	37845-37848	2.6	_	
178-256	37849-37853	0.11	_	
178-257	37856-37858	No	_	
178-258	37858-37859	.	_	
178-259	37860-37865	prior	_	
178-260	37866-37876	outpatient	_	
178-261	37877-37881	drug	_	
178-262	37882-37892	treatments	_	
178-263	37892-37893	,	_	
178-264	37894-37898	mean	_	
178-265	37899-37900	(	_	
178-266	37900-37902	SD	_	
178-267	37902-37903	)	_	
178-268	37904-37905	3	_	
178-269	37906-37909	3.6	_	
178-270	37910-37911	3	_	
178-271	37912-37915	3.8	_	
178-272	37916-37919	2.9	_	
178-273	37920-37923	3.4	_	
178-274	37924-37928	0.01	_	
178-275	37929-37933	0.92	_	
178-276	37936-37938	No	_	
178-277	37938-37939	.	_	
178-278	37940-37945	prior	_	
178-279	37946-37955	inpatient	_	
178-280	37956-37960	drug	_	
178-281	37961-37971	treatments	_	
178-282	37971-37972	,	_	
178-283	37973-37977	mean	_	
178-284	37978-37979	(	_	
178-285	37979-37981	SD	_	
178-286	37981-37982	)	_	
178-287	37983-37986	3.2	_	
178-288	37987-37990	5.2	_	
178-289	37991-37992	3	_	
178-290	37993-37996	4.7	_	
178-291	37997-38000	3.6	_	
178-292	38001-38004	6.6	_	
178-293	38005-38009	0.18	_	
178-294	38010-38014	0.68	_	
178-295	38017-38025	Lifetime	_	
178-296	38026-38028	No	_	
178-297	38028-38029	.	_	
178-298	38030-38032	of	_	
178-299	38033-38040	arrests	_	
178-300	38040-38041	,	_	
178-301	38042-38046	mean	_	
178-302	38047-38048	(	_	
178-303	38048-38050	SD	_	
178-304	38050-38051	)	_	
178-305	38052-38055	5.5	_	
178-306	38056-38059	6.3	_	
178-307	38060-38063	5.3	_	
178-308	38064-38067	6.1	_	
178-309	38068-38071	5.8	_	
178-310	38072-38075	6.9	_	
178-311	38076-38080	0.07	_	
178-312	38081-38084	0.8	_	
178-313	38087-38096	Estimated	_	
178-314	38097-38099	IQ	_	
178-315	38100-38101	(	_	
178-316	38101-38108	Shipley	_	
178-317	38108-38109	)	_	
178-318	38109-38110	,	_	
178-319	38111-38115	mean	_	
178-320	38116-38117	(	_	
178-321	38117-38119	SD	_	
178-322	38119-38120	)	_	
178-323	38121-38125	90.5	_	
178-324	38126-38130	12.8	_	
178-325	38131-38135	90.1	_	
178-326	38136-38140	12.8	_	
178-327	38141-38145	91.2	_	
178-328	38146-38150	13.2	_	
178-329	38151-38155	0.11	_	
178-330	38156-38160	0.74	_	
178-331	38163-38168	Route	_	
178-332	38169-38171	of	_	
178-333	38172-38179	Cocaine	_	
178-334	38180-38183	Use	_	
178-335	38186-38190	    	_	
178-336	38190-38195	Smoke	_	
178-337	38195-38196	,	_	
178-338	38197-38199	No	_	
178-339	38199-38200	.	_	
178-340	38201-38202	(	_	
178-341	38202-38203	%	_	
178-342	38203-38204	)	_	
178-343	38205-38207	52	_	
178-344	38208-38212	70.3	_	
178-345	38213-38215	37	_	
178-346	38216-38220	69.8	_	
178-347	38221-38223	15	_	
178-348	38224-38228	71.4	_	
178-349	38229-38232	0.5	_	
178-350	38233-38237	0.92	_	
178-351	38240-38244	    	_	
178-352	38244-38249	Snort	_	
178-353	38249-38250	,	_	
178-354	38251-38253	No	_	
178-355	38253-38254	.	_	
178-356	38255-38256	(	_	
178-357	38256-38257	%	_	
178-358	38257-38258	)	_	
178-359	38259-38261	15	_	
178-360	38262-38266	20.3	_	
178-361	38267-38269	11	_	
178-362	38270-38274	20.8	_	
178-363	38275-38276	4	_	
178-364	38277-38279	19	_	
178-365	38284-38288	    	_	
178-366	38288-38290	IV	_	
178-367	38290-38291	,	_	
178-368	38292-38294	No	_	
178-369	38294-38295	.	_	
178-370	38296-38297	(	_	
178-371	38297-38298	%	_	
178-372	38298-38299	)	_	
178-373	38300-38301	6	_	
178-374	38302-38305	8.1	_	
178-375	38306-38307	4	_	
178-376	38308-38311	7.5	_	
178-377	38312-38313	2	_	
178-378	38314-38317	9.5	_	
178-379	38322-38326	    	_	
178-380	38326-38335	Speedball	_	
178-381	38335-38336	,	_	
178-382	38337-38339	No	_	
178-383	38339-38340	.	_	
178-384	38341-38342	(	_	
178-385	38342-38343	%	_	
178-386	38343-38344	)	_	
178-387	38345-38346	1	_	
178-388	38347-38350	1.4	_	
178-389	38351-38352	1	_	
178-390	38353-38356	1.9	_	
178-391	38357-38358	0	_	
178-392	38359-38360	0	_	
178-393	38365-38372	Percent	_	
178-394	38373-38380	cocaine	_	
178-395	38381-38389	negative	_	
178-396	38390-38396	urines	_	
178-397	38396-38397	,	_	
178-398	38398-38402	mean	_	
178-399	38403-38404	(	_	
178-400	38404-38406	SD	_	
178-401	38406-38407	)	_	
178-402	38408-38412	21.6	_	
178-403	38413-38417	28.9	_	
178-404	38418-38420	23	_	
178-405	38421-38423	28	_	
178-406	38424-38426	18	_	
178-407	38427-38431	31.5	_	
178-408	38432-38436	0.46	_	
178-409	38437-38440	0.5	_	
178-410	38444-38445	4	_	
178-411	38446-38457	individuals	_	
178-412	38458-38462	were	_	
178-413	38463-38471	excluded	_	
178-414	38472-38475	due	_	
178-415	38476-38478	to	_	
178-416	38479-38489	incomplete	_	
178-417	38490-38492	or	_	
178-418	38493-38500	missing	_	
178-419	38501-38505	data	_	
178-420	38505-38506	;	_	
178-421	38507-38509	17	_	
178-422	38510-38514	were	_	
178-423	38515-38523	excluded	_	
178-424	38524-38527	due	_	
178-425	38528-38530	to	_	
178-426	38531-38540	excessive	_	
178-427	38541-38547	motion	_	
178-428	38548-38554	during	_	
178-429	38555-38562	scannin	_	
